2009/11/28 Saturday
¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø
¤³¤Î¾ðÊó¤Ï11·î28Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ»ö¤Ç¤Ï¡¢²¼µ¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ»ö½ç¤Ç¤¹¡£
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ (11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤ¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ (11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊѰۤ·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ (11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)
2009ǯ11·î28Æü
¡¡
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¤Çȯ¸«¤ÎD225GÊѰۥ¦¥¤¥ë¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢»ä¤Î¥Ö¥í¥°µ»ö¡Ö¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ ¡×¤ò¤´»²¾È¤¤¤¿¤À¤¤¿¤¤¤¬¡¢¤³¤³¤Ë¤¤Æ¡¢¥¤¥®¥ê¥¹¤ÎMill Hill¤Ë¤¢¤ëWHO¤ÎÃϰ襻¥ó¥¿¡¼¤ÎNIMR( National Institute for Medical Research) ¤¬¡¢¶âÍËÆü¤Ë¡¢¤³¤ì¤é¤ÎD225GÊѰۥ¦¥¤¥ë¥¹¤ËÂФ·¤Æ¤Ï¡¢¸½ºß¤Î¥ï¥¯¥Á¥ó¤Ï¸úÎϤòȯ¤·¤Ê¤¤( D225G Vaccine Failure¡¢¥ï¥¯¥Á¥óÉÔÁ´¡¢¥ï¥¯¥Á¥ó¤òÀܼ路¤Æ¤â½½Ê¬¤Ê¹³ÂΤ¬ÆÀ¤é¤ì¤Ê¤¤)¤È¤Î³Îǧ¤ò¤·¤¿¤¬¡¢¤³¤ì¤Ë¤Ä¤¤¤Æ¤ÎWHO¤«¤é¤Î¸ø¼°Åª¤Ê¸«²ò¤ÎɽÌÀ¤Ï¤µ¤ì¤Ê¤¤¤Þ¤Þ¤Ë¤¢¤ë¤è¤¦¤À¡£(¤³¤Î¥Ú¡¼¥¸¤Î²¼Éô¤Ë¤¢¤ë11·î26Æü¤ÎWHO¤ÎDr Keiji Fukuda»á¤Î¥Ð¡¼¥Á¥ã¥ëµ¼Ô²ñ¸«»²¾È)
¤¹¤Ê¤ï¤Á¡¢¾åµ¤Î¥í¥ó¥É¥ó¤ÎMillHill¤Ë¤¢¤ëWHO¤Î¸¦µæ½ê¤Ç³Îǧ¤·¤¿¤È¤³¤í¤Ë¤è¤ë¤È¡¢¥¦¥¯¥é¥¤¥Ê¤«¤é¸¡ÂΤΤҤȤÄA/Lviv/N6/2009¤Ë¡¢¥ï¥¯¥Á¥ó¤ËÂФ·¤ÆÄ㤤¥ê¥¢¥¯¥¿¡¼(ÄãÈ¿±þÍÛÀ)¤ò»ý¤Ä¥¦¥¤¥ë¥¹¤¬¤¢¤ê¡¢¤½¤Î¾¤Î¥¦¥¤¥ë¥¹¤Ë¤Ï¡¢¥¿¥ß¥Õ¥ëÂÑÀ¤¬¤¢¤Ã¤¿¤È¤Î¤³¤È¤Ç¤¢¤ë¡£
¤³¤ì¤Ï¡¢D225GÊѰۤˤè¤Ã¤Æ¡¢ÌȱÖÈ¿±þ¤¬²óÈò(ÌÈ±ÖÆ¨Èò¡¢ immunological escape)¤µ¤ì¤¿¤È¤Î¸«Êý¤¬¤µ¤ì¤Æ¤¤¤ë¡£
»²¹Í
¡ÖD225G Evades Immune Response ¡×
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¥Ë¥å¡¼¥è¡¼¥¯¥¿¥¤¥à¥º»æ¤ÎDonald McNeil»á¤Îµ»ö¡ÖExperts Say Swine Flu Mutations Do Not Warrant New Alarm ¡×¤Ë¤ª¤¤¤Æ¤â¡¢D222GÊѰۤäD225GÊѰۤˤĤ¤¤Æ¤Î¥ï¥¯¥Á¥óÉÔÁ´·üǰ¤¬¼¨¤µ¤ì¤Æ¤¤¤ë¡£
»²¹Í¡ÖVaccine Failure Confirmed in New York Times by UK National Institute for Medical Research ¡×
¤Þ¤¿¡¢¤³¤Î¥µ¥¤¥È¡ÖMill Hill Designates Ukraine with D225G a Low Reactor¡× ¤Ç¤Ï¡¢¸½ºß¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤¬¡¢¤â¤¦¤·¤Ð¤é¤¯¤¹¤ë¤È¡¢ÌµÍѤΤâ¤Î¤È¤Ê¤ê¤«¤Í¤Ê¤¤¡¢¤È¤Î¸«Êý¤â¤·¤Æ¤¤¤ë¡£
ÌäÂê¤Ï¡¢¥¦¥¤¥ë¥¹¸¡ÂΤκμ褬¡¢¸½ºß¤Ï¡¢¾åµ¤Æ»¤«¤é¤Î¤ß¤ÎºÎ¼è¤È¤Ê¤Ã¤Æ¤¤¤ë¤È¤³¤í¤«¤é¡¢ÇÙÁÈ¿¥¤Ë¤È¤É¤Þ¤Ã¤Æ¤¤¤ëD225GÊѰۤΥ¦¥¤¥ë¥¹¤¬¡¢È¯¸«¤µ¤ì¤Ë¤¯¤¤¾õÂ֤Ǥ¢¤ê¡¢¸½ºßȯ¸«¤µ¤ì¤Æ¤¤¤ë°Ê¾å¤ÎD225GÊѰۥ¦¥¤¥ë¥¹¤¬¡¢À¤³¦Ãæ¤ËÌ¢±ä¤·¤Æ¤¤¤ë²ÄǽÀ¤¬¤¢¤ë¤³¤È¡¢¤½¤·¤Æ¡¢¤½¤ì¤ËÂФ¹¤ë¥ï¥¯¥Á¥ó¤¬¡¢D225GÊѰۡ¦D225EÊѰۡ¦D225NÊѰۥ¦¥¤¥ë¥¹¤ËÂФ·¤Æ¤Ï¡¢¥ï¥¯¥Á¥óÉÔÁ´¤Ç¤¢¤ë¡¢¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£
¡ÖWHO Silence on D225G Vaccine Mismatch Confuses Media ¡×¤Ç¤Ï¡¢
¡Ö4ÇÜÎ̤Υ說¥Á¥ó¤òÀܼ路¤Ê¤±¤ì¤Ð¡¢¥¿¥¤¥¿¡¼(ÎϲÁ¡Ë¤¬Áý²Ã¤·¤Ê¤¤¤È¤¤¤¦¤³¤È¤Ï¡¢¡Ø¥ï¥¯¥Á¥ó¤Î¥ß¥¹¥Þ¥Ã¥Á¡Ù¤È¤â¤¤¤¨¡¢¤³¤Î¥ï¥¯¥Á¥óÀܼï¤Ë¤è¤Ã¤Æ¤Ï¡¢¥¿¥¤¥¿¡¼¤ò¸º¾¯¤µ¤»¤ë¿·¤¿¤ÊÊѰۤò¸º¾¯¤¹¤ë¤³¤È¤Ë¤Ï¤Ä¤Ê¤¬¤é¤Ê¤¤¤¬¡¢ÌîÀ¸¥¿¥¤¥×¤ÎÊѰۥ¦¥¤¥ë¥¹¤Î¤ß¤ò¸º¾¯¤µ¤»¤ë¤³¤È¤Ë¤Ä¤Ê¤¬¤ë¡£¤½¤Î·ë²Ì¡¢¥ß¥¹¥Þ¥Ã¥Á¤·¤¿¥ï¥¯¥Á¥ó¤ò³¤±¤Æ»È¤Ã¤Æ¤¤¤¯¤È¡¢¥ï¥¯¥Á¥óÂÑÀ¥¦¥¤¥ë¥¹¤ÎÁý²Ã¤òÀ¸¤à¤³¤È¤Ë¤Ê¤ë¡£¡×
¤È¤·¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢¥Õ¥é¥ó¥¹¤«¤é¤ÎÊóÆ»¤Ç¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¤Î¥ï¥¯¥Á¥ó¤Ç¤Ê¤±¤ì¤Ð¡¢¥¿¥¤¥¿¡¼(ÎϲÁ¡Ë¤¬Áý²Ã¤·¤Ê¤¤¤È¤ÎÉ÷À⤬ή¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¢¤ë¡£
(” Ces nouvelles mutations doivent au contraire inciter tous les Fran½æMais ½æA aller se faire vacciner, avec adjuvant.”¡Ö¤³¤ì¤é¤ÎÊѰۤϡ£µÕ¤Ë¡¢¤¹¤Ù¤Æ¤Î¥Õ¥é¥ó¥¹¿Í¤ò¤·¤Æ¡¢¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥óÀÜ¼ï¤Ø¤È¡¢¸þ¤«¤ï¤»¤ë¡£¡×¡Ö“Ces mutations du virus H1N1 doivent ½æStre prises tr½æQs au s½æPrieux “¡×¤è¤ê)
D225GÊѰۥ¦¥¤¥ë¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤ì¤Þ¤Ç¤Î¥¦¥¯¥é¥¤¥Ê¡¢¥Î¥ë¥¦¥§¥¤¡¢¹á¹Á¤Ë³¤¤¤Æ¡¢¥Õ¥é¥ó¥¹¤Ç¤â¡¢Æ±ÍͤÎÊѰۥ¦¥¤¥ë¥¹¤¬³Îǧ¤µ¤ì¤¿¡£
¥Õ¥é¥ó¥¹¤Ç¤ÎD225GÊѰۥ¦¥¤¥ë¥¹¤òͤ·¤Æ¤¤¤ë´µ¼Ô¤Ï¡¢Æó¿Í¤ª¤ê¡¢¤½¤Î¤¤¤º¤ì¤â½ÅÂ֤Ǥ¢¤ê¡¢¤½¤Î¤¦¤Á¤Î°ì¿Í¤Ë¤Ï¡¢¥¿¥ß¥Õ¥ëÂÑÀ¤¬¸«¤é¤ì¤¿¤È¤¤¤¦¡£
¥Ö¥é¥¸¥ë¤Ç¤âƱ¼ï¤ÎÊѰۥ¦¥¤¥ë¥¹¤¬¡¢¸«¤Ä¤«¤Ã¤Æ¤¤¤ë
»²¹Í
2009ǯ11·î26Æü¤ÎWHO¤Î¥Ð¡¼¥Á¥ã¥ëµ¼Ô²ñ¸«¤Ç¤Î¥¦¥¤¥ë¥¹ÊѰۤ˴ؤ¹¤ëÉôʬȴ¿è
(Transcript of virtual press conference with Kristen Kelleher, Communications Officer for pandemic (H1N1) 2009, and Dr Keiji Fukuda, Special Adviser to the Director-General on Pandemic Influenza, World Health Organization 26 November 2009 )
Dr Keiji Fukuda:
Now the last point that I want to address before I throw it open to questions is that in the last several days we have also seen a lot of reports in the media about a mutation and this was specifically raised because it was Norway which recently reported seeing mutations in three patients who had severe disease.
Since then there have been additional reports of the same mutation being seen in viruses in a number of other countries, such as Brazil, China, Japan, Ukraine and the US [CORRECTION FOR ACCURACY: AND MEXICO].
The question is whether this mutation again suggests that there is a fundamental change going on in viruses out there or whether there is a turn for the worse in terms of the severity.
I think that the answer right now is that we are not sure .
I want to answer why we are not sure in a way which explains why more investigations are needed .
As you know these influenza viruses change frequently.
Their gene properties change because these are viruses which frequently undergo mutations and so mutations in and of themselves are not necessarily important and in fact, if every mutation was reported out there, it would be like reporting changes in the weather - saying that there is a temperature difference of one degree one hour and then an hour later, saying there is a temperature increase or decrease of one¡¡degree .
This kind of information does not really help anybody.
But, what we try to do when we see reports of mutations is to identify whether these mutations are leading to any kind of changes in the clinical picture - do they cause more severe disease or less severe disease and also we try to look at whether these viruses are increasing out there, suggesting that there may be a change in the epidemiology .
With this particular mutation we have seen that it is reported in people who have severe disease and we have also seen that it is also been reported in people who have milder disease.
Right now one of the questions is, is it really associated with severe disease more often.
The second point that though, is are these viruses becoming more common or are they relatively infrequent.
So again, this requires looking at more viruses over time to get a sense of whether there is a change in the overall prevalence or number of these viruses.
It is these kinds of investigations which require time and it is these kinds of questions which have to be answered before we can fully talk about the importance of one mutation or another mutation.
»²¹Í¡¡225¥Ý¥¸¥·¥ç¥ó¤Ç¤ÎÊѰ۰ìÍ÷
RPKVRD QEGRI,>A/Kansas/UR06-0068/2007(H1N1)
RPKVRG QAGRI,>A/Index/1977(H1N1)
RPKVRD QSGRM,>A/Denver/1957(H1N1)
RPKVRD QAGRM,>A/Index/early human
RPKVRD QAGRM,>A/Brevig Mission/1/1918(H1N1)
RPKVRG QAGRM,>A/Index/early swine
RPKVRG QAGRM,>A/swine/Jamesburg/1942(H1N1)
RPKVRG QAGRM,>A/New Jersey/1976(H1N1)
RPKVRD QEGRM,>A/******/index/2009/02/01
RPKVRG QEGRI,>A/Taiwan/01/1986///
RPKVRG QEGRI,>A/Beijing/262/1995///
RPKVRD QEGRI,>A/New Caledonia/20/1999///
RPKVRD QEGRI,>A/Solomon Islands/3/2006/08/21/
RPKVRD QEGRI,>A/Brisbane/59/2007/07/01/
RPKVRE QAGRM,>A/swine/Germany/2/1981(H1N1)=1578
RPKVRD QAGR-,>A/******-match/1-2/07(H3N2)
RPKVRD QPGRM,>A/UK/1/1933(H1N1)
RPKVRD QAGRM,>A/Puerto Rico/8-1/1934(H1N1)
RPKVRG QEGRI,>A/Texas/36/1991(H1N1)
RPKVRN QEGRI,>A/Chile/1/1983(H1N1)
¡ÖOne of the D225G cases is a low reactor? ¡×¤è¤ê
»²¹Í
¡ÖWHO Confirms That The H1N1 Swine Flu Has Mutated In Ukraine – But That We Should Not Worry ¡×
D225GÊѰ۴ØÏ¢¥Ó¥Ç¥ª
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢2,950±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/26 Thursday
2009/11/26(Thu)
¡¡
ÀÖ¾¾¹Î´ÇÀÁ꤬¡¢º£Æü¡¢£±£±·î£²£¶Æü¤Î½©Åĸ©Âç³ã¼¤Î»ë»¡¤Ë¤ª¤¤¤Æ¡¢¡ÖÂç³ã¼¤Ï¹ñ¤ÎÀ¯ºö¤ËËÝÏ®¤µ¤ì¡¢¶ìÏ«¤µ¤ì¤Æ¤¤¿¡£¹ñ¤ÎÀÕǤ¤À ¡×¤È¼Õºá¤·¤¿¤È¤¤¤¦¤Î¤Ç¤¹¤¬¡¢ÀÖ¾¾¤µ¤ó¡¢¤Þ¤º°ìÈ֤μպá¤ÎÁê¼ê¤ò´Ö°ã¤Ã¤Æ¤Ï¤¤¤Þ¤»¤ó¤Ç¤·¤ç¤¦¤«?
Âç³ã¼¤Î²áµî¤Î¸ºÈ¿¤ä¤Ö¤ê¤Ç¡¢°ìÈÖÌÂÏǤò¤³¤¦¤à¤Ã¤¿¤Î¤Ï¡¢½©Åĸ©Æâ¤ÎÈóÆþ¿¢¼Ô¤Ç¤¢¤ë°ìÈÌÇÀ²È¤Ê¤Î¤Ç¤¹¡£
¤½¤·¤Æ¡¢¤½¤Î¸ºÈ¿Çˤê¤Î¤½¤Î¤Ä¤É¡¢¸©Æâ¸ºÈ¿Ä´À°¤ä¸©´Ö¸ºÈ¿Ä´À°(ÅÔÆ»Éܸ©´ÖÄ´À°)¤Ç¡¢°ìÈÖ¸ª¿È¤Î¶¹¤¤»×¤¤¤ò¤·¤¿¤Î¤â¡¢¸©Æâ°ìÈÌÇÀ²È¤Ê¤Î¤Ç¤¹¡£
¤ª¤½¤é¤¯¡¢Âç³ã¼¤Î¸©ÆâÆþ¿¢¼Ô¤â¤½¤¦¤À¤Ã¤¿¤Ë°ã¤¤¤¢¤ê¤Þ¤»¤ó¡£
¤Ê¤¼¤Ê¤é¡¢¸©Æâ¤Ë¤¢¤ë¼«Ê¬¤Î½Ð¿È¤Î¼¤Ç¤Ï¡¢¸ºÈ¿½ç¼é¤·¤Æ¤¤¤ë¤Î¤Ë¡¢¼«Ê¬¤¬¸©ÆâÆþ¿¢¤·¤¿Âç³ã¼¤Ç¤Ï¡¢Æ²¡¹¤È¸ºÈ¿Çˤê¤ò¤·¤Æ¤¤¤¿¤ó¤Ç¤¹¤«¤é¡£
¤Ç¤¹¤«¤é¡¢¤â¤·¡¢¡Ö¹ñ¤ÎÀ¯ºö¤ËËÝÏ®¡×¤µ¤ì¤¿¤È¤·¤Æ¡¢¼Õ¤ë¤Î¤Ç¤¢¤ì¤Ð¡¢Âç³ã¼¤è¤ê¤âÀè¤Ë¡¢½©Åĸ©Æâ°ìÈÌÇÀ²È¤ËÀè¤Ë¼Õ¤ë¤Î¤¬¶Ú¤Ã¤Æ¤â¤ó¤Ç¤Ï¤Ê¤¤¤Ç¤·¤ç¤¦¤«¡£
¤Ê¤¼¤Ê¤é¡¢Âç³ã¼¤Ë¤â¡¢½ç¼éÇÉ(¸ºÈ¿½ç¼éÇÉ)¤â¤¤¤¿¤·¡¢Èà¤é¤Î¤è¤¦¤ÊÈó½ç¼éÇÉ(¥ä¥ßÊÆÇÉ¡á²á¾êºîÉÕ¤±ÇÉ)¤â¤¤¤¿¤ï¤±¤Ç¤¹¤«¤é¡¢Èó½ç¼éÇɤΤ«¤¿¤¬¤¿¤Ï¡¢¤½¤ÎÅö»þ¡¢¸ºÈ¿¤ò¼é¤é¤Ê¤¤¤³¤È¤Ë¤è¤ê¡¢°ìÄê¤Îµ¡²ñÍø±×¤òÆÀ¤Æ¤¤¤¿¤Ï¤º¤Ê¤Î¤Ç¤¹¤«¤é¡£
¤Ç¤¹¤«¤é¡¢¤³¤ÎÏÀÍý¤Ç¤¹¤È¡¢Åö»þ¤Î¥ä¥ßÊÆÇɤˤϡ¢¤³¤Î»þÅÀ¤Ç¥³¥ó¥×¥é¥¤¥¢¥ó¥¹°ãÈ¿¤ò¤·¤Æ¤¤¤¿¤ï¤±¤Ç¤¹¤«¤é¡¢¹ñ¤ÎÉÔºî°Ù¤ÏÌ䤨¤Þ¤»¤ó¤¬¡¢Åö»þ¡¢¸ºÈ¿¤ò½å¼é¤·¤Æ¤¤¤¿ÇÀ̱¤Ë¤Ï¡¢¹ñ¤ÎÉÔºî°Ù¤òÌ䤦¸¢Íø¤¬¤¢¤ë¤È¤¤¤¦¤³¤È¤Ë¤Ê¤Ã¤Æ¤·¤Þ¤¤¤Þ¤¹¤è¡£
¤½¤ì¤Ç¤¤¤¤¤Î¤Ç¤¹¤«?
Åö»þ¤Î½ç¼éÇɤϡ¢º£Æü¤ÎÀÖ¾¾È¯¸À¤ò´ð¤Ë¤·¤Æ¡¢¹ñÇåÁʾ٤˻ý¤Á¹þ¤ß¤Þ¤¹¤è¡£
ÀÖ¾¾¹Î´ÇÀÁê¤Ï¡¢ÌÀ¤é¤«¤Ë¡¢¼Õ¤ë½ç½ø¤ò´Ö°ã¤¨¤Æ¤¤¤ë¤È¤·¤«¤¤¤¨¤Þ¤»¤ó¡£
¤³¤ì¤Ç¤Ï¡¢¤Þ¤µ¤Ë¡¢¡ØÀµÄ¾¼Ô¤¬Çϼ¯¤ò¸«¤ë¡Ù¤Î¹½¿Þ¤Ç¤¹¡£
¤Þ¤ë¤Ç¡¢ÀïÁè¤Î³«ÀÇÔÀï¤ÎÀÕǤ¤ò¡¢½¾·³Ê¼¤ËÂФ·¤Æ¤Ç¤Ê¤¯¡¢¤Þ¤º¡¢Æ¨Ë´Ê¼¤ËÂФ·¤Æ¡¢¤ªÏÍ¤Ó¤ÇÆ¬¤ò²¼¤²¤Æ¤¤¤ë¤Î¤È¡¢¤ª¤ó¤Ê¤¸¹½¿Þ¤Ç¤¹¡£
º£²ó¤Î¼«¼çºîÉÕ¤±ÇɤθÍÊ̽êÆÀÊä½þ¤Ë¤«¤±¤ë»×ÏǤʤɤˤĤ¤¤Æ¤Ï¡¢¤³¤ÎÅÚÌç¹ä¤µ¤ó¤Î¥µ¥¤¥È¡Ø¸ºÈ¿ÇËþ¤Î¾ÝħŪÉñÂæ¤È¤Ê¤ë¤«Âç³ã¼(¸ºÈ¿Êä½õ¶â¤Ç¼Ú¶â¥Á¥ã¥éºîÀï) ¡Ù¤Ê¤ó¤«¤ò¸«¤ë¤È¤è¤¯¤ï¤«¤Ã¤Æ¤¯¤ë¤«¤â¤·¤ì¤Þ¤»¤ó¡£
¤Ä¤Þ¤ê¡¢Âç³ã¼¤Î¼«¼çºîÉÕ¤±ÇɤˤȤäơ¢¶á»þ¤Î¥³¥áÈÎÇä´Ä¶¤ÎÊѲ½¤Ç¡¢¤³¤ì¤Þ¤Ç¥³¥ó¥×¥é¥¤¥¢¥ó¥¹°ãÈ¿¤Ç¥¹¥¥ß¥ó¥°¤·¤Æ¤¤¿¤è¤¦¤ÊÍ¥°Ì¤ÊÈÎÇäÀïά¹½ÃÛ¤¬Æñ¤·¤¯¤Ê¤Ã¤Æ¤¤Æ¤¤¤ëÃæ¤Ç¡¢¤³¤³¤Ç¸ºÈ¿½å¼éÀë¸À¤ò¤·¡¢¸ÍÊ̽êÆÀÊä½þ¥¹¥¡¼¥à¤Ë¤Ê¤À¤ì¹þ¤à¤³¤È¤Ë¤è¤Ã¤Æ¡¢¼«¼çºîÉÕ¤±Ï©Àþ¤Îž´¹¡¦Å±ÂàÈñÍѤθ¶»ñ¤È¤·¤Æ¡¢¸ÍÊ̽êÆÀÊä½þ¥¹¥¡¼¥à¤òÎßÀÑÉéºÄÀ°Íý¤Î¥Ä¡¼¥ë¤È¤·¤ÆÍøÍѤ·¤è¤¦¤È¤·¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ä¤¤¤Æ¤Îµ¿¿´°Åµ´¤¬¡¢¸©Æâ°ìÈÌÇÀ²È¤ÎÃæ¤Ë¤Ï¤¢¤ë¤È¤¤¤¦¤³¤È¤Ç¤¹¤Í¡£
¤³¤Î¤«¤®¤ê¤Ë¤ª¤¤¤Æ¡¢¸©Æâ°ìÈÌÇÀ²È¤Ï¡¢¤Þ¤¿¤·¤Æ¤â¡¢Èà¤é¤ÎƧ¤ßÂæ¤Ë¤µ¤ì¤Æ¤·¤Þ¤¦¤È¤¤¤¦¤ï¤±¤Ç¤¹¡£
¤¿¤È¤¨¤Æ¸À¤¨¤Ð¡¢¤³¤ó¤Ê¤È¤³¤í¤Ç¤·¤ç¤¦¤«¤Í?
¡Ö¥Þ¥ó¥·¥ç¥ó¤Î´ÉÍýÁȹ礬¡¢¥Þ¥ó¥·¥ç¥ó´ÉÍýÈñ¤òʧ¤Ã¤Æ¤¤¤ëÆþµï¼Ô¤Ë¸Â¤Ã¤Æ¡¢¤³¤ì¤«¤é¡¢´ÉÍýÈñ¤òÂçÉý¤ËÃͲ¼¤²¤¹¤ë¤È·èÄꤷ¤¿¤È¤¿¤ó¤Ë¡¢¤³¤ì¤Þ¤Ç¡¢¥Þ¥ó¥·¥ç¥ó´ÉÍýÁȹç¤Ë´ÉÍýÈñ¤òʧ¤Ã¤Æ¤³¤Ê¤«¤Ã¤¿ÉÔÎÉÆþµï¼Ô¤¬¡¢¤³¤ì¤«¤é¤Ï¡¢´ÉÍýÈñ¤ò¤Ï¤é¤¤¤Þ¤¹¤è¡¢¤È¤¤¤Ã¤Æ¡¢µÞ¤ËÂÖÅÙ¤òÊѲ½¤µ¤»¤Æ¡¢´ÉÍýÁȹç¤ËÆþ²ñ¤·¤Æ¤¤¿¡£¤¸¤ã¤¢¡¢¤³¤ì¤Þ¤Ç¤ÎÂÚǼ¤·¤Æ¤¤¿ÉÔÎÉÆþµï¼Ô¤ÎÂÚǼ´ÉÍýÈñÎßÀÑʬ¤Ï¡¢ÍøÂ©Ê¬¤â´Þ¤á¤Æ¡¢¤³¤³¤Ç¡¢¥Á¥ã¥é¤Ë¤·¤Æ¤·¤Þ¤¦¤Î?¡×
¤Ã¤Æ¤¤¤¦´¶¤¸¤Ç¤·¤ç¤¦¤«¡£
¡Ö¥Þ¥ó¥·¥ç¥ó¤Î½¤Á¶ÀÑΩ¶â¤ÎÉÔÂʬ¤Ï¡¢¤³¤ì¤Þ¤Ç¡¢»Ä¤ê¤ÎÆþµï¼Ô¤ÎÉéôʬ¤Ç¤Þ¤«¤Ê¤Ã¤Æ¤¤¿¤Î¤Ë¡£¡×¤Ã¤Æ¸À¤¦¤Î¤¬¡¢¤³¤ì¤Þ¤Ç¸ºÈ¿½å¼é¤·¤Æ¤¤¿½©Åĸ©Æâ°ìÈÌÇÀ²È¤Î¸À¤¤Ê¬¤È¤Ê¤ë¤Î¤Ç¤·¤ç¤¦¡£
¤À¤ó¤À¤ó¡¢Åܤ꤬¤³¤ß¾å¤²¤Æ¤¤Æ¤¤¤Þ¤¹¡£
¤ª¤½¤é¤¯¡¢½©Åĸ©Æâ°ìÈÌÇÀ²È¤â¡¢Âç³ã¼¤Î½ç¼éÇɤΤ«¤¿¤¬¤¿¤â¡¢Æ±¤¸µ¤»ý¤Á¤Ç¤·¤ç¤¦¡£
Äɵ¡¡£²£°£°£¹Ç¯£±£²·î9Æü¡¡¼«¤é¿Ê¤ó¤Ç½©Åĸ©°ìÈÌÇÀ̱¤Î¿´¤ÎÃæ¤Ë¤¢¤ë¥È¥é¤ÎÈø¤òƧ¤ó¤Ç¤·¤Þ¤Ã¤Æ¤¤¤ëÀÖ¾¾ÇÀÁê
ºòÆü¡¢ÀÖ¾¾ÇÀÁê¤Ï¡¢µ¼Ô²ñ¸«¤Ç¡¢¡Ø½©Åĸ©¤ò¸ÍÊ̽êÆÀÊä½þ¤ÎÂоݤ«¤é¤Ï¤º¤¹¡Ù¤È¤Î¶Ú°ã¤¤È¯¸À¤ò¤µ¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¹¡£
ÀÖ¾¾¤µ¤ó¤Ï¡¢¾åµ¤ÎÂç³ã¼¤Ç¤Î¼«¤é¤Î·ÚΨ¤Êȯ¸À¤Ç¡¢¤¤¤Ã¤¿¤ó¤ÏÉõ°õ¤µ¤ì¤«¤±¤¿¥Ñ¥ó¥É¥é¤ÎÈ¢¤ò¼«¤é·ÚΨ¤Ë³«¤±¡¢½©Åĸ©°ìÈÌÇÀ̱¤Î˺¤ì¤«¤±¤Æ¤¤¤¿¥ä¥ßÊÆÇɤȤβáµî¤Î¸©Æâ³Î¼¹¤ò¤Õ¤¿¤¿¤Ó»×¤¤½Ð¤µ¤»¡¢¼«¤é¡¢»öÂÖ¤ò¤ä¤ä¤³¤·¤¯¤µ¤ì¤Æ¤¤¤ë¤³¤È¤Ë¡¢¤Þ¤À¡¢¤ªµ¤¤Å¤¤Ç¤Ê¤¤¤é¤·¤¤¤Î¤Ç¤¹¤¬¡£
°Ê²¼¤Ï¡¢ºòÆü¤ÎÂç¿Ãȯ¸À¤ÎÆâÍÆ¤Ç¤¹¡£(¤Á¤ç¤Ã¤È¡¢¼è¤êα¤á¤Î¤Ê¤¤»¨ÃÌÄ´¤Ê¤Î¤Ç¡¢ÆÉ¤ß¤Å¤é¤¤¤Î¤Ç¤¹¤¬¡£¤È¤¯¤Ë”¤¢¤ì”¤È¤¤¤¦¸ÀÍÕ¤¬¤ª¹¥¤¤Î¤è¤¦¤Ç¡¢¤³¤ÎÆü¤Îµ¼Ô²ñ¸«¤Ç¤â¡¢£±£³²ó¤âϢȯ¤µ¤ì¤Æ¤¤¤Þ¤¹¤Í¡£
¸½ºß¤Î¥Ú¥Ê¥ë¥Æ¥£¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È¡ÖÇÀÀ¯²þ³×»°Âкö¤ÎÃå¼Â¤Ê¿ä¿Ê¤Ë¤Ä¤¤¤Æ¡× ¤´»²¾È)
¡Öº£Æü¤Ï¡¢¤Á¤ç¤Ã¤È»þ´Ö¤¬¤¢¤ë¤ó¤Ç¤æ¤Ã¤¯¤êÏä·¤Þ¤¹¤¬¡¢
Î㤨¤Ð¡¢¤³¤Î´Ö¡¢Âç³ã¼¤Ø¹Ô¤Ã¤Æ¤¤¿¤È¡¢
¤½¤¦¤¹¤ë¤È¡¢Âç³ã¼¤Ç¡¢¤¢¤ì¤À¤±È¿Ìܤ·¹ç¤Ã¤Æ¤¤¤¿¿Í¤¿¤Á¤¬¡¢º£¡¢ËÜÅö¤ËÃçÎɤ¯¤Ê¤Ã¤Æ¡¢º£¤Þ¤Ç¡¢¸ºÈ¿¤ä¤Ã¤Æ¤¤¿¿Í¡¢È¿ÂФ·¤Æ¤¤¿¿Í¡¢¤½¤ì¤¬ËÜÅö¤Ë°ì¤Ä¤Ë¤Ê¤Ã¤Æ¡¢¤³¤ì¤òµ¡²ñ¤Ëϲò¤·¤Æ¡¢¤ß¤ó¤Ê¤Ç¤¤¤¤Âç³ã¼¤òºî¤í¤¦¤È¤¤¤¦¤³¤È¤Ç¤Ê¤Ã¤Æ¤¤¤ë¤ó¤Ç¤¹¤Í¡£
¤È¤³¤í¤¬¡¢¸©¤ÎÃλö¤äÇÀÀ¯Éô¤¢¤¿¤ê¤Î¡¢¤½¤¦¤¤¤¦ÃÏÊý¤Î´´Éô¤¬Íý²ò¤·¤Æ¤Ê¤¤¤È¡¢
º£¡¢²¿¤ò¸À¤Ã¤Æ¤¤¤ë¤«¤È¤¤¤¦¤È¡¢¡Ö¤¤¤ä¤¤¤ä¡¢¤½¤ó¤Ê¤ȿ¤·¤Æ¤¤¿¡¢¤¢¤ì¤ä¤Ã¤Æ¤¤¿¤ä¤Ä¤ÏÂÌÌܤÀ¡× ¤È¡¢
ÆÃ¤Ë¼«Ì±Åޤθ©µÄ²ñ²¿¤«¡¢¡Ö¤¢¤ó¤ÊͰ°æ(Ű)¤ß¤¿¤¤¤Ê¤ä¤Äµö¤»¤ë¤«¡× ¤È¡¢¡Ö¤¢¤ó¤Ê¼Ô¤Ïº£¤Þ¤Ç¤É¤ª¤ê¡¢³ä¤êÅö¤Æ¤Ï30¥Ñ¡¼¥»¥ó¥È¤À¡× ¤Ê¤ó¤Æ¤¤¤¦¤³¤È¤ò¡¢Ê¿µ¤¤Ç¸À¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤¹¡£
¤¸¤ã¤¢¡¢30¥Ñ¡¼¥»¥ó¥È¤Ç¡¢¤¸¤ã¤¢¡¢Í°°æ¤µ¤ó¤Ë¤ä¤ì¤È¸À¤Ã¤¿¤Ã¤Æ¡¢º£¤Þ¤Ç¤Ïºî¤é¤Ê¤¤30¥Ñ¡¼¥»¥ó¥È¤À¤«¤é¡¢¤½¤ó¤Ê¤â¤Î¤Ï¡¢10¥Ñ¡¼¥»¥ó¥È¤À¤Ã¤Æ¤Ê¤ó¤À¤Ã¤Æ¡¢´Ø·¸¤Ê¤¤¤ó¤À¤±¤É¤â¡¢º£Å٤Ϸè¤á¤é¤ì¤¿À¸»º¿ôÎÌÌÜɸ¤ò¼é¤ë¤È¸À¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤¹¤«¤é¡¢¼é¤ë¤¿¤á¤Ë¤Ï¡¢ºÎ»»¤ò¹ç¤ï¤»¤è¤¦¤È»×¤Ã¤¿¤é¡¢¤³¤ì¤Ï¡¢¤Þ¤¢¡¢Á´Éô¡¢º£¤Þ¤Ç¡¢Ï»½½²¿¤È¤«¤Þ¤Ç¤Ï¤¤¤«¤Ê¤¤¤Ë¤·¤Æ¤â ¡¢¾¯¤Ê¤¯¤È¤â¡¢¤³¤ì¤Ï¤â¤¦¡¢Î¾Êý¤Ë¸À¤Ã¤Æ¤¤¤ë¤Î¤Ç¤¹¤±¤ì¤É¤â¡¢º£¤Þ¤Ç¡¢¤¢¤ó¤¿¡¢¿Í¤Î¤¢¤ì¤ò¤«¤µ¾å¤²¤·¤Æ¡¢¤¿¤¯¤µ¤ó¤â¤é¤¤¤¹¤®¤Æ¤¤¤¿¤ó¤À¤«¤é¡¢ ¤³¤ì¤Ï¡¢¤Á¤ã¤ó¤È¸º¤é¤¹¤Î¤Ç¡¢¸º¤ê¤Þ¤¹¤è¤È¡¢
¤·¤«¤·¡¢¤¢¤Ê¤¿¤â¡¢°ì¤Ú¤ó¤Ë¡¢¤ß¤ó¤Ê¤È°ì½ï¤È¤¤¤¦¤ï¤±¤Ë¤Ï¤¤¤«¤Ê¤¤¤«¤é¡¢¤¤¤í¤¤¤í¤Ê·Ð°Þ¤â¤¢¤ë¤Î¤À¤«¤é¡¢¤Þ¤¢¡¢¤½¤³¤½¤³¤Î¤È¤³¤í¤Ç²æËý¤·¤Ê¤µ¤¤¤è¤È¤¤¤¦¤³¤È¤ò ¡¢Ëͤϡ¢¸½ÃϤǸÀ¤Ã¤Æ¤¤¿¤Î¤Ç¤¹¤±¤ì¤É¤â¡¢
¤·¤«¤·¡¢¤½¤¦¤¤¤¦¤³¤È¤¬¼é¤é¤ì¤º¤Ë ¡¢¥Ú¥Ê¥ë¥Æ¥£¡¼¤Ï¤Ê¤·¤À¤È¤¤¤¦¤Î¤¬¡¢¤³¤ÎÂçÊý¿Ë¤Ç¤¹¤«¤é¡¢¥Ú¥Ê¥ë¥Æ¥£¡¼¤Ï¤³¤ì¤«¤é¤â¤ä¤Ã¤Æ¤¤¤¯¤ó¤À¤ß¤¿¤¤¤Ê¤³¤È¤ò¡¢¾¡¼ê¤Ë¡¢ÃÏÊý¤Î¤½¤¦¤¤¤¦¿Í¤¿¤Á¤¬¸À¤Ã¤Æ¤¤¤ë¤È ¡¢
¤Þ¤º¡¢¸©Á´ÂΤǡ¢Âç³ã¼¤ò¡¢¤Þ¤ºº¹¤òÉÕ¤±¤Æ¡¢Âç³ã¼¤ÎÃæ¤Ç¡¢¤Þ¤¿º¹¤òÉÕ¤±¤Æ¡¢¤ªÁ°¤ÏÍè¤Ê¤¤¤è¤¦¤Ë¤ä¤ë¤ó¤À¤ß¤¿¤¤¤Ê¤³¤È¤ò¤ä¤Ã¤Æ¤¤¤ë¤³¤È¤¬¤¢¤ë¤â¤Î¤Ç¤¹¤«¤é ¡¢
¤³¤ì¤Ï¡¢8Æü¤Ã¤Æº£Æü¤À¤Ã¤±¡£
º£Æü¡¢Ã´Åö¤ÎÀÕǤ¼Ô¤ò¸½ÃϤ˹Ԥ«¤»¤Æ¡¢¤â¤·¤â¡¢¤½¤ó¤Ê¤Õ¤¦¤Ç¤ä¤ë¤ó¤À¤Ã¤¿¤é¡¢½©Åĸ©Á´ÂΤò¡¢¤½¤ÎÂоݤ«¤é³°¤·¤Þ¤¹ ¤è¤È¡¢
À¸»º¿ôÎÌÌÜɸ¤ò¼é¤ë¿Í¤¿¤Á¤â´Þ¤á¤Æ¡¢Á´Éô¡¢¸©Á´ÂΤ¬¡¢ºÇ½é¤«¤é³ä¤êÅö¤Æ¡¢°ã¤¦Êý¸þ¤Ç¤ä¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤¹¤«¤é¡¢¤³¤ì¤ÏˡΧ°ãÈ¿¤À¤«¤é¡¢¤ä¤í¤¦¤È¡¢¤Þ¤À·è¤Þ¤Ã¤¿¤ï¤±¤¸¤ã¤Ê¤¤¡¢¤ä¤í¤¦¤È¤·¤¿¤È¤·¤¿¤é¡¢¤³¤ì¤ÏˡΧ°ãÈ¿¤Ë¤Ê¤ë¤ó¤Ç¡¢¤½¤¦¤¤¤¦¤³¤È¤â¤¢¤êÆÀ¤Þ¤¹¤è¤È¤¤¤¦¤³¤È¤ò ¡¢Âç¿Ã¤Î°Õ»×¤À¤È¸À¤Ã¤Æ¡¢¤Ï¤Ã¤¤ê¸À¤Ã¤Æ¤³¤¤¤È¸À¤Ã¤Æ¤ª¤¤Þ¤·¤¿¡£
¤Þ¤¢¡¢Íý²ò¤ò¤·¤Æ¤¤¤¿¤À¤±¤ì¤Ð·ë²Ì¤È¤·¤Æ¤½¤¦¤Ê¤é¤Ê¤¤¤È»×¤¤¤Þ¤¹¤¬¡¢¤Þ¤À¤Þ¤À¡¢ÃÏÊý¤Ø¹Ô¤¯¤È¡¢»þÂ夬ÊѤï¤Ã¤¿¤È¡¢¤â¤¦º£¤Þ¤Ç¤Î»ÅÁȤߤϡ¢É´È¬½½Åٰ㤦¤ó¤À¤È¤¤¤¦¤³¤È¤òÍý²ò¤·¤Æ¤¤¤Ê¤¤¿Í¤Ï¡¢»Äǰ¤Ê¤¬¤é¡¢¤Þ¤À¤¤¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢¤½¤ÎÊդμñ»Ý¤ò¡¢¤¤Á¤Ã¤ÈÍý²ò¤·¤Æ¤â¤é¤¨¤ë¤è¤¦¤Ë¤ä¤Ã¤Æ¤¤¤¯¤È¤¤¤¦¤³¤È¤¬¡¢»ä¤ÏɬÍפÀ¤È»×¤Ã¤Æ¤Þ¤¹¡£
¤À¤«¤é¡¢¤³¤ì¤«¤é¤¬¡¢¤à¤·¤í¡¢ÂçÊѤÀ¤Ê¤È»×¤Ã¤Æ¤¤¤Þ¤¹¤¬¤Í¡£¡×
http://www.maff.go.jp/j/press-conf/min/091208.html
Äɵ¡¡¸½ºß¤Î¥Ú¥Ê¥ë¥Æ¥£¤ÎÁ¼Ã֤γµÍ×
ÌÜɸ̤ãÀ®¤ÎÅÔÆ»Éܸ©¡¦Ãϰ衦ÇÀ¶È¼Ô¤Ø¤ÎÂнè¡Ê ¥Ú¥Ê¥ë¥Æ¥£¡Ë
¡Ê £± ¡Ë ÌÜɸ¤òãÀ®¤·¤¿¤«¤É¤¦¤«¤Ï¡¢Åö³ºÃϰèÁ´ÂΤȤ·¤Æ¤Î¼ç¿©ÍѺîÉÕÌÌÀÑ¡Ê Á´¿å°ðºîÉÕÌÌÀѤ«¤é²Ã¹©ÍÑÊÆ¡¦¿·µ¬¼ûÍ×ÊÆ¤ÎºîÉÕÌÌÀѤò¹µ½ü¤·¤¿¤â¤Î¡Ë ¤ÇȽÄꤹ¤ë¤³¤È¤ò´ðËܤȤ¹¤ë¡Ê ºî¶·¤Ë¤è¤ëÀ¸»º¥ª¡¼¥Ð¡¼¤¬È¯À¸¤·¤¿¾ì¹ç¤Ï¡¢½¸²Ù±ß³ê²½ÂкöÅù¤ÇÂбþ¡Ë¡£
¤¿¤À¤·¡¢Åö³ºÃϰèÁ´ÂΤȤ·¤Æ¤Î¼ç¿©ÍÑÈÎÇä¿ôÎÌ¡Ê Áí¼ý³ÏÎ̤«¤é¤¯¤ºÊÆ¡¦²Ã¹©ÍÑÊÆ¡¦¿·µ¬¼ûÍ×ÊÆ¡¦¶èʬ½Ð²ÙÊÆ¤ÎÈÎÇäͽÄê¿ôÎ̤ò¹µ½ü¤·¤¿¤â¤Î¡Ë ¤¬À¸»º¿ôÎÌÌÜɸ¤ÎÈÏ°ÏÆâ¤È¤Ê¤Ã¤Æ¤¤¤ë¾ì¹ç¤âãÀ®¤È¤¹¤ë¡£
¡Ê £² ¡Ë £² £° ǯ»º¤ÎÀ¸»ºÄ´À°¤¬ÌÜɸ̤ã¤È¤Ê¤Ã¤¿ÅÔÆ»Éܸ©¡¦Ãϰè¤Ë¤Ä¤¤¤Æ¤Ï¡¢
¡ £² £° ǯ»º¤Î»ºÃϤŤ¯¤êÂкö¤¬¡¢Í½ÄêÄ̤ê¸òÉÕ¤µ¤ì¤Ê¤¤¤³¤È¤¬¤¢¤êÆÀ¤ë¡£
¢ £² £± ǯ»º¤Î³Æ¼ïÊä½õ»ö¶È¡¦Í»»ñ¤Ë¤Ä¤¤¤Æ¡¢ÉÔÍø¤Ê¼è°·¤¤¤ò¼õ¤±¤ë¤³¤È¤¬¤¢¤êÆÀ¤ë¡£
£ £² £± ǯ»º¤Î»ºÃϤŤ¯¤êÂкö¤Ë¤Ä¤¤¤Æ¡¢ÉÔÍø¤Ê¼è°·¤¤¤ò¼õ¤±¤ë¤³¤È¤¬¤¢¤êÆÀ¤ë¡£
¤Ê¤ª¡¢´Ø·¸¼Ô¤ÏÌÜɸ̤ãÀ®¤È¤Ê¤é¤Ê¤¤¤è¤¦Á´ÎϤò¤¢¤²¤ë¤³¤È¤È¤·¡¢Ì¤Ã£¤È¤Ê¤Ã¤¿ÅÔÆ»Éܸ©¡¦Ãϰè¤Î¶ñÂÎŪ¤Ê¼è°·¤¤¤Ë¤Ä¤¤¤Æ¤Ï¡¢£² £° ǯ»º¤ÎÀ¸»ºÄ´À°¤Î¥¹¥Æ¡¼¥¸¤´¤È¤Î¿ä¿Ê¾õ¶·¡¦Ã£À®¾õ¶·Åù¤ò¸«¤Ê¤¬¤é¡¢Å¬Àڤʥ¿¥¤¥ß¥ó¥°¤Ç·èÄꤹ¤ë¡£
¡Ê £³ ¡Ë ǧÄêÇÀ¶È¼Ô¤Ç¤¢¤ë¤³¤È¤¬Í×·ï¤È¤Ê¤Ã¤Æ¤¤¤ëÇÀÎÓµù¶È¶âÍ»¸ø¸Ë¤Î¥¹¡¼¥Ñ¡¼£Ì »ñ¶â¤Ë¤Ä¤¤¤Æ¤Ï¡¢º£¸å¡Ê Ê¿À®£± £¶ ǯ£¸ ·î¤Î¼ÚÍѾڽñÊѹ¹°Ê¹ß¤Î¼ÚÆþ¤ì¤ËŬÍѡˡ¢À¸»ºÄ´À°Èó¼Â»Ü¤È¤Ê¤Ã¤¿¤³¤È¤òÍýͳ¤ËǧÄêÇÀ¶È¼Ô¤ÎǧÄ꤬¼è¤ê¾Ã¤µ¤ì¤¿¾ì¹ç¤Ë¤Ï¡¢·«¾å½þ´Ô¤òµá¤á¤ë¤È¤È¤â¤Ë¡¢ÇÀÎӿ建Ĺ´ü¶âÍ»¶¨²ñ¤«¤é¤ÎÍø»Ò½õÀ®¤ÎÁ¼ÃÖ¤òÄä»ß¤¹¤ë¡£
¥¹¡¼¥Ñ¡¼£Ì »ñ¶â°Ê³°¤ÎÀ¯ºöÍ»»ñ¡¢Í»»ñ»ÄÊä½õ¤ò¤Ï¤¸¤á¤È¤¹¤ë³Æ¼ïÀ¯ºö»Ù±çÁ¼Ã֤ˤĤ¤¤Æ¤Ï¡¢ºÒ³²»ñ¶â¤Ê¤É°ìÄê¤ÎʬÌî¤ò½ü¤¡¢À¸»ºÄ´À°Èó¼Â»Ü¼Ô¤ò¤½¤ÎÂоݤȤ·¤Ê¤¤Êý¸þ¤Ç¸¡Æ¤¤¹¤ë¡£
»²¹Í¡¡»ä¤Î¥Ö¥í¥°µ»ö¤Ë¤ª¤±¤ëÂç³ã¼ÌäÂêµ»ö
¡Ö½©Åĸ©¤Î郎¥Ú¥Ê¥ë¥Æ¥£¤ò²Ê¤¹¤È¤¤¤Ã¤¿¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢·ë¶É¼¨¤»¤Ê¤«¤Ã¤¿¡¢º£Æü¤ÎÀÖ¾¾ÇÀÁêµ¼Ô²ñ¸«¤Î¤ß¤Ã¤È¤â¤Ê¤µ ¡×
¡ÖÀÖ¾¾ÇÀÁê¡Ö½©ÅĤò¸ÍÊ̽êÆÀÊä½þ¤«¤é³°¤¹¡×¥È¥ó¥Ç¥â´ª°ã¤¤È¯¸À¤Î¥½¡¼¥¹¤Ï?¡×
¡ÖÀÖ¾¾ÇÀÁ꤬Âç³ã¼¤Ë¼Õºá¤È¤¤¤¦¤¬¡¢¤ª¤«¤·¤¯¤Í?¡×
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/25 Wednesday
2009/11/25(Wed)
¡¡
°Ê²¼Renho»á¤Î¤Ä¤Ö¤ä¤¤«¤é°úÍÑ
¡ÖºòÆü¡¢ÇÀ¿å¾Ê¤Î¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó¤òôÅö¤¹¤ë¶ÉŤ«¤éºî¶ÈÃæ¤Ë°Õ¸«½ñ¤ò¤¤¤¿¤À¤¤Þ¤·¤¿¡£Ãæ¿È¤Ï»ö¶È»Åʬ¤±¤Ë·¸¤Ã¤¿Ì±´Ö¤Î»Åʬ¤±¿Í¤¬¥¹¡¼¥Ñ¡¼¤Ë̳¤á¤Æ¤¤¤¿¤Î¤Ç¡¢»Åʬ¤±¤Ç¼è¤ê¾å¤²¤¿¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó»ö¶È¤ËÍø³²´Ø·¸¤¬¤¢¤ë¤È¤¤¤¦»ØÅ¦¤Ç¤·¤¿¡£¤Ç¤â¡¢¤³¤ÎÊý¤Ï8ǯÁ°¤ËÂ࿦¤·¤Æ¤¤¤ë¡£
¤½¤Î¸å¡¢¤³¤ÎÊý¤Ï»ÔµÄ²ñµÄ°÷¡¢Éû»ÔŤò·Ð¸³¤µ¤ì¤Æ¤¤¤Þ¤¹¤¬¡¢¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó»ö¶È¤ò»Åʬ¤±¤¹¤ëΩ¾ì¤Ë¤Ê¤¤¤È¤¤¤¦ÇÀ¿å¾Ê²ÝŤλØÅ¦¤Ï¤¢¤Æ¤Ï¤Þ¤é¤Ê¤¤¤Î¤Ç¤Ï¡¢¤È»×¤¦¡£»ö¶È¼«ÂΤ¬ÇѻߤÈȽÃǤµ¤ì¤¿¸å¡¢¤³¤ÎÊý¤Î¤³¤È¤ò¿ïʬĴ¤Ù¤¿¤è¤¦¤Ç¤¹¤¬¡¢¤½¤ÎÎϤò¿·¤¿¤Ê»ö¶È³«ÂóÄ´ºº¤Ë¸þ¤±¤Æ¤Û¤·¤¤¤È¤â»×¤¤¤Þ¤·¤¿¡£
¤¹¤ß¤Þ¤»¤ó¡£°Õ¸«¥Ú¡¼¥Ñ¡¼¤ò¤¤¤¿¤À¤¤¤¿¤Î¤ÏÇÀ¿å¾Ê¶ÉŤǤ¹¡£°ìÉô²ÝĹ¤È½ñ¤¤¤Á¤ã¤¤¤Þ¤·¤¿¡£»ÞÌîÅý³ç¤È¤âÏ䷹礤¡¢¤³¤Î¥Ú¡¼¥Ñ¡¼¤ÏÊóÆ»¿Ø¤Ë¸ø³«¤·¤Þ¤¹¡£¡×
http://twitter.com/renho_sha ¡¡¤è¤ê
°Ê¾å°úÍѽª¤ï¤ê
¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó¤Î»ö¶È»Åʬ¤±·ë²Ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤Î¥µ¥¤¥È ¤´»²¾È
¤Þ¤¢¡¢¤Ä¤Ö¤ä¤¤Ç¤Ï¤¢¤Ã¤Æ¤â¡¢»Åʬ¤±¿Í¤Ç¤¢¤ëRenho»á¤´¼«¿È¤¬¡¢¡¢ÇÀÎӿ建¾Ê¤¬Áä¶Ì¤Ë¤¢¤²¤¿»Åʬ¤±¿Í¤Î¸ÇÍ̾»ì¤òÆÃÄê¤Ç¤¤ë¤è¤¦¤Ê¤Ä¤Ö¤ä¤¤ò¤·¤Æ¤·¤Þ¤¦¤³¤È¤Ï¡¢¤½¤Î¤³¤È¼«ÂΡ¢»Åʬ¤±¿Í¼º³Ê¤È¤â¤ª¤â¤ï¤ì¡¢¤¤¤«¤¬¤Ê¤â¤Î¤«¤È¤Ï¡¢»×¤¤¤Þ¤¹¤¬¤Í¡£
(¤â¤Ã¤È¤â¡¢¡Ö¤Ê¤ê¤¹¤Þ¤·¡×¤Ã¤Æ¤Î¤¬Twitter¤Ë¤¤¤ë¤è¤¦¤Ç¤¹¤Î¤Ç¡¢¤Û¤ó¤â¤Î¤Î¤Ä¤Ö¤ä¤¤«¤É¤¦¤«¤Ï¡¢¤ï¤«¤ê¤Þ¤»¤ó¤¬¡£)
¤È¤¤¤¦¤³¤È¤Ç¡¢Renho»á¤Î¤Ä¤Ö¤ä¤¤Ç¡¢·ë²Ì¡¢ÆÃÄꤵ¤ì¤¿ÏÃÂê¤Î»Åʬ¤±¿Í¤Ç¤¢¤ë»³Æâ·É¤µ¤ó¤Î²áµî¤Î·ÐÎò¤ò¤Ê¤é¤Ù¤Æ¤ß¤ë¤È
1947ǯÀ¸¤Þ¤ì¡£¹âÅç¹âÅù³Ø¹»¤ò·Ð¤Æ¡¢1970ǯ¡¢Áá°ðÅÄÂç³ØÂ裱À¯¼£·ÐºÑ³ØÉô·ÐºÑ³Ø²Ê´¶È¡£1974ǯ¡¢¥¤¥º¥ß¥ä³ô¼°²ñ¼ÒÆþ¼Ò¡Ê°áÎÁÈÎÇä¡¢¹¹ðÀëÅÁôÅö¤ò·Ð¤ÆÅ¹ÊÞ³«È¯¤Ë½¾»ö¡Ë¡£2001ǯ10·î¡Á2004ǯ12·î¡¢º£ÄÅÄ®µÄ²ñµÄ°÷¡£2005ǯ2·î¡Á2005ǯ5·î¡¢¹âÅç»ÔµÄ²ñµÄ°÷¡£2005ǯ5·î¤è¤ê¹âÅç»ÔÉû»ÔĹ
¤È¤¤¤¦¤³¤È¤Ç¡¢¤Þ¤¢¡¢ÇÀÎӿ建¾Ê¤¬¤½¤ó¤Ê¤Ëµ¤¤Ë¤¹¤ë¸ºß¤Ç¤Ï¤Ê¤µ¤½¤¦¤Ç¤¹¤Í¡£
¤³¤Î¤Ê¤«¤Î¥¤¥º¥ß¥ä ¤Ç²¿¤ò¤ä¤Ã¤Æ¤¤¤¿¤«¤È¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤·¤ç¤¦¤¬¡£(¡Ö¤Þ¤ë¤È¤¯»Ô¾ì¡× ¤Ê¤ó¤Æ¤Î¤òÌäÂê¤Ë¤·¤Æ¤¤¤ë¤ó¤Ç¤·¤ç¤¦¤«¤Í¡£)
°Ê²¼¤Ï¹½ÁÛÆüËܤÎÂè129²óJ.I.¥Õ¥©¡¼¥é¥à¡¡2008.04.23
ÃÏÊýµÄ²ñ¤ÏɬÍפ« ¡¡¤Ç¤Î»³Æâ·É¤µ¤ó¤Îȯ¸ÀÌÏÍÍ
¤Á¤Ê¤ß¤Ë¡¢»Åʬ¤±¿Í¤ÎÃæ¤Ë¤Ï¡¢»³Æâ·ÉÁ°Éû»ÔĹ¤È¥Ú¥¢¤À¤Ã¤¿¡¢³¤Åì±ÑÏÂÁ°»ÔŤâ¤Ï¤¤¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢·ë¹½¡¢¤³¤Î»Åʬ¤±¿Í¤Î¿ÍÁª¤Ã¤Æ¡¢¹½ÁÛÆüËÜ²ÃÆ£»á¤Î¸Ä¿ÍŪ¤Ê¤Ò¤¤Ç¤ä¤Ã¤Æ¤¤¤ë¤è¤¦¤Ê¡¢¤Á¤È¡¢¤¤¤¤²Ã¸º¤Ê´¶¤¸¤Ï¼õ¤±¤Þ¤¹¤Í¡£
º£²ó¤Î»Åʬ¤±¿Í¤Î¿ÍÁª¤â¡¢¹½ÁÛÆüËܤβáµî¤ÎJ.I.¥Õ¥©¡¼¥é¥à½ÐÀÊ¼Ô ¤«¤éÁª¤ó¤À¤è¤¦¤Ê´¶¤¸¤â¸«¼õ¤±¤é¤ì¤Þ¤¹¤Í¡£
¤Þ¤¢¡¢¤³¤ì¤Þ¤Ç¡¢²È·×Êí¤·¤«¸«¤¿¤³¤È¤¬¤Ê¤¤¤Ò¤È¤¬¡¢Âç´ë¶È¤Îºâ̳½ôɽʬÀϤ·¤Æ¤¤¤ë¤Ã¤Æ´¶¤¸¤Ç¤·¤ç¤¦¤«¡£
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø
¤³¤Î¾ðÊó¤Ï11·î25Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ»ö¤Ç¤Ï¡¢²¼µ¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ»ö½ç¤Ç¤¹¡£
D225GÊѰÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤ¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ (11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊѰۤ·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ (11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)
£²£°£°£¹Ç¯£±£±·î£²£µÆü
¡¡
¥¦¥¯¥é¥¤¥Ê¤ä¥Î¥ë¥¦¥§¥¤¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎÊѰۤˤĤ¤¤Æ¤Ï¡¢Á°¤Î»ä¤Î¥Ö¥í¥°µ»ö
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ ¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊѰۤ·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ ¡×
¡Ö³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤ¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ ¡×
¤Ê¤É¤Ç¾Ò²ð¤·¤¿¡£
¤³¤³¤Ë¤¤Æ¡¢¹á¹Á¤Ç¤â¡¢¥Î¥ë¥¦¥§¥¤¤ÈƱ¤¸ÊѰۤò»ý¤Ä¥¦¥¤¥ë¥¹¤¬³Îǧ¤µ¤ì¤¿¤È¤¤¤¦¡£
¤³¤³¤Ç¡¢¤Á¤ç¤Ã¤È¡¢À°Íý¤ò¤·¤Æ¤ª¤³¤¦¡£
ÊѰۤϡ¢£²£²£µ¥Ý¥¸¥·¥ç¥ó¤Ë¤ª¤±¤ëÊѰۤǤ¢¤ë¡£
¥¦¥¯¥é¥¤¥Ê¤Î¾ì¹ç
10¸¡ÂΤΤ¦¤Á¡¢4¸¡ÂΤˡ¢HA¤Ë¤ª¤¤¤Æ¡¢D225GÊѰۤò¼¨¤·¤Æ¤¤¤¿¤È¤¤¤¦¡£
D225GÊѰۤòµ¯¤³¤·¤Æ¤¤¤ë¥¦¥¤¥ë¥¹Ì¾¤Ï²¼µ¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£
A/Lviv/N6/2009
A/Ternopil/N11/2009
A/Ternopil/N10/2009
A/Lviv/N2/2009
¤³¤Î¤¦¤Á¡¢1¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¹¢¤«¤é¤Î¤â¤Î¤Ç¤¢¤ê¡¢3¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢ÇÙÁÈ¿¥¤«¤é¤Î¤â¤Î¤Ç¤¢¤Ã¤¿¡£
¥Î¥ë¥¦¥§¥¤¤Î¾ì¹ç
£µ·î¤«¤é£±£°·î¤Ë¤«¤±¤ÆºÎ¼è¤·¤¿¸¡ÂΤΤ¦¤Á¡¢¤¹¤Ù¤Æ¤¬£²£²£µ¥Ý¥¸¥·¥ç¥ó¤Ë¤ª¤±¤ëÊѰۤ¬¸«¤é¤ì¤¿¡£
¤½¤Î¤¦¤Á¡¢£µ¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢D225EÊѰۤǤ¢¤Ã¤¿¡£
¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢²¼µ¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£
A/Norway/4023/2009
A/Norway/3478/2009
A/Norway/3059/2009
A/Norway/2690/2009
A/Norway/2674/2009
£±¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¥ï¥¤¥ë¥É¡¦¥¿¥¤¥×¤È¤Îº®¹çʪ¤È¤ß¤é¤ì¤ëD225¤Ç¤¢¤ê¡¢D225GÊѰۤǤ¢¤Ã¤¿¡£
¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢²¼µ¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£
A/Norway/2924/2009
¹á¹Á¤Î¾ì¹ç
¥Î¥ë¥¦¥§¥¤¤ÈƱÍͤÎÊѰۤ¬¸«¤é¤ì¤¿¤È¤ÎÊ󯻤À¤¬¡¢¶ñÂÎŪ¤Ê¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢È¯É½¤µ¤ì¤Æ¤¤¤Ê¤¤¡£
¤³¤Î¥µ¥¤¥È¡ØÕó²È¡§¹Ã·¿H1N1ή´¶ÚμïÉÂÆÇ ÃæÔ¢6·î½¢Öá⤸½ ¡Ù¤Ë¤è¤ë¤È¡¢ÊѰۤϡ¢D225GÊѰۤÈD225EÊѰÛ(H3¥Ù¡¼¥¹¤Ç225¤Ç¤¢¤ê¡¢H1¥Ù¡¼¥¹¤Ç222¤Ç¤¢¤ë¡£HA´ð°ø222°Ì氨´ð»À°ÌóÚÚΰÛ)¤Ç¤¢¤ê¡¢¤½¤Î°ìÎã¤Ï¡¢º£Ç¯6·î¤Ë¥¤¥®¥ê¥¹¤«¤é¤Îµ¢¹ñ¼Ô¤«¤é¸«¤Ä¤«¤Ã¤¿¤â¤Î¤Ç¡¢¤â¤¦°ìÎã¤Ï¡¢9·î¤ËÞ¶¹¾¾ÊÞ¶¹¾îвÊÂçÕܤÇȯ¸«¤µ¤ì¤¿¤â¤Î¤Ç¤¢¤ë¤È¤Î¤³¤È¤Ç¤¢¤ë¡£
¤Þ¤¿¡¢¤³¤Î¥µ¥¤¥È ¤Ë¤è¤ì¤Ð¡¢¸½ºß¡¢Ãæ¹ñ¤Ç¤Ï¡¢8Îã¤Î225Úΰۤ¬¤¢¤ë¤È¤¤¤¦¡£
»²¹Í
¡ÖMutation detected in Hong Kong toddler ¡×
¹á¹Á¤Î¿·¤·¤¤H1N1ÊѼï¾ðÊó¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤Î¥µ¥¤¥È ¤´»²¾È
¡Ö¹á¹Á±ÒÀ¸½ðº¬Ú¡挪°Ò¸øÉÛŪÚμïÉÂÆÇ»ñÎÁ¡¤Üý查³º½ð´ÆÂ¬·ÏÅýÁ½¿Ê¹ÔŪ¹Ã·¿Î®´¶ÉÂÆÇÜëËÜŪ´ð°ø½øÎ󡤷ë²Ì⤸½ºß³º½ð¿Ê¹ÔŪ123¸Ä´ð°ø½øÎó¸¦µæ¡¤Â¶ÃæÍ°ì¸ÄÉÂÆÇÜëËÜÁ½½Ð¸½ÚμÉÂÆÇŪ´ð°ø½øÎóËòçÐ挪°Ò½Ð¸½ÅªÃ×Ì¿ÚμïÉÂÆÇÁêÆ±¡£ ¡×
(¹á¹Á±ÒÀ¸½ð´ÆÆÄ·ÏÅý¤Ï123¸Ä¤ÎH1N1·¿¥¤¥ó¥Õ¥ë¤ÎDNAÇÛÎó¤ËÂФ¹¤ë¸¦µæ¤ò¹Ô¤¤¡¢ÃË»ù¤Î¥µ¥ó¥×¥ë¤¬¥Î¥ë¥¦¥§¡¼¤Çή¹Ô¤·¤Æ¤¤¤ëÊѰۥ¦¥¤¥ë¥¹¤ÈƱ¤¸¤Ç¤¢¤ë¤³¤È¤òȯ¸«¤·¤¿¡£Æ±¥¦¥¤¥ë¥¹¤Ï¡¢¥¿¥ß¥Õ¥ë¤ä¥ì¥ì¥ó¥¶¤ËÂФ·¡¢¹³ÌôÀ¤Ï¸½¤ì¤Æ¤¤¤Ê¤¤¤È¤¤¤¦¡£)
¡ÖËܹÁ1歲ÃËÆ¸Èïñä½Ð´¶À÷Úμï¹ÃήÉÂÆÇ(çÐ挪°ÒÉÂÆÇÁêÆ±)¡¤Á½ºß7·îÄìÆþ½»º»ÅİҼ¤»Ûîб¡¡£»ñÎÁÔ¦ÊÒ ¡×
¼õÍÆÂÎÊѰۤˤĤ¤¤Æ
¥Ñ¥¿¡¼¥óǧ¼±¼õÍÆÂÎÅÁã¤ò¾ã³²¤¹¤ëÊѰۤ¬¤¢¤Ã¤¿¤«¤É¤¦¤«¤¬¡¢ºÇÂç¤Î¥Ý¥¤¥ó¥È¤Î¤è¤¦¤Ç¤¢¤ë¡£
¤¹¤Ê¤ï¤Á¡¢¤³¤Î¤³¤È¤Ï¡¢¤Ê¤¼¡¢¥¦¥¯¥é¥¤¥Ê¤Ç¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ç»àË´¤·¤¿´µ¼Ô¤ÎÇÙÁÈ¿¥¤ËÊѰۤ¬¸«¤é¤ì¤¿¤Î¤«¡¢¤È¤¤¤¦¤³¤È¤Ë´Ø·¸¤·¤Æ¤¯¤ë¡£
¤¹¤Ù¤Î¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ºÙ˦¤Ë¼è¤êÉÕ¤¯¤¿¤á¤Ë¡¢¥·¥¢¥ë»À¤òɬÍפȤ¹¤ë¡£
¥·¥¢¥ë»À¤Ë¤Ï¡¢¤¤¤í¤¤¤í¤Ê²½³ØÅª¤Ë¤³¤È¤Ê¤ë¼ïÎब¤¢¤ê¡¢¤½¤ì¤Ë¤è¤Ã¤Æ¡¢¥¦¥¤¥ë¥¹¤È¤Î¿ÆÏÂÀ¤¬¤³¤È¤Ê¤ë¡£
Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á 2,3 ·ë¹ç¤·¤¿¤â¤Î¡ÊSA¦Á2,3Gal¡Ë¤òǧ¼±¤·¡¢
¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¼ç¤È¤·¤Æ¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á2,6·ë¹ç¤·¤¿¤â¤Î (SA¦Á2,6Gal )¤òǧ¼±¤¹¤ë¡£
¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¡¢¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¤Ç¤Ï°Û¤Ê¤ê¡¢
¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¡¢¥Ò¥È¤Î¾åÉôµ¤Æ»¤ÎɡǴËì¡¢ÉûÉ¡¹Ð¡¢°öƬ¡¢µ¤´É¡¤µ¤´É»Ù¤Î¾åÈéºÙ˦¤Ë¤·¤«¤Ê¤¤¤¬¡¢
Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¥Ò¥È¤Î¸ÆµÛ´ï¤Î¿¼Éô¡Ê¸ÆµÛºÙµ¤´É»Ù¤ÈÇÙ˦ºÙ˦¤Î°ìÉô¤Ç¤¢¤ê¡¢¸ÆµÛºÙµ¤´É»Ù¤È˦¤ÈII·¿ÇÙ˦¾åÈéºÙ˦¤È¤Î´Ö¤Î·ë¹çÉô¤Ç¤¢¤ëÈóÀþÌÓµ¤Æ»ºÙ˦-nonciliated bronchiolar cells-¤Ë¤¢¤ë¡£¡Ë¤Ë¡¢Â¿¤¯Â¸ºß¤¹¤ë¡£
¥¦¥¤¥ë¥¹¤Î¡Ö¼õÍÆÂηë¹ç¥É¥á¥¤¥ó¡×(receptor-binding domain )(RBD)¤Ç¤ÎÊѰۤ¬¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó¤ò¥Ò¥È¼õÍÆÂΤ˷ë¹ç¤·°×¤¯¤·¡¢¿Í¤Ø¤Î´¶À÷¤ÎÍÆ°×¤µ¤ò·èÄê¤Å¤±¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£
¤³¤Îreceptor-binding site(RBD)¤Ï¡¢£È£Á¤Ë¤è¤Ã¤Æamino acids position ¤Î²¿ÈÖÌܤ˰ÌÃÖ¤¹¤ë¤«¤¬°Û¤Ê¤Ã¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£
¤³¤³¤Ç¡¢¥Ñ¥¿¡¼¥óǧ¼±¼õÍÆÂÎÅÁã¤ò¾ã³²¤¹¤ëÊѰۤ¬¤¢¤ì¤Ð¡¢ÇÙÁÈ¿¥¤Ë¤ª¤±¤ë¥ì¥»¥×¥¿¡¼¤¬¡¢¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤òǧ¼±¡ÊSA¦Á2,3Gal¡Ë¤¹¤ë¤³¤È¤â¤¢¤ê¤¦¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£
¤Ä¤Þ¤ê¡¢¥Ò¥È¤«¤éʬΥ¤µ¤ì¤¿H1N1¥¦¥¤¥ë¥¹¤¬¡¢¥Ò¥È¤ª¤è¤ÓÄ»¤ÎξÊý¤Î¼õÍÆÂΤ˷ë¹ç¤Ç¤¤ëÂÎÀ©¤¬¡¢ÊѰۤˤè¤Ã¤Æ¡¢À°¤¦¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£
¤¢¤ë¤¤¤Ï¡¢Ç§¼±¤ÎÂоݤ¬¡¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤Îº®¹çʪ¤Ç¤¢¤Ã¤¿¾ì¹ç¤â¡¢ÇÙÁÈ¿¥¤Ç¡¢SA¦Á2,3Gal°Ê³°¤Îº®¹çʪ¤òǧ¼±¤¹¤ë¤³¤È¤â¤¢¤ê¤¦¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£
¥¦¥¤¥ë¥¹¤Ë¹¥¤Þ¤ì¤ë¥·¥¢¥ë»À¤ò¥³¥ó¥È¥í¡¼¥ë¤¹¤ë¤Î¤Ï¡¢¥Ý¥¸¥·¥ç¥ó190¤È¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊѰۤǤ¢¤ë¤È¤¤¤ï¤ì¤ë¡£
¤½¤³¤Ç¡¢D225GÊѰۤޤ¿¤ÏD225EÊѰۤ¬¡¢¼õÍÆÂÎÊѰۤˤª¤¤¤Æ¡¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤Î¤É¤Á¤é¤Îǧ¼±¤Ë±Æ¶Á¤òµÚ¤Ü¤¹¤«¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¤Î¤À¤¬¡£
D225GÊѰۤϡ¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤ò¤È¤â¤Ë¥¿¡¼¥²¥Ã¥È¤Ë¤·¤¦¤ë¡¢¤È¤µ¤ì¤ë¡£
¤³¤ì¤é¤Ë¤Ä¤¤¤Æ¤Ï¡¢»ä¤Î°ÊÁ°¤Î¥Ö¥í¥°µ»ö
¡Ö¿Í´Ö¤Î¾åµ¤Æ»¤¬¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¤Î¾ì½ê¡×¤È¤¤¤¦Àµ·î°ÊÍèÏÃÂê¤ÎÏÀʸ ¡×
¡ÖH5N1¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î¥Ò¥È·¿¼õÍÆÂΤؤηë¹ç¤ò²Äǽ¤Ë¤¹¤ë¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó¤ÎÊÑ°Û ¡×
¡ÖHaemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors ¡×
¤Ê¤É¤â¤´»²¾È
¤Ê¤¼¡¢D225GÊѰۤ¬ÇÙ¤òľ·â¤¹¤ë¤Î¤«?
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬Ç§¼±¤¹¤ëSA¦Á2,3Gal¼õÍÆÂΤ¬II·¿ÇÙ˦¾åÈéºÙ˦( Type II Alveolar Epithelial Cells )¤Î¾å¤Ë¤¢¤ë¤¿¤á¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£
¤³¤ÎII·¿ÇÙ˦¾åÈéºÙ˦¤Ï¡¢¥µ¥¤¥È¥«¥¤¥ó¤Îȯ¸½¤ò´Þ¤àÌȱÖËɸæ¤È¤È¤â¤Ë¡¢ÇÙ¤ÎɽÌÌÄ¥ÎϤòÄ´À°¤¹¤ëÌò³ä¤òô¤Ã¤Æ¤¤¤ë¡£
D225GÊѰۤˤè¤Ã¤Æ¡¢H1N1¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤¬¡¢ËÜÍè¤Ï¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬Ç§¼±¤¹¤ëSA¦Á2,3Gal¼õÍÆÂΤòǧ¼±¤·¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤Ã¤Æ¡¢II·¿ÇÙ˦¾åÈéºÙ˦¤Ë¤È¤ê¤Ä¤¡¢¥µ¥¤¥È¥«¥¤¥ó¤Îȯ¸½¤òÂ¥¤¹¡¢¤È¤¤¤¦¤³¤È¤Î¤è¤¦¤À¡£
¤·¤«¤·¡¢°ìÊý¡¢°Ê²¼¤Î¤è¤¦¤ÊÀâ¤â¤¢¤ë¤è¤¦¤À¡£
¤¹¤Ê¤ï¤Á¡¢D225GÊѰۤϡ¢´¶À÷¤òÁ˳²¤¹¤ëÊѰۤǤ⤢¤ë¤Î¤Ç¡¢Áý¿£¤Ï¤È¤Þ¤é¤Ê¤¤¤¬¡¢´¶À÷¤Ï°ìÄê¤Î²Õ½ê¤Ç¤È¤É¤Þ¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢¥¦¥¯¥é¥¤¥Ê¤Ê¤É¤Ç¡¢ÇÙÁÈ¿¥¤Ê¤É°ìÄê¤ÎÉôʬ¤Î¤ß¤¬¥¦¥¤¥ë¥¹¤Ë¤ª¤«¤µ¤ì¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤Î¤«¡¢¤È¤¤¤¦¸«Êý¤À¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖThe D225G change in 2009 H1N1 influenza virus is not a concern¡× ¤ò¤´»²¾È
»²¹Í¡Ö1918 RBD D225G in Lung Cases in the United States ¡×
¡ÖCytokine Regulation in Type II Alveolar Epithelial Cells as the Mechanism for Interstitial Pneumonia by Gefitini b¡×
¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÈD225GÊѰۤȤδط¸
¾åµ¤ÎD225GÊѰۤޤ¿¤ÏD225EÊѰۤϡ¢£±£¹£±£¸Ç¯¤È£±£¹£±£¹Ç¯¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤Ë¤ª¤¤¤Æ¤â¡¢¸«¤é¤ì¤¿ÊѰۤǤ¢¤ë¡£
¤½¤Î¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢¼¡¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£
A/New York/1/1918
A/London/1/1919
ÊѰۥ¦¥¤¥ë¥¹¤Ç¤Ê¤¤A/South Carolina/1/18 ¤Ï¡¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±)¤ò¹¥¤ß¡¢A/New York/1/1918 ¤Ï¡¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±) ¤È¡¡alpha(2,6)(¥Ò¥È¡¦¥¦¥¤¥ë¥¹Ç§¼±)¡¡¤È¤ÎξÊý¤ò¹¥¤ó¤À¡£
A/South Carolina/1/18 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ë¤ª¤¤¤Æ¡¢ÊѰۤ·¤Æ¤ª¤é¤ºD¤Ç¤¢¤Ã¤¿¡£
A/New York/1/1918 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ë¤ª¤¤¤Æ¡¢ÊѰۤ·¤Æ¤ª¤ê¡¢G¤Ç¤¢¤Ã¤¿¡£
A/New York/1/1918 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó190¤Ë¤ª¤¤¤Æ¡¢D¤«¤éE¤Ë¡¢D190EÊѰۤ·¤Æ¤¤¤¿¡£
¤³¤ÎD190EÊѰۤϡ¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±)¤È¤Î¥Ð¥¤¥ó¥É¤ò¹¥¤à¡£
¤³¤ÎD190EÊѰۤÈD225GÊѰۤȤ¬¡¢Æ±»þ¤Ëµ¯¤³¤ë¤È¡¢¤½¤Î¥¦¥¤¥ë¥¹¤Î¦Á(2,6)¤Ø¤Î¼è¤êÉÕ¤(¥Ð¥¤¥ó¥Ç¥£¥ó¥°)¤Ï¡¢Ãø¤·¤¯¼å¤Þ¤ë¤È¤¤¤¦¡£
1918¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤òÍѤ¤¤Æ¤Î¡¢SC18¤È¸Æ¤Ð¤ì¤ë¡¢1918Âçή¹Ô¤Î¸¶°ø¥¦¥¤¥ë¥¹¤È¡¢SC18¤È¤Ï1¤Ä¤À¤±¥¢¥ß¥Î»À¤¬°Û¤Ê¤ëNY18¤È¡¢2¸Ä¤Î¥¢¥ß¥Î»À¤¬°ã¤¦AV18¤È¸Æ¤Ð¤ì¤ë¥¦¥¤¥ë¥¹¤È¤òÈæ³Ó¤·¤¿·ë²Ì¡¢¤³¤Î¤¦¤ÁAV18¤È¸Æ¤Ð¤ì¤ë¥¦¥¤¥ë¥¹¤Ï¡¢D190EÊѰۤÈD225GÊѰۤȤòƱ»þ¤Ëµ¯¤³¤·¤Æ¤ª¤ê¡¢¤³¤ÎAV18¥¦¥¤¥ë¥¹¤Ï¡¢¦Á(2,6)¤Ø¤Î¼è¤êÉÕ¤(¥Ð¥¤¥ó¥Ç¥£¥ó¥°)¤¬¤Þ¤Ã¤¿¤¯¤Ê¤«¤Ã¤¿¤È¤¤¤¦¡£
»²¹Í¡ÖMIT explains spread of 1918 flu pandemic¡×
CDC¤ÎNancy J. Cox »á¤ò¤Ï¤¸¤á¤È¤¹¤ë59¿Í¤«¤é¤Ê¤ë¸¦µæ¥Á¡¼¥à¤ÎH1N1 ¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒʬÀϤˤè¤ì¤Ð¡¢8¤Ä¤Î¥»¥°¥á¥ó¥È¤Î¤¦¤Á¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó(H)¤ò´Þ¤à3¤Ä¤Î°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ï¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÎH1N1¤ËͳÍ褹¤ë¤â¤Î¤Ç¤¢¤ê¡¢¤½¤Î¸å¡¢¤º¤Ã¤ÈÆÚ¤Ë¸ºß¤·¤Æ¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤¬¡¢¤½¤Î´Ö¤Ë¤ª¤¤¤Æ¤â¡¢ÊѰۤϤ·¤Æ¤¤¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ç¤Ï¡¢¥Ý¥ê¥á¥é¡¼¥¼B(PB)°äÅÁ»Ò¤Ï¥Ò¥ÈͳÍ衢¾¤ÎÆó¤Ä¤ÏĻͳÍè¤Ç¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢1918ǯ¤ÎH1N1¤ÈH5N1¤È¤Ï¡¢ÆÇÀ¤¬¤¢¤ë¤³¤È¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤ò¡¢Æ±¤¸NS1¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤ÆÍ¤·¤Æ¤¤¤ë¤¬¡¢º£²ó¤Î¿·H1N1¤Ï¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤È¤¤¤¦¡£
´¶À÷À¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤Æ¤â¡¢º£²ó¤Î¿·H1N1¤Ï¡¢1918ǯ¤ÎH1N1¤Ë¤¢¤Ã¤¿¤â¤Î¤ò¼º¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¡£
»²¹Í1.
¤³¤ì¤Þ¤ÇD225GÊѰۤò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷ (¥¦¥¯¥é¥¤¥Ê¤È¥Î¥ë¥¦¥§¥¤¤Îʬ¤ò½ü¤¯)
01¡¡A/******/index/2009/02/01 (A/swine-flu/index/2009-02-01(H1N1))
02¡¡A/Hiroshima/201/2009/06/17
03¡¡A/Georgia/01/2009/04/27
04¡¡A/Zhejiang-Yiwu/11/2009/09/06
05¡¡A/Zhejiang/DTID-ZJU03/2009/09/07
06¡¡A/Zhejiang/DTID-ZJU02/2009/09/07
07¡¡A/Sao Paulo/53206/2009/07/19
08¡¡A/Sao Paulo/53225/2009/08/01
09¡¡A/New York/04/2009/04/
10¡¡A/Catalonia/NS1706/2009/07/29
11¡¡A/Mexico/InDRE4114/2009//
12¡¡A/Texas/11/2009/04/23
13¡¡A/Texas/05/2009/04/15
14¡¡A/Mexico/3955/2009/04/02
15¡¡A/Cancun-NY/Index/2009/04/15
»²¹Í2.
¤³¤ì¤Þ¤ÇD225EÊѰۤò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷
¡ÖRhiza Labs FluTracker Forum ¡×¤«¤é
A/Norway/4023/2009(H1N1)¡¡¡¡¡¡
A/Norway/3478/2009(H1N1)
A/Norway/3059/2009(H1N1)
A/Norway/2690/2009(H1N1)
A/Norway/2674/2009(H1N1)
(A/Catalonia/S1761/2009(H1N1)
A/Catalonia/S1758/2009(H1N1)
A/Catalonia/S1748/2009(H1N1)
A/Catalonia/S1698/2009(H1N1).
A/Catalonia/S1674/2009(H1N1)
A/Catalonia/S1672/2009(H1N1)
A/Serbia/3547/2009(H1N1)
A/Catalonia/S1641/2009(H1N1)
A/Catalonia/S1637/2009(H1N1)
A/Catalonia/S1632/2009(H1N1)
A/Catalonia/S1606/2009(H1N1)
A/Catalonia/S1605/2009(H1N1)
A/Catalonia/S1604/2009(H1N1)
A/Nagasaki/HA-44/2009(H1N1)
A/Catalonia/S1592/2009(H1N1)
A/Catalonia/S1587/2009(H1N1)
A/Catalonia/S1545/2009(H1N1)
A/Catalonia/S1479/2009(H1N1)
A/Catalonia/S1478/2009(H1N1)
A/Catalonia/S1436/2009(H1N1)
A/Catalonia/S1379/2009(H1N1)
A/Catalonia/S1369/2009(H1N1)
A/Catalonia/S1350/2009(H1N1)
A/Catalonia/S1333/2009(H1N1)
A/Catalonia/S1331/2009(H1N1)
A/Catalonia/S1304/2009(H1N1)
A/Catalonia/S1300/2009(H1N1)
A/Catalonia/S1286/2009(H1N1)
A/Catalonia/S1273/2009(H1N1)
A/Catalonia/S1272/2009(H1N1)
A/Catalonia/S1269/2009(H1N1)
A/Catalonia/S1265/2009(H1N1)
A/Catalonia/S1260/2009(H1N1)
A/Catalonia/S1254/2009(H1N1)
A/Catalonia/S1249/2009(H1N1)
A/Catalonia/S1248/2009(H1N1)
A/Catalonia/S1237/2009(H1N1)
A/Catalonia/S1236/2009(H1N1)
A/Catalonia/S1227/2009(H1N1)
A/Catalonia/S1222/2009(H1N1)
A/Catalonia/S1215/2009(H1N1)
A/Catalonia/S1209/2009(H1N1)
A/Catalonia/S1205/2009(H1N1)
A/Catalonia/S1199/2009(H1N1)
A/Catalonia/S1187/2009(H1N1
A/Catalonia/S1183/2009(H1N1)
A/Catalonia/S1182/2009(H1N1)
A/Catalonia/S1165/2009(H1N1)
A/Catalonia/S1161/2009(H1N1)
A/Catalonia/S1120/2009(H1N1)
A/Almati/01/2009(H1N1)
A/Changsha/78/2009(H1N1)
A/California/25/2009(H1N1)
A/Milan/83/2009(H1N1)
A/Milan/80/2009(H1N1)
A/Ancona/05/2009(H1N1)
A/Catalonia/378/2009(H1N1)
A/Italy/172/2009(H1N1)
A/Sapporo/1/2009(H1N1)
A/Catalonia/387/2009(H1N1)
A/Hong Kong/2369/2009(H1N1)
A/Athens/893/2009(H1N1)
A/Paris/2591/2009(H1N1)
A/New Jersey/01/2009(H1N1)
»²¹Í3.¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊѰÛ
D225N
¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¤ä¥Ë¥å¡¼¥è¡¼¥¯¤Ç¸«¤é¤ì¤¿ÊѰÛ
D225G
¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊѰÛ
D225E
ÆüËÜ¡¦Ä¹ºê¡¢ÆüËÜ¡¦»¥ËÚ¡¢Ãæ¹ñ¡¦¹á¹Á¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥¸¥ã¡¼¥¸¡¼¡¢¥¢¥á¥ê¥«¡¦¥«¥ê¥Õ¥©¥ë¥Ë¥¢¡¢¥Õ¥é¥ó¥¹¡¦¥Ñ¥ê¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¡¢ ¥«¥¶¥Õ¥¹¥¿¥ó¡¦¥¢¥ë¥Þ¥È¥¤¡¢Ãæ¹ñ¡¦Ä¹º»¡¢¥¤¥¿¥ê¥¢¡¦¥ß¥é¥Î¡¢¥¤¥¿¥ê¥¢¡¦¥¢¥ó¥³¡¼¥Ê¡¢¥®¥ê¥·¥ã¡¦¥¢¥Æ¥Í¡¢¤Ç¸«¤é¤ì¤¿ÊѰÛ
¤½¤Î¾»²¹Í¥µ¥¤¥È
¡ÖRe: Sequences at Genbank! ¡×
¡Ö225G Preliminary Worldwide Tracking & Evaluation ¡×
H1N1ÊѰۤòÅÁ¤¨¤ëÃæ¹ñ¤Î¥Æ¥ì¥Ó¡ÖH1N1±Ö¾ðÁî¹çÊóÆ» - ¸áÌëºÇÁ°Àþ 20091122¡×
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/23 Monday
2009ǯ11·î23Æü
¡¡
¾ðÊ󤬺øÁ¤Æ¤¤¤ë¤è¤¦¤Ê¤Î¤Ç¡¢¤³¤³¤Ç¡¢¤Á¤ç¤Ã¤ÈÀ°Íý¤·¤Æ¤ß¤Þ¤·¤ç¤¦¤Í¡£
¥«¥Ê¥À¤Î±ÒÀ¸Åö¶É¤Ï11·î£²£²Æü¤Þ¤Ç¤Ë¡¢±Ñ°åÌôÉÊÂç¼ê¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¤¬À½Â¤¤·¤¿¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Î¥ï¥¯¥Á¥ó£±£·Ëü²óʬ¤Î»ÈÍѤòÃæ»ß¤¹¤ë¤³¤È¤ò·è¤á¤Þ¤·¤¿¡£
¤½¤ÎÍýͳ¤È¤·¤Æ¡¢Àܼï¸å¤ËÄ̾ï¤è¤ê¤â¹â¤¤ÈæÎ¨¤Ç½Å¤¤¥¢¥ì¥ë¥®¡¼²á¾êÈ¿±þ(¥¢¥Ê¥Õ¥£¥é¥¥·¡¼¥·¥ç¥Ã¥¯)¤¬È¯À¸¤·¤¿¤¿¤á¤Ç¤¹¡£
¤È¤¯¤Ë¡¢¥«¥Ê¥ÀÃæÉô¤Î¥Þ¥Ë¥È¥Ð½£¤Ç¡¢¥°¥é¥¯¥½À½¤Î°ìÄêÎ̤Υ說¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢Ä̾¡Á£²Îã¤Ë¤È¤É¤Þ¤ë½Å¤¤ÉûºîÍѤ¬£¶ÎãȯÀ¸¤·¤¿¤È¤Î¤³¤È¤Ç¤¹¡£
¥«¥Ê¥ÀÀ¯Éܤ¬»ÈÍÑÃæ»ß¤òµá¤á¤¿¤Î¤Ï¡¢¼¡¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£
À½ÉÊ̾¡ÖArepanrix¡×
À½Â¤¥í¥Ã¥ÈÈÖ¹æ¡ÖA80CA007A¡×
¥ê¥³¡¼¥ëÂоݿôÎÌ¡Ö172,000Éþ¡×
½Ð²ÙÀè
British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Prince Edward Island
ÉûÈ¿±þÊó¹ð
11·î7Æü»þÅÀ¤Ç660Ëü²óʬ¶¡µë¡¢¤¦¤Á¡¢ÉûÈ¿±þÊó¹ð634Îã¡¢¤¦¤Á½Å¾ÉÎã36¡¢¤¦¤Á»àË´4Îã
¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Î³µÍ×
¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¡¢¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼ÒÀ½¤Î¥¢¥¸¥å¥Ð¥ó¥È(AS03)Æþ¤ê¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£
¥¦¥¤¥ë¥¹¤ÎÇÝÍܤϡ¢È¯°é·ÜÍñÇÝÍÜË¡(embryonated egg culture)¤Ë¤è¤Ä¤Æ¤¤¤Þ¤¹¡£
¥¢¥¸¥å¥Ð¥ó¥ÈAS03¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¤ò»ÈÍѤ·¤Æ¤¤¤ë¤¿¤á¡¢¥¢¥á¥ê¥«¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¤Ç¤Ï»È¤ï¤ì¤Æ¤¤¤Þ¤»¤ó¡£
¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¥«¥Ê¥À¡¦¥Ð¡¼¥¸¥ç¥ó¤Ç¤Î¾¦ÉÊ̾¤Ç¤¢¤ê¡¢¤³¤ì¤Ï¡¢Æ±¼Ò¤Î¡ÖPandemrix ¡×¤È¼Â¼Á¡¢Æ±¤¸¤â¤Î¤Ç¤¹¡£
»²¾È¡ÖPademrix and Arepanrix adjuvanted vaccines, made by GSK ¡×
¤½¤Î¡ÖPandemrix ¡×¤Ï¡¢º£²óÆüËܤ¬Í¢Æþ¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£
¡Ö¥Ñ¥ó¥Ç¥à¥ê¥¯¥¹¡×(Pandemrix)¤Ï¡¢¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¤Ç¤¹¡£
ÂоݤȤ¹¤ë¥¦¥¤¥ë¥¹³ô¤¬ÆÃÄꤵ¤ì¤Æ¤¤¤Ê¤¤Ãʳ¬¤Ç¡¢¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤òÍѤ¤¤ÆºîÀ½¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Ç¡¢À½Â¤¾µÇ§¤Ï¤³¤ÎÃʳ¬¤ÇÆÀ¤Æ¤¤¤Þ¤¹¡£
Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹H5N1Âбþ¥ï¥¯¥Á¥ó¤È¤·¤Æ³«È¯¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Î¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤ò¡¢A/Vietnam/1194/2004(H5N1)¤«¤éA/California/7/2009 (H1N1)¤ËÆþ¤ìÂØ¤¨¤Æ¡¢À½Â¤¤·¤Æ¤¤¤ë¤â¤Î¤Ç¤¹¡£
¥«¥Ê¥À¤Î¡ÖArepanrix¡×¤âÆüËܤØÍ¢Æþ¤Î¡ÖPandemrix¡×¤â¡¢²¼µ¤Î¥Ó¥Ç¥ª¤Ë¤¢¤ê¤Þ¤¹¤è¤¦¤Ë¡¢Æó¤Ä¤ÎÍÆ´ï¤ÈÃí¼Í´ï¤¬¥ï¥ó¥»¥Ã¥È¤Ë¤Ê¤Ã¤¿¤â¤Î¤Ç¤¹¡£
1.¥µ¥¹¥Ú¥ó¥·¥ç¥ó(Suspension)-¿ÉþÍÑÍÆ´ï¤Ë¥¢¥ó¥Á¥²¥ó(antigen)¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£
2.¥¨¥Þ¥ë¥¸¥ç¥ó(Emulsion)-¥¢¥¸¥å¥Ð¥ó¥È(adjuvant)¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£
¤³¤Î1¤È2¤ò¡¢¥ß¥Ã¥¯¥¹¤·¤Æ»È¤¤¤Þ¤¹¡£
¤¿¤À¡¢º®¹ç¤¹¤ëÁ°¤Ë¡¢Æó¤Ä¤¬¡¢Éô²°¤Î²¹Å٤ˤʤé¤Ê¤±¤ì¤Ð¤¤¤±¤Þ¤»¤ó¡£
»ÈÍÑÊýË¡¤Î¾ÜºÙ¤Ï¡¢¤³¤Î¥µ¥¤¥È¡ÖPandemrix suspension and emulsion for emulsion for injection ¡×¤ò¤´Í÷¤¯¤À¤µ¤¤¡£
¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢¤³¤ì¤é¤Î¥ï¥¯¥Á¥ó¤Ï´ÉÍý¤¬Æñ¤·¤¤¤È¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¡ÖArepanrix¡×¤Î¥Ñ¥Ã¥±¡¼¥¸¤Ë¤Ï¡¢¡ÖBubble Wrap¡×¤È¡ÖShoe Box¡×¤È¤ÎÆó¼ïÎब¤¢¤ê¤Þ¤¹¡£
¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¡¢»°Àé¿Í°Ê¾å¤Î¼£¸³¤ò·Ð¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤Æ¤Þ¤¹¤¬¡¢¤½¤ì¤¬¡¢H5N1¤Î¥â¥Ã¥¯¥¢¥Ã¥×¥ï¥¯¥Á¥ó¤ÎÁ°Ãʳ¬¤Ç¤Î¼£¸³¤ò´Þ¤ó¤Ç¤¤¤ë¤Î¤«¤¬ÌÀ¤é¤«¤Ç¤¢¤ê¤Þ¤»¤ó¡£¡£
¥«¥Ê¥À¤Ç¤Ï¡¢À¸¸å6¥ö·î¤«¤é3ºÐ°Ê²¼¤ÎÍÄ»ù¤Ë¤Ä¤¤¤Æ¤Ï¡¢Æó²óÀܼ»°ºÐ¤«¤é10ºÐ°Ê²¼¤Î»Ò¶¡¤ËÂФ·¤Æ¤Ï·ò¹¯¾õÂ֤˱þ¤¸¤Æ¡¢Æó²óÀܼ·ò¹¯¤Ê»°ºÐ¤«¤é10ºÐ°Ê²¼¤Î»Ò¶¡¤ËÂФ·¤Æ¤Ï¡¢°ì²óÀܼï¤ò¿ä¾©¤·¤Æ¤¤¤Þ¤¹¡£
¤·¤«¤·¡¢Arepanrix¤Ë¤Ä¤¤¤Æ¤Ï¡¢60ºÐ°Ê¾å¡¢10ºÐ¤«¤é17ºÐ¤Þ¤Ç¡¢À¸¸å6¥ö·î¤«¤é35¥ö·î¤Þ¤Ç¡¢¤³¤Î¤¤¤º¤ì¤ÎÀ¤Âå¤Ë¤Ä¤¤¤Æ¤Î clinical data¤¬ÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤Þ¤»¤ó¡£
¥¢¥Ê¥Õ¥£¥é¥¥·¡¼¥·¥ç¥Ã¥¯(anaphylactic shock )¤Î¸¶°ø¤È¤·¤Æ¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È(AS03)¤Ë´Þ¤Þ¤ì¤Æ¤¤¤ë³¦Ì̳èÀºÞ¤Ç¤¢¤ëpolysorbate 80(Tween80)¤¬¸¶°ø¤È¤Î¸«Êý¤¬ÍÎϤΤ褦¤Ç¤¹¡£
»²¹Í¡ÖPolysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.
Coors EA, Seybold H, Merk HF, Mahler V .¡×
¥«¥Ê¥À¤Ç¤Ï¡¢¤³¤Î¤Û¤«¡¢¥¢¥¸¥å¥Ð¥ó¥È¤¬Æþ¤Ã¤Æ¤¤¤Ê¤¤¡¢Ç¥ÉØÍѤΥ說¥Á¥ó¤È¤·¤Æ¡¢¥ª¡¼¥¹¥È¥é¥ê¥¢CSL Ltd¼Ò¤«¤é¡¢¡ÖPanvax¡×¤ò 200000Éþ¡¢Í¢Æþ¤·¤Æ¤¤¤Þ¤¹¡£
¤Ê¤ª¡¢»ä¤Î¥Ö¥í¥°µ»ö¡ØH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥óÀܼï²ó¿ô¤Ï¡¢10ºÐ°Ê¾å¤Ï1²óÀܼï¤Ë¤¹¤Ù¤· ¡Ù¤Ë°ÊÁ°10·î½é½Ü¤Ë½ñ¤¤Þ¤·¤¿¤è¤¦¤Ë¡¢¥«¥Ê¥À¤Ç¤Ï¡¢65ºÐ°Ê¾å¤Î¤«¤¿¤Ë¡¢µ¨ÀáÀÍѤΥ說¥Á¥ó¤òÀܼ魯¤ë¤È¡¢¤«¤¨¤Ã¤Æ¡¢H1N1¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤«¤«¤ê¤ä¤¹¤¯¤Ê¤ë¤Î¤Ç¡¢µ¨ÀáÀÍÑ¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥ó¤ÎÀܼï¤Ï¡¢2010ǯ¤Ë¤Ê¤ë¤Þ¤Ç¡¢ÂԤ俤ۤ¦¤¬¤¤¤¤¡£¡×¤È¤Î¸¦µæÀ®²Ì¤¬the B.C. Centre for Disease Control¤«¤éȯɽ¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¤³¤ì¤È¡¢º£²ó¤Î°ì·ï¤È¤Î´Ø·¸¤Ï¡¢º£¤Î¤È¤³¤í¤ï¤«¤Ã¤Æ¤¤¤Þ¤»¤ó¡£
¤Þ¤¢¡¢¤Á¤ç¤Ã¤È¡¢ÈéÆù¤Ê¸«Êý¤Ë¤Ï¤Ê¤ê¤Þ¤¹¤¬¡¢ÆüËܤǤϡ¢¤¹¤Ã¤¿¤â¤ó¤À¤ÎÀ¯Ì³´±¤ÎÀ¯¼£¼çƳ¤Î±¦±ýº¸±ý¤ÎËö¡¢¹ñ»º¥ï¥¯¥Á¥ó¤Î°ì²óÀܼ郎·è¤Þ¤ê¡¢·ë²Ì¡¢Åö½é·×²è¤Î¤«¤Ê¤ê¤Î¿ô¤ÎÍ¢Æþ¥ï¥¯¥Á¥ó¤¬ÉÔÍפȤʤꤽ¤¦¤Ê¤Î¤Ç¤¹¤«¤é¡¢¤³¤Î¥«¥Ê¥À¤Î°ì·ï¤ò¡¢¸üÀ¸Ï«Æ¯¾Ê¤Ï¡¢¥Í¥¿¤Ê¤ê°ø±ï¤Ê¤ê¥¹¥±¡¼¥×¥´¡¼¥È¤Ê¤êÅϤê¤ËÁ¥¤Ê¤ê¤Ë¤·¤Æ¡¢Í¢ÆþÂǤÁÀÚ¤ê¤Ç¤¤ì¤Ð¡¢·ë²Ì¡¢Í¢Æþ¥ï¥¯¥Á¥ó²á¾êºß¸Ë¤Ø¤ÎÀÕǤƨ¤ì¤¬¤Ç¤¤ë¤Î¤«¤â¤·¤ì¤Þ¤»¤ó¤Í¡£
°Ê¾å
»²¹Í
¥¢¥¸¥å¥Ð¥ó¥È(AS03)¤ÎÉûºîÍÑ(ÉûÈ¿±þ)¤È¤ß¤é¤ì¤Æ¤¤¤ë¾É¾õ¤Ë¤Ï¼¡¤Î¤â¤Î¤¬¤¢¤ë¤è¤¦¤Ç¤¹¡£
¡ÖALERT Canadians: Toxic Ingredients in the Arepanrix H1N1 Vaccine will Harm Your Health ¡×¤«¤é
Pain(áÖÄË)
Redness(ȯÀÖ)
Swelling(¼ðı)
Fatigue(¤±¤óÂÕ´¶)
Headaches(ƬÄË)
Arthralgia (joint inflammation)(´ØÀáÄË)(´ØÀá¤Î±ê¾É)
Myalgia (muscle inflammation)(¶ÚÆùÄË)(¶ÚÆù¤Î±ê¾É)
Shivering(¿Ì¤¨)
Sweating(ȯ´À)
Swollen lymph nodes(¥ê¥ó¥ÑÀá¤Î¼ðÂç)
Fever(ȯǮ)
Vomiting(ÓÒÅÇ)
Tingling or numbness of the hands or feet(¼ê¤Ρ¢¤¦¤º¡«¤´¶¡¢¤Þ¤¿¤Ï¡¢¤·¤Ó¤ì´¶)
Shortness of breath(©ÀÚ¤ì)
Vasculitis (inflammation of the blood vessels)(·ì´É±ê)(·ì´É¤Î¼ðı)
Serious adverse reactions are as follows(°Ê²¼¤Ï¿¼¹ï¤Êͳ²È¿±þ)
Blood and lymphatic system disorders (lymphadenopathy)(·ì±Õ¤ä¥ê¥ó¥Ñ·Ï°Û¾ï)(¥ê¥ó¥ÑÀá¼ðı¾É)
Psychiatric disorders (insomnia)(Àº¿À¾ã³²)(ÉÔ̲¾É)
Nervous system disorders (dizziness, paraesthesia, inflammation of the central nervous system, inflammation of nerves, autoimmune disorders affecting myelin sheaths of nerves such as Guillain-Barré Syndrome)(¿À·Ð·Ï¼À´µ)(Ìܤޤ¤.Ãγа۾ï¾ã³².Ãæ¿õ¿À·Ð·Ï±ê¾É.¿À·Ð±ê¾É.¥®¥é¥ó¥Ð¥ì¡¼¾É¸õ·²¤Î¤è¤¦¤Ê¿À·Ð¤Î¿ñ¾ä¤Ë±Æ¶Á¤òÍ¿¤¨¤¦¤ë¼«¸ÊÌȱְ۾ï.)
Ear and labyrinth disorders (vertigo)(¼ª¼À´µ¤ä¼ªÌÂÏ©¼À´µ)(Ìܤޤ¤)
Respiratory, thoracic and mediastinal disorders (dyspnoea)(¸ÆµÛ´ï¤ä¶»Éô¤ä½Ä³Ö¤Î°Û¾ï)(¸ÆµÛº¤Æñ)
Gastrointestinal disorders (nausea, diarrhea, abdominal pain, vomiting, dyspepsia, stomach discomfort)(°ßIJ°Û¾ï)(ÅǤµ¤.²¼Î¡.Ê¢ÄË.ÓÒÅÇ.¾Ã²½ÉÔÎÉ.°ß¤ÎÉÔ²÷´¶)
Skin and subcutaneous tissue disorders (pruritus, rash)(ÈéÉæ¤äÈé²¼ÁÈ¿¥¤Î°Û¾ï)(ÁßáÚ¾É.ȯ¿¾)
Musculoskeletal and connective tissue disorders (back pain, musculoskeletal stiffness, neck pain, muscle spasms, pain in extremity)(¶Ú¹ü³Ê°Û¾ï¡¢·ë¹çÁÈ¿¥°Û¾ï)(ÇØÄË.¶Ú¹ü³Ê¤Î¶Å¤ê.ðôÉôáÖÄË.¶ÚÚ»½Ì.»Í»è¤ÎÄˤß)
General disorders and administration site conditions (bruising, asthenia, chest pain, malaise)(¤µ¤Þ¤¶¤Þ¤Ê°Û¾ï´¶¡¢ÅêÍ¿Éô°Ì¤Î¾õÂÖ)(ºÃ½ý.̵ÎϾÉ.¶»ÄË.É԰´¶)
»²¹Í
¡ÖÍ¢Æþ¥ï¥¯¥Á¥ó¤Î°ÂÁ´À¡¦Èó°ÂÁ´À¡¡Ááʬ¤«¤ê°ìÍ÷ ¡×
Arepanrix¤Î»ÈÍÑÊýË¡¤Î¥Ó¥Ç¥ª
(¤³¤Î¥Ó¥Ç¥ª¤ò¸«¤ë¤è¤¦¤Ë¡¢Arepanrix¤Ï¡¢Æó¤Ä¤Î¥³¥ó¥Ý¡¼¥Í¥ó¥È(antigen¤Èadjuvant)¤«¤é¤Ê¤Ã¤Æ¤¤¤ë¤Î¤Ç¡¢Èó¾ï¤Ë´ÉÍý¤¬Æñ¤·¤¤¤È¤µ¤ì¤Æ¤¤¤ë¡£)
¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥ó¤Î¥ê¥¹¥¯¤Ë¤Ä¤¤¤Æ¤ÎDr. Roby Mitchell¤Î¥Ó¥Ç¥ª
¥«¥Ê¥À¤Ç¤Î¥ï¥¯¥Á¥ó»ÈÍÑÃæ»ß¤òÅÁ¤¨¤ë¥Æ¥ì¥Ó
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/22 Sunday
¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø
¤³¤Î¾ðÊó¤Ï11·î22Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ»ö¤Ç¤Ï¡¢²¼µ¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ»ö½ç¤Ç¤¹¡£
D225GÊѰÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ (11·î25Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊѰۤ·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ (11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)
2009/11/22(Sun)
¡¡
¡Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á 2,3 ·ë¹ç¤·¤¿¤â¤Î¡ÊSA¦Á2,3Gal¡Ë¤òǧ¼±¤·¡¢
¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¼ç¤È¤·¤Æ¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á2,6·ë¹ç¤·¤¿¤â¤Î (SA ¦Á2,6Gal )¤òǧ¼±¤¹¤ë¡£
¢¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¡¢¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¤Ç¤Ï°Û¤Ê¤ë¡£
£¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¡¢¥Ò¥È¤Î¾åÉôµ¤Æ»¤Î¾åÈéºÙ˦¤Ë¤·¤«¤Ê¤¤¡£
¤Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¥Ò¥È¤Î¸ÆµÛ´ï¤Î¿¼Éô¡Ê¸ÆµÛºÙµ¤´É»Ù¤ÈÇÙ˦ºÙ˦¤Î°ìÉô¡Ë¤Ë¡¢Â¿¤¯Â¸ºß¤¹¤ë¡£
¥¤³¤Î¥Ò¥È¤Î¸ÆµÛ´ï¤Ë¤ª¤±¤ë¥Ò¥È¡¦¥¦¥¤¥ë¥¹¤ÈÄ»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼Ê¬ÉÛ¤ÎÁê°ã¤Ï¡¤H5N1 ¥¦¥¤¥ë¥¹¤¬¿Í¤«¤é¿Í¤ØÅÁÇŤ·¤Ë¤¯¤¤»ö¼Â¤Ë¤â´Ø·¸¤·¤Æ¤¤¤ë¡£
¦¥Ò¥È¤¬Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ò¸úΨ¤è¤¯ÅÁÇŤ¹¤ë¤¿¤á¤Ë¤Ï¡¤HA ¤¬¥Ò¥È¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼¤òǧ¼±¤Ç¤¤ë¤è¤¦¤ËÊѰۤ¹¤ëɬÍפ¬¤¢¤ë¡£
§¥Ò¥È¤¬¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ë´¶À÷¤¹¤ë¤È¡¢½ÅÆÆ¤Ê²¼Éô¸ÆµÛ´ï¾ã³²¤ò°ú¤µ¯¤³¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ï¡¢¤³¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉÛ(¸ÆµÛ´ï¤Î¿¼Éô¤ËÄ»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼¤¬¤¢¤ë¡£)¤Î°ã¤¤¤È¡¢¥¦¥¤¥ë¥¹¤ÎÊѰۤˤè¤ë¤È¤³¤í¤¬Â礤¤¤È¸«¤é¤ì¤ë¡£
¨º£²ó¡¢¥¦¥¯¥é¥¤¥Ê¤Ç¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¡¢¤¤¤º¤ì¤â½ÅÆÆ¤Ç¡¢¤·¤«¤â¡¢¤½¤Î»àË´¼Ô¤ò´Þ¤á¤¿½ÅÆÆ¼Ô¤ÎÇ٤ǤΥ¦¥¤¥ë¥¹¤¬¡¢¤¤¤º¤ì¤â¡¢D225GÊѰۤò¤ª¤³¤·¤ª¤ê¡¢¾åµ¤Æ»¤Ç¤ÎD225GÊѰۤ¬1¤Ä¤·¤«¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤¬¡¢¾åµ¤Î¤³¤È¤È´Ø·¸¤¢¤ë¤Î¤«¡£
©¥Ý¥¸¥·¥ç¥ó225ÊѰۤϡ¢H3N2¤Ë¤è¤¯¸«¤é¤ì¤ë¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀÊѰۤǤ¢¤ê¡¢H1N1¤Ë¤ª¤¤¤Æ¤â¡¢·à¾ÉÀ¤òÉÕÍ¿¤·¤¦¤ëÊѰۤǤ¢¤ë¤µ¤ì¤Æ¤¤¤ë¡£
¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀÊѰۤǤ¢¤ë¤³¤È¤È¡¢¥¦¥¯¥é¥¤¥Ê¤È¤Î´Ø·¸¤Ï¤¢¤ë¤Î¤«?
ª¤Þ¤¿¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤Ë¤ª¤¤¤Æ¡¢ºÎ¼è¤µ¤ì¤¿Æó¤Ä¤Î¥¦¥¤¥ë¥¹¡¡A/New York/1/1918 ¤È¡¡A/London/1/1919¡¡¤Ë¤â225¤Ë¤ª¤¤¤Æ¡¢Æ±ÍͤÎD225GÊѰۤ¬¸«¤é¤ì¤¿¤³¤È¤È¤Î´Ø·¸¤Ï¤¢¤ë¤Î¤«¤É¤¦¤«¡£
«1918ǯ¤Î¥¦¥¤¥ë¥¹¤Î¥·¡¼¥±¥ó¥¹Ê¬ÀϤˤª¤¤¤Æ¡¢¼õÍÆÂÎÆÃÀ¤Ï¡¢¡ÖSA ¦Á2,6Gal¡× ¤È¡¢¡ÖSA¦Á2,3Gal¡×¤È¡¢¡ÖSA¦Á2,3Gal¤ÈSA ¦Á2,6Gal¤È¤Îº®¹ç¡×¤È¤Î»°¤Ä¤Î¥¿¥¤¥×¤¬¸«¤é¤ì¤¿¡£
¬¼õÍÆÂÎÆÃÀ¤Î¡ÖSA¦Á2,3Gal¡×¤«¤é¡ÖSA ¦Á2,6¡×¤Ø¤ÎÊѲ½¼«ÂΤϡ¢·à¾ÉÀ¤òÉÕÍ¿¤¹¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡£
¡ÖSA¦Á2,3Gal¤ÈSA ¦Á2,6Gal¤È¤Îº®¹ç¡×¤Ë¤Ä¤¤¤Æ¤Ï¤É¤¦¤«?
CDC¤ÎNancy J. Cox »á¤ò¤Ï¤¸¤á¤È¤¹¤ë59¿Í¤«¤é¤Ê¤ë¸¦µæ¥Á¡¼¥à¤ÎH1N1 ¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒʬÀϤˤè¤ì¤Ð¡¢8¤Ä¤Î¥»¥°¥á¥ó¥È¤Î¤¦¤Á¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó(H)¤ò´Þ¤à3¤Ä¤Î°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ï¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÎH1N1¤ËͳÍ褹¤ë¤â¤Î¤Ç¤¢¤ê¡¢¤½¤Î¸å¡¢¤º¤Ã¤ÈÆÚ¤Ë¸ºß¤·¤Æ¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤¬¡¢¤½¤Î´Ö¤Ë¤ª¤¤¤Æ¤â¡¢ÊѰۤϤ·¤Æ¤¤¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ç¤Ï¡¢¥Ý¥ê¥á¥é¡¼¥¼B(PB)°äÅÁ»Ò¤Ï¥Ò¥ÈͳÍ衢¾¤ÎÆó¤Ä¤ÏĻͳÍè¤Ç¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢1918ǯ¤ÎH1N1¤ÈH5N1¤È¤Ï¡¢ÆÇÀ¤¬¤¢¤ë¤³¤È¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤ò¡¢Æ±¤¸NS1¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤ÆÍ¤·¤Æ¤¤¤ë¤¬¡¢º£²ó¤Î¿·H1N1¤Ï¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤È¤¤¤¦¡£
´¶À÷À¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤Æ¤â¡¢º£²ó¤Î¿·H1N1¤Ï¡¢1918ǯ¤ÎH1N1¤Ë¤¢¤Ã¤¿¤â¤Î¤ò¼º¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¡£
»²¹Í¡¡´ØÏ¢¤¹¤ë»ä¤Î¥Ö¥í¥°µ»ö
¡Ö¤ä¤Ï¤ê¿··¿¤Ç¤Ï¤Ê¤«¤Ã¤¿¡¢º£²ó¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ ¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊѰۤ·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ ¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ ¡×
¤½¤Î¾´ØÏ¢¥µ¥¤¥È
¡ÖRole of sialic acid binding specificity of the 1918 influenza virus hemagglutinin protein in virulence and pathogenesis in mice .¡×
¡Övirus: alpha2,6-sialyllactose-avian flu citations ¡×
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009ǯ11·î22Æü
¡¡
ºòÆü¡¢È·»³Ì±¼çÅÞÀ¯¸¢¤Î¡Ö¥Ç¥Õ¥ìÀë¸À¡×¤Ë¤Ä¤¤¤Æ¤Î¤¢¤Þ¤ê¤Î̵ºö¤µ¤ò¥Ö¥í¥°¡Ö¤Ê¤ó¤Ç¡¢¤¤¤Þ¤µ¤é¡¢¥Ç¥Õ¥ìÀë¸À¤Ê¤Î?¡× ¤Ë½ñ¤Ï¢¤Í¤Æ¤¤¤ë¤¦¤Á¤Ë¡¢ÅÓÃæ¤«¤é¡¢¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô¤ä¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô¤ÇÌܻؤµ¤ì¤Æ¤¤¤ë¡Ö¥Þ¥¤¥Ê¥¹¶âÍø¡×¤ÎÏÃÂê¤Ø¤È¡¢ÅÓÃæÃ¦Àþ¤·¤Æ¤·¤Þ¤¤¡¢¤½¤Î¤¦¤Á¤Ë¡¢¤½¤³¤ÎÉôʬ¤À¤±¤¬¡¢ÈîÂç²½¤·¤Æ¤·¤Þ¤Ã¤¿¤Î¤Ç¡¢¤³¤³¤Ç²þ¤á¤Æ¡¢¤½¤³¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÉôʬ¤À¤±¤ò¼è¤ê¾å¤²¤Æ¡¢¤³¤³¤ÇºÆ½Ò¤·¤Æ¤ß¤¿¤¤¡£
ÆüËܤΥǥե졦¥¹¥Ñ¥¤¥é¥ë¤ÎºÇÂç¤Î¸¶°ø¤Ï¡¢À¯ºö¶âÍø¤ÎÈóÉéÀ©Ìó¤Ë¤¢¤ê
¤Ä¤Þ¤ê¡¢ÆüËܤ¬¥Ç¥Õ¥ì¡¦¥¹¥Ñ¥¤¥é¥ë¤Ê¤ê¥Ç¥Õ¥ì¤Îæ«(Liquidity Trap)¤Ë´Ù¤Ã¤Æ¤¤¤ë¤½¤ÎºÇÂç¤Î¸¶°ø¤È¤·¤Æ¡¢À¯ºö¶âÍø¤ÎÈóÉéÀ©Ìó¤È¤¤¤¦ÌäÂ꤬¤¢¤ë¡£
¤³¤ì°Ê¾å¡¢À¯ºö¶âÍø¤ò²¼¤²¤Æ¤·¤Þ¤¦¤È¶âÍ»À¯ºö¤½¤Î¤â¤Î¤Î̵Îϲ½¤¬¤ª¤³¤Ã¤Æ¤·¤Þ¤¦¡¢¤½¤Î¤Þ¤µ¤Ë¡¢À¤³¦¤Î°¤·¤ÌÏÈÏÎ㤬¡¢ÆüËܤΥ¼¥í¤Ë¶á¤¤À¯ºö¶âÍø¤Ç¤¢¤ê¡¢¤³¤Î¤³¤È¤³¤½¤¬¡¢ÆüËܤΡּº¤ï¤ì¤¿½½Ç¯¡×¤òÀ¸¤ó¤À¸µ¶§¤È¤â¤¤¤¨¤ë¤È¤¤¤¦¤³¤È¤À¡£
¥Ð¥¹¥±¥Ã¥È¡¦¥Ü¡¼¥ë¤Ç¡¢¤¢¤Þ¤ê¤ËÄ㤤°ÌÃ֤ǥɥê¥Ö¥ë¤ò·«¤êÊÖ¤·¤Æ¤¤¤ë¤È¡¢¤½¤Î¥É¥ê¥Ö¥ë¼«ÂΤ¬ÉÔ²Äǽ¤È¤Ê¤ê¡¢¤Ä¤¤¤Ë¤Ï¡¢¥Ü¡¼¥ë¤¬¾²¤ËÄä»ß¤·¤Æ¤·¤Þ¤¦¤Î¤ÈƱ¤¸ÍÍÁê¤À¡£
Äã¶âÍøÀè¿Ê¹ñÆüËܤòÄɤ¤±Û¤¹ÈóÉéÀ©Ìó²óÈò¥¹¥¡¼¥àºî¤ê¤Îư¤
¥ê¡¼¥Þ¥ó¡¦¥·¥ç¥Ã¥¯¤ò¶¤Ë¤·¤Æ¡¢À¤³¦³Æ¹ñ¤¬Äã¶âÍø¤Ø¤È¤Ê¤À¤ì¤òÂǤäƤ¤¤ë¡£
¸½»þÅÀ¤Ç¤¹¤Ç¤ËÀ¯ºö¶âÍø¤¬1¥Ñ¡¼¥»¥ó¥È¤òÀڤäƤ¤¤ë¹ñ¤Ï¡¢ÆüËÜ(0.1¡ó)¥«¥Ê¥À(0.25%)¥¢¥á¥ê¥«(0.25%)¥¹¥¦¥§¡¼¥Ç¥ó(0.25%)¥¤¥®¥ê¥¹(0.5%)¹á¹ÁSAR(0.5%)¤È¤Ê¤Ã¤Æ¤¤¤ë¡£
¤·¤«¤·¡¢¤³¤³¤ËÍè¤Æ¡¢¤½¤ì¤é¤ÎÀ¯ºö¶âÍø¤ò¸Â³¦¤Ë¤Þ¤Ç²¼¤²¤Æ¤·¤Þ¤Ã¤¿¹ñ¤ÎÃæ¤Ë¤Ï¡¢¤¹¤Ç¤Ë¡¢ÆüËÜ¤ÈÆ±ÍͤÎÈóÉéÀ©Ìó¤Ç¤Î¶âÍ»À¯ºö¤Î¹Ô¤µÍ¤Þ¤ê¤ò¸«±Û¤·¡¢Äã¶âÍøÀèÇÚ¹ñ¤ÎÆüËܤòÄ̤ê±Û¤·¤Æ¡¢ÈóÉéÀ©Ìó¤òÈò¤±¤¦¤ëÁ¼Ã֤Ȥ·¤Æ¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÀ¯ºö¤ò»î¹Ô¤·»Ï¤á¤Æ¤¤¤ë¡£
¥¹¥¦¥§¡¼¥Ç¥ó¤È¥¤¥®¥ê¥¹¤À¡£
¡Ö¥Í¥Ð¡¼¥¢¥²¥¤¥ó¡ª¿¿¼îÏѡפʤé¤Ì¡Ö¥Í¥Ð¡¼¥¢¥²¥¤¥ó¡ª¥¸¥ã¥Ñ¥ó’¥º¡¦¥í¥¹¥È¡¦¥Ç¥£¥±¡¼¥É¡×(Never Again¡ª Japan’s ¡ÈLost Decade¡É)¤È¤¤¤Ã¤¿¤È¤³¤í¤Ê¤Î¤À¤í¤¦¡£
¥Þ¥¤¥Ê¥¹¶âÍø¥¹¥¡¼¥à¤ÎÆó¿Í¤ÎÍýÏÀŪ¼çƳ¼Ô-Willem Buiter¤ÈGreg Mankiw-
¤³¤ì¤é¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÍýÏÀŪ¤Ê¼çÃì¤È¤Ê¤Ã¤Æ¤¤¤ë¤Î¤¬¡¢¡Ö¤Ê¤ó¤Ç¡¢¤¤¤Þ¤µ¤é¡¢¥Ç¥Õ¥ìÀë¸À¤Ê¤Î?¡× ¤Ë¤â½ñ¤¤¤¿¤è¤¦¤Ë¡¢Willem Buiter »á¤ÈGreg Mankiw »á¤Ç¤¢¤ë¡£
Á°¼Ô¤ÎWillem Buiter»á¤Ï¡¢¥Ç¥Õ¥ì¤Î櫤«¤éƨ¤ì¤ë¤¿¤á¤Ë¤Ï¡¢Æó¤Ä¤Î¥ª¥×¥·¥ç¥ó¤·¤«¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£
¤Ò¤È¤Ä¤Ï¡¢¼ûÍ×´µ¯ºö¤Ç¤¢¤ê¡¢¤â¤¦¤Ò¤È¤Ä¤Ï¡¢¡ÉTaxing currency¡É¤Ë¤è¤Ã¤Æ¡¢¡ØÉé¤Î̾ÌܶâÍø¡Ù(negative nominal interest rate)(¥Þ¥¤¥Ê¥¹¶âÍø)¤ò¡Çcarry tax¤È¤¤¤¦·Á¤Ç²Ý¤¹¤ë¤³¤È¤Ç¤¢¤ë¡¢¤È¤·¤Æ¤¤¤ë¡£
¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô¤Î¥Þ¥¤¥Ê¥¹¶âÍø¥¹¥¡¼¥à
¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô(Riksbank)¤Ï¡¢¤³¤ÎWillem Buiter¤Î¹Í¤¨Êý¤Î´ð¤Ë¡¢º£Ç¯¤Î7·î¤«¤é¡¢¼¡¤Î¤è¤¦¤Ê¥¹¥¡¼¥à¤ò¼Â»ÜÃæ¤Ç¤¢¤ë¡£
¤¹¤Ê¤ï¤Á¡¢2009ǯ7·î2Æü¤Ë¡¢Riksbank¤Ï¡¢À¯ºö¶âÍø(¥ì¥Ý¡¦¥ì¡¼¥È¡¢Repo Rate)¤ò¡¢¤½¤ì¤Þ¤Ç¤Î0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤²¼¤²¤¿¡£
Ʊ»þ¤Ë¡¢2009ǯ7·î8Æü¤«¤é¤Ï¡¢Riksbank¤Ë¸ýºÂ¤ò»ý¤Ä¾¦¶È¶ä¹Ô¤ÎͶâ¸ýºÂ¤ÎͶâ¶âÍø(Deposit Rate)¤ò¡¢¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ø¡¢Riksbank¤«¤é¾¦¶È¶ä¹Ô¤Ø¤ÎÂߤ·½Ð¤·¶âÍø¤ò¡¢0.75¥Ñ¡¼¥»¥ó¥È¤ØÊѹ¹¤·¤¿¡£
¾¦¶È¶ä¹Ô¤ÎͶâÊ¿»Ä¤¬¤¤¤¯¤é¤«¤Ë¤â¤è¤ë¤¬¡¢ÍýÏÀŪ¤Ë¤Ï¡¢À¯ºö¶âÍø¤ò0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤²¼¤²¤Æ¤â¡¢Ãæ±û¶ä¹Ô¤Î¾¦¶È¶ä¹Ô¤ËÂФ¹¤ëͶâ¶âÍø¤ò¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¡¢¾¦¶È¶ä¹Ô¤ËÂФ¹¤ë¼Â¼Á¶âÍø¤Ï¡¢¤â¤È¤Î0.5¥Ñ¡¼¥»¥ó¥È¤È¼Â¼ÁƱ¤¸¿å½à¤Ë°Ý»ý¤Ç¤¡¢ÈóÉéÀ©Ì󤫤é°ìÄê¤Î²ò½ü¤¬¤Ç¤¤ë¡¢¤È¤¤¤¦¡¢¥Õ¥í¡¼¥Æ¥£¥ó¥°¤Î¹Í¤¨Êý¤Ë´ð¤Å¤¯¤â¤Î¤Î¤è¤¦¤À¡£
¤³¤ì¤òÆüËÜ¤ÎÆü¶ä¤ËÅö¤Æ¤Ï¤á¤Æ¤ß¤ë¤È¼¡¤Î¤è¤¦¤Ë¤Ê¤ë¤Ç¤¢¤í¤¦¡£
¸½ºß¡¢ÍøÂ©¥¼¥í¤ÎÆüËܶä¹ÔÅöºÂͶâ¤ò¥Þ¥¤¥Ê¥¹¶âÍø¤È¤·¡¢¡Ý0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤·¡¢ÌµÃ´¥³¡¼¥ë(¥ª¡¼¥Ð¡¼¥Ê¥¤¥Èʪ)¥ì¡¼¥È¤ò0.75¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¡¢¤È¡¢Æ±¤¸°ÕÌ£¤Ë¤Ê¤ë¤Î¤À¤í¤¦¡£
¤¿¤À¡¢
¥Þ¥Í¥¿¥ê¡¼¥Ù¡¼¥¹¡á¡Ö¡ÆüËܶä¹Ô·ôȯ¹Ô¹â¡×¡Ü¡Ö¢²ßʾήÄ̹â¡×¡Ü¡Ö£Æü¶äÅöºÂͶâ¡×
¤Ê¤Î¤Ç¡¢£¤Î¥Þ¥¤¥Ê¥¹¶âÍø²½¤Ë¤è¤Ä¤Æ¡¢£¤ÎÊ¿»Ä¤¬¸º¾¯¤¹¤ë¤Ç¤¢¤í¤¦Ê¬¤ò¡¢¡¢¤Ç¤É¤ÎÄøÅÙÊ䤦¤«?¤È¤¤¤¦¤È¤³¤í¤Ë¡¢Ãæ±û¶ä¹Ô¥Ù¡¼¥¹¤Ç¤ÎºÛÎ̤ÎÉý¤¬Áý¤¨¤Æ¤¯¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£
º£¤Þ¤Ç¡¢£¤Î»Ä¹â¤Ï¡¢Í¿·ï¤Ç¤·¤«²á¤®¤Ê¤«¤Ã¤¿¤Î¤Ç¤¢¤í¤¦¤«¤é¡£
¤Þ¤¿¡¢¥¹¥¦¥§¡¼¥Ç¥ó¤Î¾ì¹ç¤Ï¡¢¾¦¶È¶ä¹Ô¤ÎÃæ±û¶ä¹Ô¤Ø¤Îͤ±¶â¤Î¤ß¤òÂоݤˤ·¤Æ¤¤¤ë¤Î¤À¤«¤é¡¢¤ä¤ä¡¢¸ÂÄêŪ¤Ê¥Þ¥¤¥Ê¥¹¶âÍøÀ¯ºö¤È¤â¸À¤¨¤ë¤Î¤À¤¬¡¢¤³¤ì¤¬¾¦¶È¶ä¹Ô¤Î¸Ä¿Í¸ýºÂͶâ¶âÍø¤Ë¤Þ¤Ç¤âµÚ¤Ö¤Ë¤Ï¡¢¤â¤¦°ì¹©Éפ¬É¬ÍפʤΤ«¤â¤·¤ì¤Ê¤¤¡£
¤Ê¤ó¤«¡¢¤³¤ì¤ò¸«¤ë¤È¡¢FX¼è°ú¤Ë¤ª¤¤¤Æ¡¢¥í¥ó¥°¤â¥·¥ç¡¼¥È¤â¡¢¥Þ¥¤¥Ê¥¹¤Î¥¹¥ï¥Ã¥×¶âÍø¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¡¢¤È¤¤¤¦¤è¤¦¤Ê¤³¤È¤òÏ¢ÁÛ¤·¤Æ¤·¤Þ¤¦¤Î¤À¤¬¡£
¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô(BoE)¤Ç¤â¡¢Æ±Íͤιͤ¨Êý¤ò¸¡Æ¤¤Î¤è¤¦¤À¡£
¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô¤Ç¤Ï¡¢QE(quantitative easing)¤È¸Æ¤Ð¤ì¤ëÎÌŪ´ËÏÂÁ¼ÃÖ¤ÈÆ±»þ¤Ë¡¢KingÁíºÛ¤Ï¡¢9·î»þÅÀ¤Ç¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤Ë¤Ä¤¤¤Æ¡¢¥¹¥¦¥§¡¼¥Ç¥ó¤ÎÎã¤ò°ú¤¹ç¤¤¤Ë½Ð¤·¤Æ¡¢¡Ö¥¹¥¦¥§¡¼¥Ç¥ó¤Î¤ä¤êÊý¤ÏÇÓ½ü¤·¤Ê¤¤¡£¥Þ¥¤¥Ê¥¹¶âÍø¤Ï¡¢¤Ò¤È¤Ä¤Î¹Í¤¨Êý¤Ç¤¢¤ë¡£¡×¤È¡¢Á°¸þ¤¤Î¥³¥á¥ó¥È¤ò¤·¤Æ¤¤¤ë¡£
»²¹Í¡ÖWill UK interest rates go negative? ¡×
¡ÖTaxing currency as a way out of a liquidity trap ¡×
Willem Buiter¤¬¹Í¤¨¤Æ¤¤¤ë¡¢¤è¤ê¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê¥¹¥¡¼¥à
¤³¤ì¤é¤Î¹Í¤¨Êý¤Î¸µ¤Ë¤Ê¤Ã¤Æ¤¤¤ëWillem Buiter¤Ï¡¢¤µ¤é¤Ë¡¢¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê¹Í¤¨Êý¤ò»ý¤Ã¤Æ¤¤¤ë¤è¤¦¤À¡£
°ì¸À¤Ç¸À¤¨¤Ð¡¢¡ØÆ±¤¸¶â(¥«¥Í)¤Ç¤â¡¢»Ä¹â¤È¤·¤ÆÊÝͤ·¤Æ¤¤¤ì¤Ð¡¢»þ´Ö²ÁÃͤλ½ý¤òÌȤì¤ë¤¬¡¢Ä̲ߤȤ·¤Æ¸ò´¹µ¡Ç½¤ò¹Ô»È¤¹¤ë¤È»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤ë¤Î¤Ç¡¢¿Í¡¹¤Ï¡¢Ä̲ߤȤ·¤Æ¤Îµ¡Ç½¹Ô»È(¾ÃÈñ)¤òÀè±ä¤Ð¤·¤Ë¤·¡¢¾ÃÈñ¤»¤º¡¢»Ä¹â¤È¤·¤Æ²¹Â¸¤¹¤ë¤¿¤á¤Ë¡¢¥Ç¥Õ¥ì¤Î櫤¬À¸¤Þ¤ì¤ë¡£¤À¤«¤é¡¢»Ä¹â¤Î²ÁÃͤÈÄ̲ߤβÁÃͤò¥¤¥³¡¼¥ë¡¦¥Õ¥Ã¥Æ¥£¥ó¥°¤Ë¤¹¤ë¤¿¤á¤Ë¡¢»Ä¹â¤ËÂФ·¤Æ¡¢¥¥ã¥ê¡¼¥¤¥ó¥°¡¦¥¿¥Ã¥¯¥¹¤È¤¤¤¦¤Ù¤¤â¤Î¤ò²Ý¤·¡¢ÊÝͻĹâ¤ËÂФ·¤Æ¤â¡¢»þ´Ö»½ý¤¬µ¯¤¤ë¤è¤¦¤Ë¤¹¤ì¤Ð¤¤¤¤¡£¡Ù¤È¤¤¤¦¹Í¤¨Êý¤Ë¤â¤È¤Å¤¯¤â¤Î¤Î¤è¤¦¤Ç¡¢¤³¤Î¹Í¤¨Êý¤Ï¡¢¸å¤Ë½Ò¤Ù¤ëGreg Mankiw¤Î¹Í¤¨Êý¤È¤â¡¢¤¢¤¤Ä̤¸¤Æ¤¤¤ë¡£
¤¹¤Ê¤ï¤Á¡¢Willem Buiter»á¤Ï¡¢Ì¾ÌܶâÍø¤¬ÈóÉéÀ©Ìó¤ò¼õ¤±¤Ê¤¤¤¿¤á¤Ë¡¢¼¡¤Î»°¤Ä¤ÎÊýË¡¤¬¤¢¤ë¤È¤·¤Æ¤¤¤ë¡£(¤«¤Ê¤ê¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê°Æ¤Ç¤Ï¤¢¤ë¡£)
¡Ä̲ߤòÇѻߤ·¡¢¹ṉ̃¤¹¤Ù¤Æ¤¬¡¢Ãæ±û¶ä¹Ô¤Ë¸ýºÂ¤ò»ý¤Ä¡£¤½¤Î¾ì¹ç¡¢¤½¤Î¸ýºÂ¤ËÂФ·¤Æ¤Ï¡¢¥×¥é¥¹¤Î¶âÍø¤È¥Þ¥¤¥Ê¥¹¤Î¶âÍø¤ÎξÊý¤¬»þ¤Ë±þ¤¸¤Æ¡¢¤«¤«¤ë¡£
¢Ä̲ߤÎÊÝͤËÂФ·¤Æ¡¢¥¥ã¥ê¡¼¤Ë±þ¤¸¤ÆÀǶ⤬¤«¤«¤ë¡£
£¿·¤·¤¤²ßʾ¤ÎƳÆþ(rallod¤È¤¤¤¦Ì¾¤ÎÀ¤³¦Ä̲ß)¤Ë¤è¤Ã¤Æ¡¢¸ýºÂ¤Î»Ä¹â¤È¤·¤Æ²ÁÃͤȡ¢¸ò´¹¼êÃʤȤ·¤Æ¤ÎÄ̲ߤβÁÃͤȤò¡¢¥Ç¥«¥Ã¥×¥ê¥ó¥°¤¹¤ë¡£
»²¾È¡ÖThe wonderful world of negative nominal interest rates, again ¡×
¤³¤Î¤¦¤Á¡¢¤È¤¯¤Ë¢¤Î¹Í¤¨Êý¤Ï¡¢Ä̲߲ÁÃͤâÏ·²½¤·¤¦¤ë¤È¤¤¤¦¹Í¤¨Êý¤Ç¤¢¤ê¡¢¥ª¥×¥·¥ç¥ó¤Î¥¿¥¤¥à¡¦¥Ç¥£¥±¥¤(Ëþ´ü¤¬¶á¤Å¤¯¤Ë¤Ä¤ì¤Æ¡¢¥ª¥×¥·¥ç¥ó¤Î»þ´Ö²ÁÃͤ¬¸º¤Ã¤Æ¤¤¤¯¡£)¤Î¹Í¤¨Êý¤Ë»÷¤Æ¤¤¤ë¡£
¥Þ¥¤¥Ê¥¹¶âÍø¤ÎȯÁۤθµ¤Ï¡¢ÃϰèÄ̲ߤλÏÁÄ¥²¥¼¥ë¤Ë¤¢¤ê
¤³¤Î¢¤Î¹Í¤¨Êý¤ò¤µ¤é¤Ë¤µ¤«¤Î¤Ü¤ë¤È¡¢ÃϰèÄ̲ߤÎÁĤȤ⤤¤¨¤ë¸ºß¤Î¥²¥¼¥ë(Silvio Gesell)¤Î¹Í¤¨Êý¤Ë¹Ô¤Ã夯¤³¤È¤¬¤Ç¤¤ë¡£
¤¹¤Ê¤ï¤Á¡¢¥²¥¼¥ë¤Ï¡¢Ä̲ߤؤΥ¹¥¿¥ó¥×¤òµÁ̳ÉÕ¤±¤ë¤È¤¤¤¦°Æ¤òÄ󾧤·¡¢¤³¤ì¤Ë¤è¤Ã¤Æ¡¢Ä̲ߤβÈÄíÆâË䢤ò¤µ¤±¤ë¤³¤È¤ò°Õ¿Þ¤·¤¿¡£
¤Ò¤é¤¿¤¯¤¤¤¨¤Ð¡¢¡ÖËè·î10±ßʬ¤Î¥¹¥¿¥ó¥×¤òޤé¤Ê¤¤¤È1Ëü±ß»¥¤Ï»È¤¨¤Þ¤»¤ó¤è¡×¤È¤¤¤¦¤è¤¦¤Ê°Æ¤Î¤è¤¦¤À¡£²ÈÄíÆâ¤Ç²ßʾ¤òË䢤·¤Æ¤¤¤ì¤Ð¡¢¤½¤ì¤ËÂФ¹¤ë¥¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¤¬¤«¤«¤ë¤È¤¤¤¦¥·¥¹¥Æ¥à¤Ç¤¢¤ë¡£
Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý
°ìÊý¡¢Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý¤Ï¡¢¼¡¤Î¤è¤¦¤Ê¤â¤Î¤Ç¤¢¤ë¡£
¡Ö¶â¤ò¼Ú¤ê¤¿¤è¤ê¤â¾¯¤Ê¤¯ÊÖ¤¹¤³¤È¤ò¾ò·ï¤Ë¡¢¶â¤òÂߤ¹¤³¤È¤Ï¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤Î³µÇ°¤¬¤¢¤ì¤Ð²Äǽ¤Ç¤¢¤ë¡£
r¤ò¼Â¼ÁÍøÎ¨¤È¤·¤Æ¡¢º£Æü¤Î¾¦ÉʲÁ³Ê¤ò¥Ù¡¼¥¹¤Ë¤·¤Æ¡¢ÌÀÆü¤Î¾¦ÉʲÁ³Ê¤ÎÁêÂвÁ³Ê¤ò¤¢¤é¤ï¤¹¤È¤¹¤ë¤È¡¢1/(1+r)¤Ç¤¢¤é¤ï¤µ¤ì¤¦¤ë¡£
·ÐºÑÍýÏÀ¤ÎÃæ¤Ç¡¢¤³¤ÎÌÀÆü¤Î¾¦ÉʲÁ³Ê¤ÎÁêÂвÁ³Ê¤ò°ì°Ê²¼¤Ë¤¹¤ëɬÍפȤ¹¤ë·ÐºÑÍýÏÀ¤Ï¤¢¤ë¤Î¤«?
ºß¸ËÉéô¤È¤¤¤¦¤â¤Î¤¬¤¢¤ë¸Â¤ê¡¢»ä¤Ï°ì°Ê²¼¤ËÁêÂвÁ³Ê¤Ï¤Ê¤ê¤¦¤ë¤È»×¤¦¡£
¤ê¤ó¤´¤Î²Á³Ê¤¬¤Ê¤·¤Î²Á³Ê¤ËËþ¤¿¤Ê¤«¤Ã¤¿¾ì¹ç¡¢ÌÀÆü¤Î¾ÃÈñ²Á³Ê¤Ï¡¢º£Æü¤Î²Á³Ê¤ËËþ¤¿¤Ê¤¤¡£
¤â¤·¡¢¿Í¡¹¤¬¡¢¾ÃÈñ¤¹¤ë¤³¤È¤ò±ä´ü¤¹¤ë¤³¤È¤ò˾¤ó¤Ç¤¤¤¿¤È¤¹¤ë¤È¡¢ÌÀÆü¤Î¾ÃÈñ¤Ï¡¢º£Æü¤Î¾ÃÈñ¤è¤ê¤â¡¢¤è¤ê¹â²Á³Ê¤È¤Ê¤é¤¶¤ë¤òÆÀ¤Ê¤¤¡£
¤³¤Î¤³¤È¤Ï¡¢Ê¿¶Ñ¤Î¼Â¼ÁÍøÎ¨(r)¤¬Éé¤Ç¤¢¤ë¤³¤È¤ò°ÕÌ£¤·¤Æ¤¤¤ë¡£¡×
¤¤¤Ã¤Æ¤ß¤ì¤Ð¡¢»Ä¹â¤È¤·¤Æ»ý¤Ã¤Æ¤¤¤ì¤Ð¥¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¡¦¥¼¥í¤Ç¸º²Á¤·¤Ê¤¤¤Î¤Ç¡¢¤Ò¤È¤Ó¤È¤Ï¡¢»Ä¹â¤òÄ̲ߤȤ·¤Æ¤Îµ¡Ç½¤ò¹Ô»È¤»¤º¡¢¾ÃÈñ¤òÀè±ä¤Ð¤·¤·¤Æ¡¢»Ä¹â¤È¤·¤ÆÂࢤ·¤Æ¤¤¤ë¡¢¤È¤¤¤¦¤Î¤¬¡¢º£¤Î¥Ç¥Õ¥ì¤Î櫤θµ¶§¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£
¤¤¤Ä¤Þ¤Ç¤âÉå¤é¤Ê¤¤¤ê¤ó¤´¤Ê¤é¤Ð¡¢·è¤·¤Æ¡¢º£Æü¡¢Ç㤦¤³¤È¤Ï¤Ê¤¤¤À¤í¤¦¡£
Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý¤Ë¤Ä¤¤¤Æ¤Ï¡¢¼¡¤Î¥µ¥¤¥È¤ò¤´»²¾È
¡ÖObservations on Negative Interest Rates ¡×¡ÖMore on Negative Interest Rates ¡×
¡ÖNegative Interest Rates ¡×
¤¤¤Ä¤Þ¤Ç¤âÉå¤é¤Ê¤¤¤ê¤ó¤´¤Ê¤é¤Ðº£Æü¤ÏÇã¤ï¤Ê¤¤
²¿¤ä¤é¡¢¤³¤Î¹Í¤¨Êý¤Ï¡¢¤Þ¤¹¤Þ¤¹¡¢¥ª¥×¥·¥ç¥ó¤Î¹Í¤¨Êý¤Ë¶Ë»÷¤·¤Æ¤¯¤ë¡£
¤Ä¤Þ¤ê¡¢¥¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¤¬¥¼¥í¤Ç¤Ê¤¤¸Â¤ê¡¢ÌÀÆü¤Î¾ÃÈñ²Á³Ê¤Ï¡¢º£Æü¤Î¾ÃÈñ²Á³Ê¤è¤ê¤â¡¢»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤ë¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£
¤ê¤ó¤´¤¬Éå¤ë»þ´ü¤¬¡¢Ëþ´üÆü(¤¿¤È¤¨¤Ð°ì½µ´Ö¸å)¤È¤¹¤ì¤Ð¡¢Ëþ´üÆü¤è¤ê¤â¡¢¤è¤ê´üÀè(¤Ä¤Þ¤ê¡¢º£Æü)¤Î¤Û¤¦¤¬¡¢»þ´Ö²ÁÃͤ¬Â¿¤¤¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£
¹¬¤«ÉÔ¹¬¤«¡¢¸½ºß¤ÎͶâ»Ä¹â¥Ù¡¼¥¹¤Ç¤Ï»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤Ê¤¤¤Ë¤â¤«¤«¤ï¤é¤º¡¢¤½¤Î»Ä¹â¤¬°ú¤½Ð¤µ¤ì¡¢Ä̲ߤȤ·¤Æ¸ò´¹¼êÃʤε¡Ç½¤ò¤¹¤ëÃʤˤʤë¤È¡¢¤½¤ÎÂвÁ¤È¤Ê¤ë¾¦ÉʲÁÃͤϡ¢»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤ë¤Î¤À¤«¤é¡¢¿Í¡¹¤Ï¡¢Ä̲ߤò»È¤ï¤º¤Ë¡¢¾ÃÈñ¤ò±ä´ü¤·¡¢»Ä¹â¤È¤·¤ÆÎ¯¤á¹þ¤à¤³¤È¤Ç¡¢¥Ç¥Õ¥ì¤Î櫤¬»Å¹þ¤Þ¤ì¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ê¤½¤¦¤À¡£
Ͷâ»Ä¹â¤¬Ä̲ߤȤ·¤Æ¸ò´¹¼êÃʤȤ·¤Æ¾ÃÈñ¤Ë¸þ¤«¤ï¤»¤ë¤¿¤á¤Ë¤Ï¡¢¥ª¥×¥·¥ç¥ó¤Ë¤ª¤±¤ëËþ´üÆü¤Ë¶á¤Å¤¯¤Û¤É»þ´Ö²ÁÃͤ¬¸º²Á¤¹¤ë¤È¤¤¤¦³µÇ°¤¬Æ³Æþ¤µ¤ì¤Ê¤¤¤È¡¢»Ä¹â¤È¤·¤ÆÂࢤµ¤ì¡¢Ä̲ߤȤ·¤Æ¾ÃÈñ¤Ë²ó¤é¤Ê¤¤¡£
¥ª¥×¥·¥ç¥ó¤¬SQÆü¤Ë¶á¤¯¤Ê¤ì¤Ð¤Ê¤ë¤Û¤É¡¢¼è°ú¤¬³èȯ²½¤¹¤ë¤Î¤Ï¡¢¤³¤Î¥¿¥¤¥à¡¦¥Ç¥£¥±¥¤¤¬¤¢¤ë¤¬¤¿¤á¤È¡¢¼«¤éÇã¤Ã¤Æ¤¤¤¿¥ª¥×¥·¥ç¥ó¤Î¹Ô»È²Á³Ê¤¬OTM¤È¤Ê¤Ã¤Æ¥Ñ¡¼¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤ë¤â¤Î¤Ç¤¢¤ë¡£
¤³¤ì¤é¤ÎÆó¤Ä¤ÎÍ×°ø¤¬¡¢Ëþ´üÆüÁ°¤ÎÈ¿ÂÐÇäÇã¤ò²Ã®¤µ¤»¤Æ¤¤¤ë¤Î¤Ç¤¢¤ë¡£
¥Þ¥¤¥Ê¥¹¶âÍøÀ¯ºö¤Ï¡¢¥Ó¥Ã¥°¥×¥Ã¥·¥åºâÀ¯À¯ºö¤È¤Î¥ß¥Ã¥¯¥¹¡¦¥Ý¥ê¥·¡¼¤¬É¬Í×
¤â¤Ã¤È¤â¡¢»ä¤«¤é¤¤¤ï¤»¤ì¤Ð¡¢¤³¤ì¤éWillem Buiter¤ÈGreg Mankiw¤Î¡ÖÄ̲ߤλĹâ¤È¤·¤Æ¤ÎÊÝͤˤ⡢Ä̲ߤκ߸ˤȤ·¤Æ¤Î¡¢¥¥ã¥ê¡¼¥¤¥ó¥°¤Ë¸«¹ç¤Ã¤¿¸º²Á¤ò¡×¤È¤¤¤¦¹Í¤¨Êý¤Ë¤Ï»¿À®¤·¤¦¤ë¤¬¡¢»þ´Ö²ÁÃÍ(¥»¡¼¥¿)¤Î¤â¤¦¤Ò¤È¤Ä¤Î¦Ì̤Ǥ¢¤ë¡ÖËþ´ü¤Ë¶á¤Å¤¯¤Û¤É¡¢¥Ü¥é¥Æ¥£¥ê¥Æ¥£¤Î¾å¾º(¥¬¥ó¥Þ¤ä¥Ù¥¬)¤¬¤¢¤ë¡×¤È¤¤¤¦»ÅÁȤߤ¬¤Ê¤±¤ì¤Ð¡¢ÊÒ¼êÍî¤Á¤Î¤è¤¦¤Ë»×¤¨¤ë¡£
¤Ä¤Þ¤ê¡¢¤³¤Î¤³¤È¤Ï¡¢¶âÍ»À¯ºö¤Î²ÝÂê¤Ç¤Ï¤Ê¤¯¡¢ºâÀ¯À¯ºö¤Î²ÝÂê¤Ç¤¢¤ê¡¢¤½¤ì¤Ï¡¢ÌÀÆü¤Î¾¦ÉʲÁÃͤÎÎô²½¤òËɤ®¡¢ÌÀÆü¤Î¾¦ÉʲÁÃͤξ徺¤ò¾·¤¤¦¤ë¤è¤¦¤Ê¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥åÀ¯ºö¤Ç¤¢¤ë¤È»ä¤Ï»×¤¦¤Î¤À¤¬¡¢¤É¤¦¤Ê¤ó¤À¤í¤¦?
¤³¤ì¤Ï¡¢¤¢¤ë°ÕÌ£¡¢¥¤¥ó¥Õ¥ì¥¿¡¼¥²¥Ã¥ÈÀ¯ºö¤È¤Î¥ß¥Ã¥¯¥¹¡¦¥Ý¥ê¥·¡¼¤È¤Ê¤ë¤«¤â¤·¤ì¤Ê¤¤¡£
¤ï¤«¤ê¤ä¤¹¤¤É½¸½¤Ë¤Ê¤ë¤«¡¢¤ï¤«¤ê¤Ë¤¯¤¤É½¸½¤Ë¤Ê¤ë¤«¤Ï¡¢¤Á¤ç¤Ã¤È¡¢¤¢¤ì¤À¤¬¡¢¿åÌ̤ËÉ⤫¤ÖÄà¤ê¤ÎÉ⤤¬¡¢¤À¤ó¤À¤ó¡¢ÄÀ¤ó¤Ç¡¢Æ°¤¤¤Æ¤¤¤ë¤«¤É¤¦¤«¸«¤¨¤Ê¤¯¤Ê¤Ã¤Æ¤¤Æ¤¤¤ë¤È¤¤Ë¡¢¥¤¥ó¥Õ¥ì¥¿¡¼¥²¥Ã¥ÈÀ¯ºö¤¬¡¢´û¸¤ÎÉ⤤ξå¤ËËÀ¤ò¤·¤Æ¡¢¸«¤¨¤ä¤¹¤¯¤¹¤ë¤Î¤Ç¤¢¤ì¤Ð¡¢¥Þ¥¤¥Ê¥¹¶âÍøÀ¯ºö¤Ï¡¢É⤤ÎÉâ¤¯Ãæ¿´¤ò²¼¤²¤Æ¤·¤Þ¤Ã¤Æ¡¢É⤤ò¿åÌ̤˽Ф·¤Æ¤·¤Þ¤¦¡¢¤È¤¤¤¦À¯ºö¤Ã¤Æ¤³¤È¤Ç¤É¤¦¤À¤í¤¦?
Äã¶âÍøÀè¿Ê¹ñ¤Ç¤¢¤ëÆüËܤˤª¤¤¤Æ¤â¡¢¤½¤í¤½¤í¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤Î¥¹¥¡¼¥à¹½ÃۤΤ¿¤á¤Î¸¡Æ¤¤¬Æü¶äÀ¯ºöÅö¶É¤Ç¤Ê¤µ¤ì¤ë¤Ù¤»þ¤ËÍè¤Æ¤¤¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£
Æ£´¬·ò»Ë»á¤â¡¢¤¹¤Ç¤Ë¡¢ÆüËܤΥǥե©¥ë¥È¤Ë¤Ä¤Ê¤¬¤ëÇËÌÇŪ¤ÊĹ´ü¶âÍø¹âƤò¤ß¤³¤·¤Æ¤Î¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÆüËÜ¤Ø¤ÎÆ³Æþ¤ò¡¢Á᤯¤«¤éÄó¸À¤·¤Æ¤¤¤ë¤è¤¦¤À¡£
»²¹Íʸ¸¥
¡ØSweden: negative interest rates and quantitative easing ¡Ù
¡ØUNCONVENTIONAL MONETARY POLICY: FIGHT DEFLATION BY TAXING CURRENCY ¡Ù
¡ÖOvercoming the Zero Bound on Nominal Interest Rates: Gesell’s Currency Carry Tax vs. Eisler’s Parallel Virtual Currency .¡×
¡ÖJapan¡Çs Lost Decade: Origins, Consequences, and Prospects For Recovery ¡×
¡Ø Ãæ±û¶ä¹Ô¤ÈÄ̲ßȯ¹Ô¤ò½ä¤ëË¡À©ÅÙ¤Ë ¤Ä¤¤¤Æ¤Î¸¦µæ²ñÊó¹ð½ñ ¡Ù
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/20 Friday
2009ǯ11·î20Æü
¡¡
º£Æü¤Î¡¡¿ûľ¿ÍÉûÁíÍý¤Î¡¢Í¸ú¤ÊºâÀ¯Âбþºö¤ò¼¨¤µ¤Ê¤¤¤Þ¤Þ¤Ç¤Î¡¢¤³¤È¤¢¤é¤À¤Æ¤Æ¤Î¡Ø¥Ç¥Õ¥ìÀë¸À¡Ù¤ËÂФ·¤Æ¡¢¡Ø¤¤¤Þ¤µ¤é¡¢²¿¤Ç?¡Ù¤È¤Î´ñ°Û¤Î´¶¤òÊú¤«¤ì¤¿Êý¤Ï¡¢»ä¤ò´Þ¤á¤Æ¡¢Â¿¤«¤Ã¤¿¤Î¤Ç¤Ï¤Ê¤«¤í¤¦¤«?
¡ØËÜÀÐÄ®Æüµ ¡Ù¤µ¤ó¤â¡¢Æ±Íͤδ¶ÁÛ¤òϳ¤é¤µ¤ì¤Æ¤¤¤ë¡£
¤¹¤Ç¤Ë¡¢Äã¶âÍø¤Ë¤â¤«¤«¤ï¤é¤º¡¢¥Ç¥Õ¥ì¸ú²Ì¤Ç¡¢ÆüËܤμ¼Á¶âÍø¤Ï¡¢¥¤¥®¥ê¥¹¤òÈ´¤¤¤Æ¡¢¥×¥é¥¹¤È¤Ê¤Ã¤Æ¤¤¤ë¤³¤È¤Ï¡¢Ã¯¤·¤â¤ï¤«¤Ã¤Æ¤¤¤ë¤³¤È¤Ç¤¢¤ë¡£
(¼Â¼Á¶âÍøÈæ³Ó¡á̾ÌܶâÍø¡Ý¥¤¥ó¥Õ¥ìΨ
ÆüËÜ2.7¥Ñ¡¼¥»¥ó¥È(̾ÌܶâÍø¡á0.1¥Ñ¡¼¥»¥ó¥È)¡¢¥¤¥®¥ê¥¹2.1¥Ñ¡¼¥»¥ó¥È(̾ÌܶâÍø¡á0.5¥Ñ¡¼¥»¥ó¥È)
»²¹Í¡ÖREAL INTEREST RATE FORECASTS ¡×
¡ÖÆü¶ä¤Ø¤Î¡È°µÎϡɤȡȸ£À©¡É¤¬ÁÀ¤¤¡×¤È¤Î¸«Êý¤â¤¢¤ë¤¬¡¢¤Ç¤Ï¡¢Æü¶ä¤Ë²¿¤¬¤Ç¤¤ë¤«¤È¤Ê¤ì¤Ð¡¢À¯ºö¶âÍø¤Ï¤¹¤Ç¤Ë¡¢ÈóÉéÀ©Ìó¤Î¸µ¤Ë¤Ê¤Ã¤Æ¤«¤éµ×¤·¤¤¤·¡¢ÎÌŪ´ËϺö¤Ë¤·¤Æ¤â¡¢Æü¶ä¼«¿È¤¬¤¤¤Ã¤Æ¤¤¤ë¤È¤ª¤ê¡¢¤½¤ì¤Ë¤è¤ëʪ²Á°ú¤¾å¤²¸ú²Ì¤Ë¤Ï¡¢¸Â³¦¤¬¤¢¤ë¤è¤¦¤À¡£
È·»³À¯¸¢¤Ï¡¢»Ò¶¡¼êÅö¤Æ¤äÇÀ¶È¼Ô¸ÍÊ̽êÆÀÊä½þ¤Ê¤É¤Î¡¢Ä¾ÀÜ»Ùʧ¤¤Åª¤ÊÊä½õ¶â¤Î¸òÉդˤè¤Ã¤Æ¤Î²È·×¼ûÍפÎÁýÂç¤ò°Õ¿Þ¤·¤Æ¤¤¤ë¤é¤·¤¤¤¬¡¢¤³¤ì¤È¤Æ¤â¡¢Àè¤Ë»ä¤Î¥Ö¥í¥°µ»ö¡Ø´¹¶â²óÏ©¹½ÃۤΥǥ¶¥¤¥ó¤Ê¤¡¢¹ṉ̃ÁíÁ¼ÃÖ²½¤Î¤ß¤ò¤á¤¶¤¹¡¢Ì±¼çÅÞÀ¯¸¢¤Î·ÐºÑÀ¯ºö¤Î¤¢¤ä¤Þ ¤ê¡Ù¤Ë¤â½ñ¤¤¤¿¤È¤ª¤ê¡¢¤³¤ì¤é¤ÎÀ¯ÉܻٽФϡ¢¤¹¤Ù¤Æ¡¢¥Ç¥Õ¥ì¤Îæ«( Liquidity Trap)¤Ë¤Ä¤«¤Þ¤Ã¤Æ¡¢²È·×ÆâË䢶â¤È¼ÚÆþ¶â½þ´Ôºâ¸»¤È²½¤·¤Æ¤·¤Þ¤¦²ÄǽÀ¤¬¹â¤¤¡£
¤À¤«¤é¤È¤¤¤Ã¤Æ¡¢º£¤Î̱¼çÅÞÀ¯¸¢¤Ë¤Ï¡¢¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥åÀ¯ºö¤Ï¤Ç¤¤Ê¤¤¡£
°ÕÃϰ¤Ê¸«Êý¤ò¤¹¤ì¤Ð¡¢À¯Éܦ¤¬¡¢¤³¤ì¤é¤ÎľÀÜ»Ùʧ¤¤·¿Êä½õ¶â¤Î·Êµ¤ÉâÍȸú²Ì¤Î¸Â³¦¤òÃΤ俤Τǡ¢Æü¶ä¦¤Ë¡¢¤½¤ÎÀÕǤ¤ò¤Õ¤Ã¤¿¤Î¤Ç¤Ï¤Ê¤¤¤Î¤«?¤È¤â¡¢¤«¤ó¤°¤é¤ì¤ëº£Æü¤Î¥Ç¥Õ¥ìÀë¸À¤À¡£
¤À¤Ã¤¿¤é¡¢¤³¤È¤µ¤é¡¢¥Ç¥Õ¥ì¤òÂ¥¿Ê¤·¤«¤Í¤Ê¤¤¡¢±ß¹âÍÆÇ§È¯¸À¤ò¡¢Æ£°æºâ̳Âç¿Ã¤Ï¡¢¤Ê¤¼¡¢¤³¤Î½©°Ê¹ß¡¢¼¹Ù¹¤Ë¡¢¹ñºÝ¼Ò²ñ¤Ëȯ¿®¤·¤Ä¤Å¤±¤¿¤Î¤«?
¤½¤Î¥¨¥¯¥¹¥¥å¡¼¥º¤È¤·¤Æ¡¢¶ñÂÎŪ¤ÊÆâ¼û¿¶¶½ºö¤âÄ󼨤·¤Ê¤¤¤Þ¤Þ¡¢Æ£°æºâ̳Âç¿Ã¤Ï¡¢¤Ê¤¼¡¢¡ØÆâ¼û¿¶¶½¡¢Æâ¼û¿¶¶½¡Ù¤È¡¢¶«¤Ó¤Þ¤ï¤Ã¤¿¤Î¤«?
Æü¶ä¤ËĹ´ü¹ñºÄ°ú¼õ¤Þ¤Ç¤âÂ¥¤·¤Æ¤¤¤ë¤Î¤Ç¤¢¤Ã¤¿¤é¡¢ºâÀ¯Ë¡Âè5¾ò¤¿¤À¤·½ñ¤Ï¡¢¹ñ²ñ¤ÎµÄ·è¤Ê¤ó¤Ç¤¹¤«¤é¡¢¤½¤ì¤³¤½¡¢¤ªÆÀ°Õ¤ÎÀ¯¼£¼çƳ¤Ç¡¢¤µ¤Ã¤µ¤ÈÌîÅÞÉԺߤǤª¤ä¤ê¤Ë¤Ê¤ì¤Ð¤¤¤¤¤À¤±¤ÎÏäÀ¡£
¤½¤·¤Æ¡¢º£Æü¤Î¥Ç¥Õ¥ìÀë¸À¸å¡¢Ä¹´ü¶âÍø¤ÏÄã²¼¤·¡¢¹ñºÄ²Á³Ê¤Ï¾å¾º¤·»Ï¤á¤Æ¤¤¤ë¡£
³ô²Á¤Ï¤¤¤Ã¤½¤¦²¼Íî¡¢±ß¹â¤Ï¤¤¤Ã¤½¤¦¿ÊĽ¤È¤¤¤Ã¤¿¾õ¶·¤À¡£
¤È¤¯¤Ë¡¢½µÌÀ¤±¤Î³°¹ñ°ÙÂØ»Ô¾ì¤Ï¡¢°ì¼ï¤Î¡Ø°Â¿´´¶¤È³Î¿®´¶¤ò»ý¤Ã¤Æ¡¢¤¤¤Ã¤½¤¦¤Î±ß¹â¡Ù¤Ø¤È·¹¤¯¤Ç¤¢¤í¤¦¡£
¹ñÆâÈǤΥ¥ã¥Ô¥¿¥ë¡¦¥Õ¥é¥¤¥È¤¬¤¹¤Ç¤Ë»Ï¤Þ¤Ã¤Æ¤·¤Þ¤Ã¤Æ¤¤¤ë¤È¤¤¤¦ÍÍÁê¤À¡£
¤½¤·¤Æ¡¢¤½¤ì¤¬°ìÃÊÍ¤ë¤È¡¢º£Å٤ϡ¢ËܳÊŪ¤ÊĹ´ü¶âÍø¤Î¾å¾º¡¦ÆüËܹñºÄ¤Ø¤Î¥Ç¥Õ¥©¥ë¥È·üǰ¡¦±ßÇä¤ê¤Ë¤è¤ë±ß°Âȿž¤È¤¤¤¦¡¢¹ñºÝÈǤΥ¥ã¥Ô¥¿¥ë¡¦¥Õ¥é¥¤¥È¤È¤¤¤¦¡¢µÕ¤Î¥¹¥Ñ¥¤¥é¥ë¤¬»Ï¤Þ¤ë¤Î¤Ç¤¢¤í¤¦¡£
¤Þ¤µ¤Ë¡¢ËܳÊŪ¤ÊÆüËÜÇä¤ê¤Ø¤Î³«»ÏÀë¸À¤¬¡¢º£Æü¤Î¡Ø¥Ç¥Õ¥ìÀë¸À¡Ù¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¡£
ÆÍÇ˸ý¤Ï¡¢²¿¤«¤¢¤ë¤Î¤«?
¤ä¤ëµ¤¤Ç¤¢¤ì¤Ð¡¢¤¤¤¯¤Ä¤«¤¢¤ë¤Î¤À¤í¤¦¡£
Âè°ì¤Ï¡¢ÈóÉéÀ©Ìó¤Î¸µ¤Ç¤Î»Ä¤ê¾¯¤Ê¤¤À¯ºö¶âÍø¤Î°ú¤²¼¤²¶Ò¤Ç¤Ï¤¢¤ë¤¬¡¢Àº°ìÇդξ®¹ï¤ß¶âÍø°ú²¼¤²¤Ë¤è¤Ã¤Æ¡¢¿´ÍýŪ¤Ê¸ú²Ì¤ò¤Í¤é¤¦¡£
ÂèÆó¤Ï¡¢Æü¶ä¤Ë¤è¤ëÂçÉý¤ÊήưÀ¶¡µë(¥Þ¥Í¥¿¥ê¡¼¥Ù¡¼¥¹³ÈÂç)¤ÈƱ»þ¤Ë¡¢Æü¶ä¤Ë¤è¤ë¹ñºÄ¤ÎÂçÎÌÇ㤤Æþ¤ì¤È¡¢À¯Éܤˤè¤ë¹ñºÄȯ¹Ô¤È¡¢¹ñºÄ¤Îȯ¹Ô¤Ë¤è¤ë¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥å¤Ë¤è¤ëÂç·¿·Êµ¤ÉâÍȺö¤ÎÃå¼ê¤Ë¼è¤ê³Ý¤«¤ë¡£
¤Á¤Þ¤Á¤Þ¤·¤¿»ö¶È»Åʬ¤±Åª¤Ê¤â¤Î¤Ï¡¢¤³¤³¤é¤ÇÂǤÁ»ß¤á¤È¤¹¤ë¡£
Âè»°¤Ï¡¢Æü¶ä¤Ë¤è¤ëÊÆ¹ñºÄ¤ÎÂçÎÌ¹ØÆþ¤Ç¤¢¤ê¡¢¤³¤ì¤Ë¤è¤Ã¤Æ¡¢¥Ð¥¤¥Ñ¥¹Åª¤Ê¡¢¼Â¼ÁŪ°ÙÂØ²ðÆþ¤òÁÀ¤¦¡£
¤³¤ó¤Ê¤È¤³¤í¤À¤í¤¦¤«¡£
ÂèÆó¡¦Âè»°¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤¤¤º¤ì¤â¡¢ÅÙ¶»¤¬É¬ÍפÊÂçµ»¤À¡£
¤·¤«¤â¡¢Ì±¼çÅÞÀ¯¸¢¤Ï¡¢¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥åÀ¯ºö¤¬¡¢µµ°æ¤µ¤ó¤ò½ü¤¤¤Æ¤Ï¡¢·ù¤¤¤ÈÍè¤Æ¤¤¤ë¡£
¤·¤«¤·¡¢»ä¤Î¥Ö¥í¥°¡Ø¥ê¥Á¥ã¡¼¥É¡¦¥¯¡¼»á¤Î¡Ö¥¢¥á¥ê¥«¤ÏÆüËܤβáµî¤Î¼ºÇԤ˳ؤ١×ÏÀ ¡Ù¤Ç¤â½Ò¤Ù¤¿¤è¤¦¤Ë¡¢¥¯¥ë¡¼¥°¥Þ¥ó»á¤Ï¡¢¼¡¤Î¤è¤¦¤Ë¸À¤Ã¤Æ¤¤¤ë¡£
¡ÖÅöÌ̵ðÂç²½¤¹¤ëÀ¯ÉܻٽФϡ¢À¯ÉܤκâÀ¯¼ý»Ù¤ò°²½¤µ¤»¤Ï¤¹¤ë¤¬¡¢·ÐºÑ¤ò»Ù¤¨¤ë¼ÂºÝ¤ÎºâÀ¯¥³¥¹¥È¤Ï¡¢¤â¤Ã¤È¾®¤µ¤¤¤Ï¤º¤À¡£
´Êñ¤Ë·×»»¤·¤Æ¤â(Back-of-the-envelope calculations )¡¢ºâÀ¯»Ù½Ð¤¬¡Ö¤¿¤ÀÈÓ¡×(Free Lunch)¤Ë¤Ï½ª¤ï¤é¤Ê¤¤¤³¤È¤ÏÌÀ¤é¤«¤Ç¤¢¤ë¡£¡×
¤Ä¤Þ¤ê¡¢¤¤¤Þ¤äµ¤Â©±â¡¹¤¿¤ëÆüËܷкѤˤȤäƤϡ¢¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥å¤È¤¤¤¦AED(¿´Â¡¤Ë¥·¥ç¥Ã¥¯¤òÍ¿¤¨¡¢ÁÉÀ¸¤µ¤»¤ë½ùºÙư´ï)¤¬É¬ÍפȤ¤¤¦¤ï¤±¤Ç¤¢¤ë¡£
¤Þ¤¢¡¢¤³¤³¤Þ¤Ç¤ß¤ë¤È¡¢¥Ð¡¼¥Ê¥ó¥¤µ¤ó¤¬²áµî¤ÎÆüËֱܹé¤Ç¡¢ÆüËܤΥ¤¥ó¥¿¥²Çɤˤµ¤µ¤²¤¿Èëºö(Ž¢Æü¶ä¤¬¹ñºÄ¤ò¹ØÆþ¤·Â³¤±¤ì¤Ð¤¤¤Ä¤«¤Ïɬ¤º¥¤¥ó¥Õ¥ì¤ò¾·Íè¤Ç¤¤ë¤Ï¤º¤Ç¤¢¤ë¡£Ž£¤È¤¤¤¦¥Ð¡¼¥Ê¥ó¥¤ÎÇØÍýË¡)¤½¤Î¤â¤Î¤Î°ìÉô¼Â¹Ô¤È¤Ê¤ë¤è¤¦¤Ê¤Î¤À¤¬¡¢¤É¤¦¤â¡¢º£¤Î¡¢È·»³À¯¸¢¤Ë¤·¤Æ¤â¡¢Æü¶äÁíºÛ¤Ë¤·¤Æ¤â¡¢¡Ö¤Á¤ó¤Þ¤ê¤È¥«¥·¥³Ì̤·¤¿¡×ÌÌ¡¹¤·¤«¤¤¤Ê¤¤¤È¤³¤í¤«¤é¡¢µµ°æÀŹᤵ¤ó¤ÏÊ̤Ȥ·¤Æ¡¢¤³¤ì¤Û¤É¤ÎÂçµ»¤¬¤Ç¤¤ëÅÙ¶»¤È´ïÎ̤ò¡¢»ý¤Á¹ç¤ï¤»¤Æ¤¤¤ë¤È¤Ï»×¤ï¤ì¤Ê¤¤¤Î¤À¤¬¡£
·ÐºÑ¶¨Îϳ«È¯µ¡¹½¡Ê£Ï£Å£Ã£Ä¡Ë¤Î¥¢¥ó¥Ø¥ë¡¦¥°¥ê¥¢»ö̳ÁíĹ¤Ï¡Ö¥Ç¥Õ¥ì¤ÈÆ®¤¨¡×¤ÈÆüËܤò¼¸Ó£¤·¡¢°Å¤Ë¹ñºÄÇ㤤Àڤꥪ¥ÚÁý³Û¤Ê¤É¤ò´Þ¤à¹ÈϤÊÎÌŪ´ËÏÂÁ¼ÃÖ¤ò¼¨º¶¤·¤¿¤È¤¤¤¦¤Î¤À¤¬¡¢¤½¤Î¤è¤¦¤ÊÌïË¥ºö¤Ï¤â¤Î¤È¤â¤»¤º¡¢¥Ç¥Õ¥ì¤Î櫤ϡ¢È·»³¿·À¯¸¢¤ÎÌܶÌÀ¯ºö¤Ç¤¢¤ëľÀÜ»Ùʧ¤¤ÅªÊä½õ¶â¤Î¤â¤Ä¸ú²Ì¤ò¡¢²»¤â¤Ê¤¯²È·×ÆâË䢶â¤È¤·¤Æ¡¢ÄÀÅ¡¦µÛÃ夵¤»¤ë¤¿¤á¤Î¥¹¥¡¼¥à¤È¤·¤Æ¤ÎÌò³ä¤ò³Î¼Â¤Ë²Ì¤¿¤½¤¦¤È¤·¤Æ¤¤¤ë¤è¤¦¤À¡£
¤È¤³¤í¤Ç¡¢ÀÄ»³³Ø±¡Âç³Ø¤Î¹ÁŰͺ¤µ¤ó¤È¤¤¤¦Êý¤¬¡¢ÀijؤΥá¥ë¥Þ¥¬¡ÖÀijأ֡ݣΣţԥޥ¬¥¸¥ó ¡×(2003/2/5 »þÅÀ¤Ç¤Î¤«¤Ê¤ê¸Å¤¤µ»ö¤Ç¤¹¤¬¡£)¤Ç¤³¤ó¤ÊÄ󰯤ò¤·¤Æ¤¤¤¿¤¬¡¢¼Â¸½À¤Ï¤É¤¦¤Ê¤ó¤À¤í¤¦?
¤«¤Ê¤ê¡¢¥È¥ó¥Ç¥â°Æ¤À¤¬¡¢¥Ç¥Õ¥ì¤Î櫲ò¾Ãºö¤È¤·¤Æ¤Ï¡¢¤Á¤ç¤Ã¤È¶½Ì£¤ò¤Ò¤«¤ì¤ëÄó°Æ¤Ç¤Ï¤¢¤Ã¤¿¡£
¡Ö¹âÎð¼Ô¤ÏÄã¶âÍø¤Ç¤âºÇ¤â°ÂÁ´À¤Î¹â¤¤¹ñºÄ¤òÁª¹¥¤·¤Æ¤ª¤ê¡¢£²·î£´Æü¤Îȯ¹Ô¤µ¤ì¤¿¸Ä¿Í¸þ¤±¹ñºÄ¤Î¹ØÆþ´õ˾¤Ïȯ¹Ô³Û¤Î²¿Çܤˤâ¤Ê¤Ã¤Æ¤¤¤ë¡£
¤³¤ÎºÝ¡¢¹âÎð¼Ô¸þ¤±¤ËÇ¯Íø1.5¡ó¤Î¹â¶âÍø¹ñºÄ¤ò30Ãû±ßµ¬ÌÏȯ¹Ô¤·¡¢¤½¤Î»ñ¶â¤ò¤â¤Ã¤ÆÈ¯¹ÔºÑ¤ß³ô¼°Áí³Û¤Î10¿ô¡ó¤ò¹ØÆþ¤¹¤ì¤Ð³ô¼°»Ô¾ì¤Î¼ûµë¤Ï°ìÅ٤˵Õž¤·¡¢³ô¼°¤Ï¤½¤ÎÀµ¾ï¤Ê²Á³Ê¤Ë¤Þ¤Ç²óÉü¤¹¤ë¤Ç¤¢¤í¤¦¡£¡×
¤Þ¤¢¡¢¸Ä¿Í¸þ¤±¡¢¤È¤¯¤Ë¡¢¹âÎð¼Ô¸ÂÄê¤Ç¤Î¹â¶âÍø¹ñºÄ¤òȯ¹Ô¤·¤Æ¡¢¥Ç¥Õ¥ì¤Î櫤θµ¶§¤Î²ÈÄíÆâË䢶â¤ò°ú¤½Ð¤¹¤È¤¤¤¦ÀïË¡¤Î¤è¤¦¤À¤¬¡¢¤½¤Î¹â¶âÍø¹ñºÄ¤Î½þ´Ô»þ¤Þ¤Ç¡¢ÆüËܷкѤ¬»ý¤Áľ¤·¤Æ¤¤¤ì¤Ð¡¢·ë²Ì¥ª¡¼¥é¥¤¤ÎÏäʤó¤À¤¬¡¢¤â¤·¡¢¤½¤¦¤Ç¤Ê¤¤¤È¡¢¸½ºß(¹ñ¤ÎÀǼý¤ËÂФ¹¤ëÍøÊ§¤¤Èñ¤ÎÈæÎ¨¤¬10ǯ¤Ö¤ê¤Ë20¡óĶ)ƱÍÍ¡¢²áµî¤Î¹â¶âÍø¹ñºÄ¤Î¶âÍø»Ùʧ¤¤¤Ë¡¢¹ñ¸Ë¤Ï¤µ¤é¤Ë²Ð¤Î¼Ö¤È¤¤¤¦»öÂ֤ˤʤäƤ·¤Þ¤¦¤Î¤À¤¬¡£
Willem Buiter (¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô)¤Ë¤è¤ì¤Ð¡¢¥Ç¥Õ¥ì¤Î櫤«¤éƨ¤ì¤ë¤¿¤á¤Ë¤Ï¡¢Æó¤Ä¤Î¥ª¥×¥·¥ç¥ó¤·¤«¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£
¤Ò¤È¤Ä¤Ï¡¢¼ûÍ×´µ¯ºö¤Ç¤¢¤ê¡¢¤â¤¦¤Ò¤È¤Ä¤Ï¡¢”Taxing currency”¤Ë¤è¤Ã¤Æ¡¢¡ØÉé¤Î̾ÌܶâÍø¡Ù(negative nominal interest rate)(¥Þ¥¤¥Ê¥¹¶âÍø)¤ò’carry tax¤È¤¤¤¦·Á(ÃϰèÄ̲ߤÎÁĤȤ⤤¤¨¤ë¸ºß¤ÎSilvio Gesell¤¬¹Í¤¨½Ð¤·¤¿Ä̲ߤؤΥ¹¥¿¥ó¥×¤òµÁ̳ÉÕ¤±¤ë¤È¤¤¤¦°Æ¤Ë»÷¤¿¤â¤Î¤Î¤è¤¦¤À¡£¡ÖËè·î10±ßʬ¤Î¥¹¥¿¥ó¥×¤òޤé¤Ê¤¤¤È1Ëü±ß»¥¤Ï»È¤¨¤Þ¤»¤ó¤è¡×¤È¤¤¤¦¤è¤¦¤Ê°Æ¤Î¤è¤¦¤À¡£²ÈÄíÆâ¤Ç²ßʾ¤òË䢤·¤Æ¤¤¤ì¤Ð¡¢¤½¤ì¤ËÂФ¹¤ë¥¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¤¬¤«¤«¤ë¤È¤¤¤¦¥·¥¹¥Æ¥à¤Î¤è¤¦¤À¡£)¤Ç²Ý¤¹¤ë¤³¤È¤Ç¤¢¤ë¤È¤¤¤¦¡£
¥Þ¥¤¥Ê¥¹¶âÍø¤Ï¡¢¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô(Riksbank)¤Ç»î¹Ôºø¸íÃæ¤Ç¤¢¤ë¡£
2009ǯ7·î2Æü¤Ë¡¢Riksbank¤Ï¡¢À¯ºö¶âÍø(¥ì¥Ý¡¦¥ì¡¼¥È¡¢Repo Rate)¤ò¡¢¤½¤ì¤Þ¤Ç¤Î0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤²¼¤²¤ë¤ÈƱ»þ¤Ë¡¢2009ǯ7·î8Æü¤«¤é¤Ï¡¢Riksbank¤Ë¸ýºÂ¤ò»ý¤Ä¾¦¶È¶ä¹Ô¤ÎͶâ¸ýºÂ¤ÎͶâ¶âÍø(Deposit Rate)¤ò¡¢¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ø¡¢Riksbank¤«¤é¾¦¶È¶ä¹Ô¤Ø¤ÎÂߤ·½Ð¤·¶âÍø¤ò¡¢0.75¥Ñ¡¼¥»¥ó¥È¤ØÊѹ¹¤·¤Æ¤¤¤ë¡£
¤³¤ì¤é¤Î¥Þ¥¤¥Ê¥¹¶âÍø¥¹¥¡¼¥à¤Ï¡¢, Greg Mankiw ¤ä¡¢Willem Buiter¤Î¹Í¤¨Êý¤Ë±è¤Ã¤¿¤â¤Î¤À¡£
¾¦¶È¶ä¹Ô¤ÎͶâÊ¿»Ä¤¬¤¤¤¯¤é¤«¤Ë¤â¤è¤ë¤¬¡¢ÍýÏÀŪ¤Ë¤Ï¡¢À¯ºö¶âÍø¤ò0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤²¼¤²¤Æ¤â¡¢Ãæ±û¶ä¹Ô¤Î¾¦¶È¶ä¹Ô¤ËÂФ¹¤ëͶâ¶âÍø¤ò¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¡¢¾¦¶È¶ä¹Ô¤ËÂФ¹¤ë¼Â¼Á¶âÍø¤Ï¡¢¤â¤È¤Î0.5¥Ñ¡¼¥»¥ó¥È¤È¼Â¼ÁƱ¤¸¿å½à¤Ë°Ý»ý¤Ç¤¡¢ÈóÉéÀ©Ì󤫤é°ìÄê¤Î²ò½ü¤¬¤Ç¤¤ë¡¢¤È¤¤¤¦¡¢¥Õ¥í¡¼¥Æ¥£¥ó¥°¤Î¹Í¤¨Êý¤Ë´ð¤Å¤¯¤â¤Î¤Î¤è¤¦¤Ç¤¹¤Í¡£
¤³¤ì¤òÆüËܤˤ¢¤Æ¤Ï¤á¤Æ¤ß¤ë¤È¡¢ÍøÂ©¥¼¥í¤ÎÆüËܶä¹ÔÅöºÂͶâ¤ò¥Þ¥¤¥Ê¥¹¶âÍø¤È¤·¡¢¡Ý0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤·¡¢ÌµÃ´¥³¡¼¥ë(¥ª¡¼¥Ð¡¼¥Ê¥¤¥Èʪ)¥ì¡¼¥È¤ò0.75¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¡¢¤È¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤·¤ç¤¦¤«¤Í?
¤¿¤À¡¢
¥Þ¥Í¥¿¥ê¡¼¥Ù¡¼¥¹¡á¡Ö¡ÆüËܶä¹Ô·ôȯ¹Ô¹â¡×¡Ü¡Ö¢²ßʾήÄ̹â¡×¡Ü¡Ö£Æü¶äÅöºÂͶâ¡×
¤Ê¤Î¤Ç¡¢£¤Î¥Þ¥¤¥Ê¥¹¶âÍø²½¤Ë¤è¤Ä¤Æ¡¢£¤ÎÊ¿»ÄÇÉ¡¢¸º¾¯¤¹¤ëʬ¤ò¡¢¡¢¤Ç¤É¤ÎÄøÅÙÊ䤦¤«?¤È¤¤¤¦¤È¤³¤í¤Ë¡¢Ãæ±û¶ä¹Ô¥Ù¡¼¿Þ¤Ç¤ÎºÇÎɤÎÉý¤¬Áý¤¨¤Æ¤¯¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£
º£¤Þ¤Ç¡¢£¤Î»Ä¹â¤Ï¡¢Í¿·ï¤Ç¤·¤«²á¤®¤Ê¤«¤Ã¤¿¤Î¤Ç¤¢¤í¤¦¤«¤é¡£
¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô¤Ç¤â¡¢Æ±Íͤιͤ¨Êý¤ò¸¡Æ¤¤Î¤è¤¦¤À¡£
¥¹¥¦¥§¡¼¥Ç¥ó¤Î¥¼¥í¶âÍø¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ØSweden: negative interest rates and quantitative easing ¡Ù¤Ê¤É¤ò¤´»²¾È
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ØUNCONVENTIONAL MONETARY POLICY: FIGHT DEFLATION BY TAXING CURRENCY ¡Ù¤Ê¤É¤â¤´»²¾È
Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖObservations on Negative Interest Rates ¡×¡ÖMore on Negative Interest Rates ¡×¤Ê¤É¤ò¤´»²¾È
Willem Buiter¤Ï¡¢Ì¾ÌܶâÍø¤¬ÈóÉéÀ©Ìó¤ò¼õ¤±¤Ê¤¤¤¿¤á¤Ë¡¢¼¡¤Î»°¤Ä¤ÎÊýË¡¤¬¤¢¤ë¤È¤·¤Æ¤¤¤ë¡£(¤«¤Ê¤ê¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê°Æ¤Ê¤Î¤Ç¡¢¤Ó¤Ã¤¯¤ê¤µ¤ì¤Ê¤¤¤è¤¦¤Ë)
¡Ä̲ߤòÇѻߤ·¡¢¹ṉ̃¤¹¤Ù¤Æ¤¬¡¢Ãæ±û¶ä¹Ô¤Ë¸ýºÂ¤ò»ý¤Ä¡£¤½¤Î¾ì¹ç¡¢¤½¤Î¸ýºÂ¤ËÂФ·¤Æ¤Ï¡¢¥×¥é¥¹¤Î¶âÍø¤È¥Þ¥¤¥Ê¥¹¤Î¶âÍø¤ÎξÊý¤¬»þ¤Ë±þ¤¸¤Æ¡¢¤«¤«¤ë¡£
¢Ä̲ߤÎÊÝͤËÂФ·¤Æ¡¢¥¥ã¥ê¡¼¤Ë±þ¤¸¤ÆÀǶ⤬¤«¤«¤ë¡£
£¿·¤·¤¤²ßʾ¤ÎƳÆþ(rallod¤È¤¤¤¦Ì¾¤ÎÀ¤³¦Ä̲ß)¤Ë¤è¤Ã¤Æ¡¢¸ýºÂ¤Î»Ä¹â¤È¤·¤Æ²ÁÃͤȡ¢¸ò´¹¼êÃʤȤ·¤Æ¤ÎÄ̲ߤβÁÃͤȤò¡¢¥Ç¥«¥Ã¥×¥ê¥ó¥°¤¹¤ë¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖThe wonderful world of negative nominal interest rates, again ¡×¤ò¤´»²¾È
Ä̲߲ÁÃͤâÏ·²½¤·¤¦¤ë¤È¤¤¤¦¹Í¤¨Êý¤Ï¡¢¥ª¥×¥·¥ç¥ó¤Î¥¿¥¤¥à¡¦¥Ç¥£¥±¥¤(Ëþ´ü¤¬¶á¤Å¤¯¤Ë¤Ä¤ì¤Æ¡¢¥ª¥×¥·¥ç¥ó¤Î»þ´Ö²ÁÃͤ¬¸º¤Ã¤Æ¤¤¤¯¡£)¤Î¹Í¤¨Êý¤Ë»÷¤Æ¤¤¤ë¡£
¤¤¤µ¤µ¤«¡¢¥Á¥ó°Æ¤Ë°¤¹¤ë¥Ç¥Õ¥ì¤Îæ«Âкö¤À¤¬¡¢¤³¤Î¤è¤¦¤Ê°Æ¤ËÆüËܤΥǥեìÂкö¤òµá¤á¤ë³Ø¼Ô¤â¤¤¤ë¤è¤¦¤À¡£
»²¹Í¡ÖOvercoming the Zero Bound on Nominal Interest Rates: Gesell’s Currency Carry Tax vs. Eisler’s Parallel Virtual Currency .¡×
¡ÖJapan¡Çs Lost Decade: Origins, Consequences, and Prospects For Recovery ¡×
ÆüËܸìʸ¸¥¤Ç¤Ï¡¢¤³¤Î¤¢¤¿¤ê¡Ø Ãæ±û¶ä¹Ô¤ÈÄ̲ßȯ¹Ô¤ò½ä¤ëË¡À©ÅÙ¤Ë ¤Ä¤¤¤Æ¤Î¸¦µæ²ñÊó¹ð½ñ ¡Ù¤¬»²¹Í¤Ë¤Ê¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/19 Thursday
¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø
¤³¤Î¾ðÊó¤Ï11·î19Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ»ö¤Ç¤Ï¡¢²¼µ¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ»ö½ç¤Ç¤¹¡£
D225GÊѰÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ (11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤ¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ (11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)
2009ǯ11·î19Æü
¡¡
¤«¤Í¤Æ¤«¤é¤³¤Î¥Ö¥í¥°¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ ¡×¤Ê¤É¤Ç¤âÅÁ¤¨¤Æ¤¤¤ë¥¦¥¯¥é¥¤¥Ê¤Ç¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤è¤ë»àË´¤À¤¬¡¢¤³¤³¤ËÍè¤Æ¡¢¤³¤ì¤Ë¤è¤ë»à¼Ô¤Ï¡¢344¿Í¤Ë㤷¤¿¤È¤Î¤³¤È¤Ç¤¢¤ë¡£
°ìÆü¤¢¤¿¤ê16¿Í¤º¤Ä»àË´¼Ô¤¬Áý²Ã¤·¤Æ¤¤¤ë¤È¤¤¤¦¥Ú¡¼¥¹¤Î¤è¤¦¤Ç¤¢¤ë¡£
¤³¤³¤ËÍè¤Æ¡¢¥¦¥¤¥ë¥¹¤Î¥·¡¼¥±¥ó¥¹¤âȯɽ¤µ¤ì¤¿¤¬¡¢¤³¤ì¤Ë¤è¤ë¤È¡¢10¸¡ÂΤΤ¦¤Á¡¢4¸¡ÂΤˡ¢HA¤Ë¤ª¤¤¤Æ¡¢D225GÊѰۤò¼¨¤·¤Æ¤¤¤¿¤È¤¤¤¦¡£
D225GÊѰۤòµ¯¤³¤·¤Æ¤¤¤ë¥¦¥¤¥ë¥¹Ì¾¤Ï²¼µ¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£
A/Lviv/N6/2009
A/Ternopil/N11/2009
A/Ternopil/N10/2009
A/Lviv/N2/2009
¤³¤Î¤¦¤Á¡¢1¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¹¢¤«¤é¤Î¤â¤Î¤Ç¤¢¤ê¡¢3¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢ÇÙÁÈ¿¥¤«¤é¤Î¤â¤Î¤Ç¤¢¤Ã¤¿¡£
¤³¤Î4¸¡ÂΤòºÎ¼è¤·¤¿´µ¼Ô¤Ï¤¤¤º¤ì¤â»àË´¼Ô¤Ç¤¢¤Ã¤¿¡£
É¡°öƬ¤«¤é¤Î¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢D225GÊѰۤϸ«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¤¤¦¡£
¤³¤Î¤³¤È¤«¤é¡¢D225GÊѰۤ¬¡¢ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¸«¤é¤ì¤ë¤Î¤«¤É¤¦¤«¤¬¡¢´Ø¿´¤Î¤â¤È¤È¤Ê¤Ã¤Æ¤¤¤ë¤è¤¦¤À¡£
¤½¤Î¤¿¤á¤Ë¤Ï¡¢¤³¤ÎÇÙÁÈ¿¥¤«¤é¤Î¸¡ÂΤ¬É¡°öƬ¤«¤é¤ÎÇ´±Õ¤«¤é¤¤Æ¤¤¤ë¤â¤Î¤«¤É¤¦¤«¤òÁáµÞ¤Ë¸¡ºº¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£
¤Ê¤¼¤Ê¤é¡¢¾åµ¤Æ»¤Ç¤Î¥¦¥¤¥ë¥¹¤¬¤Û¤È¤ó¤É¤Ê¤¯¡¢Ç٤˥¦¥¤¥ë¥¹¤¬½¸Ã椷¤Æ¤¤¤ë²ÄǽÀ¤¬¶¯¤¤¤«¤é¤À¡£
¶Ëü¤Ë¤Ï¡¢É¡°öƬ¤«¤é¤Î¸¡ÂΤǤϡ¢±¢À¤ò¼¨¤¹¤³¤È¤¹¤é¤¢¤ë¤«¤é¤À¡£
CDC¤Î¸«²ò¤Ç¤Ï¡¢¥é¥Ô¥Ã¥É¡¦¥Æ¥¹¥È¤Ç¤Ï¡¢10¥Ñ¡¼¥»¥ó¥È¤«¤é70¥Ñ¡¼¥»¥ó¥È¤Î¶Ò¤Ç¤Î´¶Å٤κ¹¤¬¤¢¤ë¤È¤¤¤¦¡£
¤·¤¿¤¬¤Ã¤Æ¡¢¾õ¶·¤Ë¤è¤Ã¤Æ¤Ï¡¢¼ÂÂÖ¤Î10¥Ñ¡¼¥»¥ó¥È¤·¤«¡¢ÍÛÀ¤ò¼¨¤µ¤Ê¤¤¾ì¹ç¤â¤¢¤ë¤È¤¤¤¦¡£
±¢À¤ò¼¨¤·¤Æ¤¤¤ë¥é¥Ô¥Ã¥É¡¦¥Æ¥¹¥È¤Î¥µ¥ó¥×¥ë¤Ï¡¢¤³¤Î¾ì¹ç¡¢¤è¤êÀººº¤ò¤¹¤ë¤³¤È¤¬É¬ÍפǤ¢¤ë¤È¤¤¤¦¡£
¤³¤ÎD225GÊѰۤ¬ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¤¤¤ë¤È¤¤¤¦¤³¤È¤Ï¡¢H1N1¥¦¥¤¥ë¥¹¤¬ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¤¤¤ë¤³¤È¤ò°ÕÌ£¤·¤Æ¤ª¤ê¡¢¤³¤Î¤³¤È¤¬¡¢¥µ¥¤¥È¥«¥¤¥ó¸½¾Ý¤ò°ú¤µ¯¤³¤·¤Æ¤¤¤ë¤È¸«¤ë¸þ¤¤â¤¢¤ë¤è¤¦¤À¡£
¤³¤ÎD225GÊѰۤϡ¢¤³¤ì¤Þ¤Ç¡¢¤¹¤Ç¤Ë¡¢¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊѰۤǤ⤢¤ë¡£
¤·¤«¤·¡¢D225GÊѰۤ¬¸«¤é¤ì¤¿¤È¤¤¤¦¤³¤È¤Ï¡¢¤³¤Î¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒŪ¤ÊÎò»ËÇØ·Ê(multiple genetic backgrounds via recombination)¤ò¸ì¤ë¤â¤Î¤Ç¤¢¤ë¤È¤¹¤ë¸«Êý¤â¤¢¤ë¡£
¤¹¤Ê¤ï¤Á¡¢»°¼ï¤Î¥¦¥¤¥ë¥¹¤ÎºÆ·ë¹ç(triple reassortant viruses)¤Ë¤ß¤é¤ì¤ëÊѰۤǤ¢¤ë¤È¤¤¤¦Àâ¤Ç¤¢¤ë¡£
¤½¤ÎÍýͳ¤È¤·¤Æ¡¢1918ǯ¤«¤é1919ǯ¤Ë¤«¤±¤Æ¤Î¥¹¥Ú¥¤¥ó¤«¤¼¤Ë¤ª¤¤¤ÆºÎ¼è¤µ¤ì¤¿Æó¤Ä¤Î¥¦¥¤¥ë¥¹¡¡A/New York/1/1918 ¤È¡¡A/London/1/1919¡¡¤Ë¤â225¤Ë¤ª¤¤¤Æ¡¢Æ±ÍͤÎD225GÊѰۤ¬¸«¤é¤ì¤¿¤³¤È¤Ë¤Ä¤¤¤Æ¤Î·üǰ¤«¤éÍè¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£
°ìÊý¡¢¥Î¥ë¥¦¥§¥¤¤Ë¤ª¤¤¤Æ¤â¡¢Æ±ÍͤÎÊѰۤò»ý¤Ä´µ¼Ô¤¬È¯¸«¤µ¤ì¤¿¡£
H3¥Ê¥ó¥Ð¥ê¥ó¥°¤Ç¤Ï¡¢¥Ý¥¸¥·¥ç¥ó222¤¬¥Ý¥¸¥·¥ç¥ó225¤Ë¤¢¤¿¤ë¡£
¤Þ¤¿¡¢¥í¥·¥¢¤Ë¤ª¤¤¤Æ¤Ï¡¢A/Vladivostok/1/2009Æó¡¢Æ±ÍͤÎÊѰۤ¬¸«¤Ä¤«¤Ã¤Æ¤¤¤ë¡£
¥Î¥ë¥¦¥§¥¤¤Î¾ì¹ç¤Ï¡¢70¿Í¤Ë¤Ä¤¤¤Æ¸¡ºº¤ò¤·¡¢¤½¤Î¤¦¤Á¡¢8¿Í¤Î´µ¼Ô¤Ï»àË´¤·¤Æ¤¤¤ë¡£
D225GÊѰۤ¬¸«¤é¤ì¤¿¤Î¤Ï¡¢¤³¤Î¤¦¤Á¤Î5¿Í¤Ç¤¢¤ê¡¢¤½¤Î¤¦¤Á¤Î2¿Í¤Ï»àË´¤·¤Æ¤¤¤ë¡£
¾¤Î»°¿Í¤Ï¡¢½¸Ãæ¼£Îż¼¤ËÆþ¤Ã¤Æ¤ª¤ê¡¢½Å¾É¤Ç¤¢¤ë¡£
¤³¤³¤Ç¤â¡¢¥¦¥¯¥é¥¤¥Ê¤ÈƱ¤¸¤¯¡¢ÊѰۥ¦¥¤¥ë¥¹¤Ï¡¢Ç٤˽¸Ã椷¤Æ¡¢È¯¸«¤µ¤ì¤Æ¤¤¤ë¤È¤¤¤¦¡£
¥Ý¡¼¥é¥ó¥É¤Ë¤ª¤¤¤Æ¤â¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤è¤ë»à¼Ô¤¬µÞÁý¤·¤Æ¤¤¤ë¤¬¡¢¤³¤ì¤é¤Ë¤âD225GÊѰۤ¬¤¢¤Ã¤¿¤«¤É¤¦¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢º£¤Î¤È¤³¤í¡¢³Îǧ¤Ç¤¤Æ¤¤¤Ê¤¤¤è¤¦¤À¡£
È÷¹Í
¤³¤ì¤Þ¤ÇD225GÊѰۤò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷(¥¦¥¯¥é¥¤¥Êʬ¤ò½ü¤¯)
01¡¡A/******/index/2009/02/01 (A/swine-flu/index/2009-02-01(H1N1))
02¡¡A/Hiroshima/201/2009/06/17
03¡¡A/Georgia/01/2009/04/27
04¡¡A/Zhejiang-Yiwu/11/2009/09/06
05¡¡A/Zhejiang/DTID-ZJU03/2009/09/07
06¡¡A/Zhejiang/DTID-ZJU02/2009/09/07
07¡¡A/Sao Paulo/53206/2009/07/19
08¡¡A/Sao Paulo/53225/2009/08/01
09¡¡A/New York/04/2009/04/
10¡¡A/Catalonia/NS1706/2009/07/29
11¡¡A/Mexico/InDRE4114/2009//
12¡¡A/Texas/11/2009/04/23
13¡¡A/Texas/05/2009/04/15
14¡¡A/Mexico/3955/2009/04/02
15¡¡A/Cancun-NY/Index/2009/04/15
»²¹Í
¡ÖH5N1Experts.org - View Single Post - swine flu sequences ¡×
my supposed index-strain , the virus which I consider the best candidate¡¡for the original ancestor virus of all ****** .
Presumably the virus¡¡which jumped from swine to a human or (IMO less likely) which reassorted in a human
A/swine-flu/index/2009-02-01(H1N1)
A/******-match/1-2/07(H3N2)¡¡(A/Mexflu-match/1-2/07(H3N2))
A/Sw/Index/triple-reassortant/1998(H3N2)
»²¹Í
¡ÖAntigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans ¡×
»²¹Í
¡ÖA/Mexflu-match/1-2/07(H3N2 )¡×
»²¹Í
¡ÖUkraine Dead Increase to 344 - Sequences Released ¡×
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£
2009/11/19(Thu)
¡¡
¡ÖÌîÅIJÂɧºâ̳ÉûÂç¿Ã¤Ï£±£¹Æü¤Îµ¼Ô²ñ¸«¤Ç¡¢¥Þ¥Ë¥Õ¥§¥¹¥È¡ÊÀ¯¸¢¸øÌó¡Ë¤Î´ØÏ¢Í½»»°µ½Ì¤Ç¾ÇÅÀ¤È¤Ê¤Ã¤Æ¤¤¤ëÇÀ²È¤Ø¤Î¸ÍÊ̽êÆÀÊä½þÀ©Å٤ˤĤ¤¤Æ¡ÖËÜÍè¤Ï¡Ê¼«µëΨ¸þ¾å¤òÌܻؤ¹¡ËÇþ¤äÂçÆ¦¤ÎÊý¤¬½çÈÖ¤ÏÀè¤À¡×¤È½Ò¤Ù¡¢¥³¥á¤ÎÀè¹Ô¼Â»Ü¤òÌܻؤ¹ÇÀ¿å¾Ê¤ËºÆ¹Í¤òÂ¥¤¹¹Í¤¨¤òɽÌÀ¤·¤¿¡£
Çþ¤äÂçÆ¦¤ÎÊý¤¬Í½»»Á¼ÃÖ¤¬¾¯¤Ê¤¯ºÑ¤à¤È¤ß¤é¤ì¤Æ¤¤¤ë¡£¡×
¤È¤¤¤¦µ»ö ¤Ê¤Î¤À¤¬¡¢¤³¤³¤Ë¤Ï¡¢Â礤ÊÌäÂ꤬¤Ò¤È¤Ä¤¢¤Ã¤Æ¡¢¤³¤ì¤Þ¤Ç¤ÎÃϰèÄó°ÆÂбþ·¿¤Î¡Ö»ºÃϤŤ¯¤ê¸òÉÕ¶â¡×¤Îή¤ì(»ÔĮ¼ñ°Ì¤Ë¡ÖÃϰè¿åÅÄÇÀ¶È¿ä¿Ê¶¨µÄ²ñ¡×ÀßÃÖ¢ª¡Ö¿åÅÄÇÀ¶È¥Ó¥¸¥ç¥ó¡×ºöÄꢪ¿åÅÄÇÀ¶È¸òÉնⱿ±Ä¶¨²ñ¤«¤é¸òÉÕ¶â¸òÉÕ)¤¬¡¢°ìÊѤ·¤Æ¤·¤Þ¤¤¡¢¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤Ç¤Ï¡¢Á´¹ñ°ìΧñ²Á¤Î¸òÉդȤʤꡢÃϰè¤Ç¤ÎÀïάºîʪ¤Ø¤Î¥¤¥ó¥»¥ó¥Æ¥£¥Ö¤¬Æ¯¤«¤Ê¤¯¤Ê¤Ã¤Æ¤·¤Þ¤¦¡¢¤È¤¤¤¦°ìÂç½ÅÍ×·ç´Ù¤¬ÏªÄ褷¤Æ¤·¤Þ¤¦¤Î¤À¡£
ÇÀ¶È´Ø·¸¼Ô¤ÎÃæ¤Ë¤Ï¡¢¡Ö¤»¤Ã¤«¤¯¡¢£µÇ¯Á°¤ÎÊÆÀ¯ºö²þ³×¤Ç¡¢Ã±²Á¤ÎÀßÄê¤òÃÏ°è´Ø·¸¼Ô¤¬ÀïάŪ¤Ë¡¢¼«¤é¤Ç¤¤ë¤è¤¦¤Ë¤·¤¿¤Î¤Ë¡¢½õÀ®Ã±²Á¤ÎÀßÄê¤Ë´Ø¤¹¤ëÃϰè¤ÎºÛÎ̸¢¤ò¼è¤ê¾å¤²¡¢ºÆ¤Ó¡¢¹ñ¤ËÊ־夵¤»¤ë¤Ä¤â¤ê¤Ê¤Î¤«¡£¡×¤Ê¤É¤È¤¤¤¤Þ¤¯¶Ú¤â¤¢¤ë¤è¤¦¤À¡£
¤¿¤È¤¨¤Ð¡¢¤¢¤ë»ºÃϤǤθ½ºß¤Î»ºÃϺî¤ê¸òÉÕ¶â¤Îñ²Á¤Ï¡¢²¼µ¤Î¤è¤¦¤Ë¤Ê¤Ã¤Æ¤¤¤ë¡£
žºîºîÉÕ10¥¢¡¼¥ë¤¢¤¿¤ê½õÀ®¶â³Û
Çþ¡¦ÂçÇþ15000±ß¡¢
²ÖÒÃ11000±ß¡¢
²Ì¼ù6000±ß¡¢
°ìÈÌÌîºÚ6000±ß¡¢
·Ê´Ñ·ÁÀ®11000±ß¡¢
»ôÎÁºîʪ[»ºÃϤŤ¯¤ê¸òÉÕ¶â22000±ß¡Ü¿·¼õµëÄ´À°¥·¥¹¥Æ¥àÄêÃå¸òÉÕ¶â16000±ß]¡Ë
¤³¤ì¤¬¡¢¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤Ç¤Ï¡¢Á´¹ñ°ìΧ¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¤³¤È¤Ç¡¢¸½ºß¡¢¤³¤ì¤é¤Î»ºÃϤǤϡ¢¤è¤¦¤ä¤¯ÄêÃå²½¤·¤¿¤³¤ì¤é»ö¶È¤ÎºÆ¹½ÃÛ¤òÇ÷¤é¤ì¤Æ¤¤¤ë¡¢¤È¤¤¤¦ÍÍͤΤ褦¤Ç¤¢¤ë¡£
¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤Ç¤Ï¡¢²¼µ¤Î¤È¤ª¤ê¤È¤Ê¤Ã¤Æ¤¤¤ë
Çþ¡¢ÂçÆ¦¡¢»ôÎÁºîʪ¡¡35000±ß
¿·µ¬¼ûÍ×ÊÆ80000±ß
¤½¤Ð¡¢ºÚ¼ï¡¢²Ã¹©ÍÑÊÆ20000±ß
¤½¤Î¾ºîʪ¡ÝÃϰè¤ÇÀßÄê²Äǽ¡¡10000±ß
¤Þ¤À¡¢Ã±²Á¤Ï¡¢ºÇ½ª·èÄꤵ¤ì¤Æ¤¤¤Ê¤¤ÍͤÀ¤¬¡¢À¸»ºÀ©¸Â¤òÀߤ±¤Æ¤¤¤Ê¤¤¤È¤¤¤¦Í׷狼¤é¤¹¤ì¤Ð¡¢¾åµ¤Îñ²Á¤Ç¤¤¤±¤ë¤Ï¤º¤Ï¤Ê¤¯¡¢¾åµÃ±²Á¤ò¤«¤Ê¤ê²¼²ó¤ë¤³¤È¤Ë¤Ê¤ë¤À¤í¤¦¡£
¤³¤Î¥¸¥ì¥ó¥Þ¤Ï¡¢¤½¤â¤½¤â¡¢¿·À¯¸¢¤Î¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤¬¡¢ÉÊÌܲ£ÃÇŪ¤Ç¤â¤Ê¤¯¡¢À¸»ºÀ©¸ÂŪ¤Ç¤â¤Ê¤¤¡¢¤È¤¤¤¦¡¢À³Ê¤ò¤â¤Ã¤Æ¤¤¤ë¤¬¤¿¤á¤Î½ÉÌ¿¤È¤â¸À¤¨¤ë¡£
¤¹¤Ê¤ï¤Á¡¢ÀÐÇËÌÐÁ°ÇÀÎӿ建Âç¿Ã¤Î¡ØÊÆÀ¯ºö¤ÎÂ裲¼¡¥·¥ß¥å¥ì¡¼¥·¥ç¥ó·ë²Ì¤ÈÊÆÀ¯ºö²þ³×¤ÎÊý¸þ¡Ù¹½Áۤˤâ¤È¤º¤¯¡Ö¸ºÈ¿ÁªÂòÀ©¥×¥é¥¹Ä¾ÀÜ»Ùʧ¤¤¡×¤È¤¤¤¦¥¹¥¡¼¥à¤«¤é¡¢¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤¬°ïæ¤Ç¤¤Æ¤¤¤Ê¤¤¤È¤¤¤¦¤³¤È¤Ç¤â¤¢¤ë¡£
ľÀÜ»Ùʧ¤¤¤È¤¤¤¦Ì¾Á°¤¬¤Ä¤¤¤Æ¤Ï¤¤¤ë¤â¤Î¤Î¡¢¤½¤ì¤Ï¡¢¤¿¤À¡¢¡Ö¾©Îå¶âŪ¤Ê»Ùʧ¤¤¤Î·ÁÂÖ¤¬À¸»º¼Ô¤ØÄ¾¤Ë»Ùʧ¤ï¤ì¤ë¡Ù¤È¤¤¤¦¤Î¤ß¤Î°ÕÌ£¤Î¤è¤¦¤Ç¡¢WTOÇÀ¶È¶¨Äê¤ËÄê¤á¤é¤ì¤¿Ä¾ÀÜ»Ùʧ¤¤¤ÎÄêµÁ¤Ç¤¢¤ë¡ÖÉÊÌܲ£ÃÇŪ¤Ç¤¢¤ê¡¢À¸»ºÍÞÀ©Åª¤Ç¤¢¤ê¡¢À¸»º²Á³Ê¤ËÂФ·¤Æ¤âÈÎÇä²Á³Ê¤ËÂФ·¤Æ¤â¥Ë¥å¡¼¥È¥é¥ë¤ÊľÀÜ»Ùʧ¤¤¡×¤Î³µÇ°¤È¤Ï¡¢Ãø¤·¤¯ÐªÎ¥¤·¤¿¡Ø¥¤¥ß¥Æ¡¼¥·¥ç¥ó¡¦Ä¾ÀÜ»Ùʧ¤¤¡Ù¤Î¥¹¥¡¼¥à¤Ç¤¢¤ë¡£
(ÀÖ¾¾¹ñ̳Âç¿Ã¤ÎÅúÊÛ
¡¡¤³¤ì¤ÏÈó¾ï¤Ë¤ï¤«¤ê¤ä¤¹¤¯¿½¤·¾å¤²¤ë¤È¡¢¸ÍÊ̽êÆÀÊä½þ¤Ç¤¹¤«¤é¡¢¸ÍÊ̤ËľÀܤª¶â¤ò»Ùʧ¤¤¤Þ¤¹¤è¡¢¸òÉÕ¶â¤òʧ¤¤¤Þ¤¹¤è¤È¡£¤â¤Ã¤È¶Ëü¤Ë¸À¤¨¤Ð¡¢¹ñ¤Îµ¡´Ø¤Ç¤¢¤ê¤Þ¤¹ÇÀÀ¯¶É¤«¤é¡¢ÇÀ¶È¼Ô¤Î¡¢¤³¤ì¤ÏÇÀ¶¨¤Ë¸ýºÂ¤¬¤¢¤ë¤«¤â¤·¤ì¤Þ¤»¤ó¡¢Í¹Êضɤ«¤â¤·¤ì¤Þ¤»¤ó¡¢¤½¤³¤ËľÀÜ»Ùʧ¤¤¤Þ¤¹¤è¡¢¿¶¤ê¹þ¤ß¤ò¤·¤Þ¤¹¤è¤È¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤¹¡£
¡¡º£¤Þ¤Ç¤Ï¤¤¤í¤¤¤í¤ÊÃÄÂΤòÄ̤¸¤ÆÊ§¤Ã¤Æ¤¤¤Þ¤·¤¿¤¬¡¢»ä¤É¤â¤Î¸À¤Ã¤Æ¤¤¤ë¸ÍÊ̤Ȥ¤¤¦¤Î¤Ï¤½¤¦¤¤¤¦°ÕÌ£¤Ê¤ó¤Ç¤¹¡£Ä¾ÀÜ»Ùʧ¤¤¤Þ¤¹¤è¡¢¤½¤¦¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤¹¡£¤¼¤Ò¤½¤¦¤¤¤¦¤³¤È¤Ç¸æÍý²ò¤¤¤¿¤À¤¤¿¤¤¡£)(www)(¤Þ¤¢¡¢ÀÖ¾¾Âç¿Ã¤Ë¤Ï¡¢ÂçÊѼºÎé¤Ê¤Î¤À¤¬¡¢¤³¤ÎÄøÅ٤Τ´Ç§¼±¤Î¤è¤¦¤Ç¤¢¤ë¡£Ã²¤«¤ï¤·¤¤¡£)
¤³¤³¤¤¤é¤Ç¡¢Ì±¼çÅÞÀ¯¸¢¤Î³§¤µ¤ó¤Ï¡¢¡ØÄ¾ÀÜ»Ùʧ¤¤¡Ù¤Î¿¿¤Î°ÕÌ£¤òºÆ³Îǧ¤µ¤ì¡¢¥¹¥¡¼¥à¤ÎºÆ¹½Ãۤˤ¢¤¿¤é¤ì¤¿¤é¤è¤í¤·¤¤¤Î¤Ç¤Ï¤Ê¤«¤í¤¦¤«¡£
¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤¬¸ºÈ¿ÁªÂòÀ©¥¹¥¡¼¥à¤ÎÇÉÀ¸Êª¤Ç¤¢¤ë°Ê¾å¡¢¤³¤ÎÌîÅĺâ̳ÉûÂç¿Ã¤Î¤¤¤ï¤ì¤ë¤è¤¦¤Ê¡¢¥³¥áÌäÂê¤ÈžºîºîʪÌäÂê¤È¤Î¥¹¥¡¼¥à¤Î¥Ä¥¤¥óÀÚ¤êÎ¥¤·¹½ÁۤϤʤ«¤Ê¤«¤à¤º¤«¤·¤¯¡¢¤³¤Ã¤Á¤¬·è¤Þ¤é¤Ê¤±¤ì¤Ð¡¢¤¢¤Ã¤Á¤â·è¤á¤é¤ì¤Ê¤¤¡¢¤È¤¤¤Ã¤¿¥È¡¼¥È¥í¥¸¡¼¤ÎÎØ²ö¤Ë¡¢ÇÀÎӿ建¾Ê¤ÏǺ¤Þ¤µ¤ì¤ë¤³¤È¤Ë¤Ê¤ë¤Î¤À¤í¤¦¡£
¥é¥É¥ä¡¼¥É¡¦¥¥Ã¥×¥ê¥ó¥°(Rudyard Kipling)¤Î¡ÖÅì¤ÈÀ¾¤Î¥Ð¥é¡¼¥É¡×(¡ÈThe Ballad of East and West¡É 1892)¤Ë¤Ê¤¾¤é¤¨¤Æ¸À¤¨¤Ð¡¢
¡Ö¤¢¤¢¡¢¥³¥á¤Ï¥³¥á¡¢Å¾ºîºîʪ¤Ïžºîºîʪ¡¢¤³¤ÎÆó¤Ä¤¬¸ò¤ï¤ë¤³¤È¤Ï·è¤·¤Æ¤Ê¤¤¡£
ÂçÃϤȶõ¤¬¿À¤Î¿³È½¤ÎÁ°¤ËΩ¤ÄºÇ¸å¤Î¤È¤¤Þ¤Ç¡£
¤·¤«¤·¡¢¤¿¤¬¤¤¤ËÃϤβ̤Ƥ«¤éÍè¤è¤¦¤È¤â¡¢Æó¿Í¤Îͦ¼Ô¤¬¸þ¤«¤¦¤È¤¤Ë¤Ï¡¢ ¥³¥á¤â¤Ê¤¯Å¾ºîºîʪ¤â¤Ê¤¯¡¢¹ñ¶¤â¤Ê¤¯¡¢Ì±Â²¤äÀ¸¤Þ¤ì¤Î°ã¤¤¤â¤Ê¤¤¡ª¡×
(Oh, East is East, and West is West, and never the twain shall meet,Till Earth and Sky stand presently at God’s great Judgment Seat;
But there is neither East nor West, Border, nor Breed, nor Birth,
When two strong men stand face to face, tho¡Ç they come from the ends of the earth!)
¤Þ¤µ¤Ë¡¢ÆüËܤˤª¤¤¤Æ¤Ï¡¢Çþ¡¢ÂçÆ¦¡¢¥³¥á¤Ï¡¢¥·¥ã¥à¤Î»°·»Äï¤Ê¤Î¤Ç¤¢¤ë¡£
¡¡
¤ªÃΤ餻:
ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£
ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯ ¤·¤Æ¤¯¤À¤µ¤¤¡£
¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯
¤·¤Æ¤¯¤À¤µ¤¤¡£